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The mechanisms for DNA repair in mitochondria is an area in which there is limited 
knowledge in comparison to the DNA repair mechanisms that have been defined in the 
nucleus. Although it is understood that mitochondria have less DNA repair mechanisms 
than in the nucleus there is still a lot more scope for identifying new proteins involved 
in the repair of mitochondrial DNA (mtDNA).  
The main focus of this thesis was to attempt to determine whether there was presence 
and activity of a DNA repair enzyme in mitochondria, namely tyrosyl-DNA-
phosphodiesterase 1 (TDP1), and if so what is the exact role of this enzyme in mtDNA 
repair. This enzyme has already been characterised as an single strand break repair 
(SSBR) enzyme in the nucleus, and a mutation in this gene can cause the autosomal 
recessive disorder spinocerebellar ataxia with axonal neuropathy 1 (SCAN1).  
The data in this thesis provides evidence for the presence and activity of TDP1 in 
mitochondria and that the function of this enzyme on mtDNA is most likely limited to 
the removal of mitochondrial topoisomerase 1 (TOP1mt). It has also been shown that 
phosphorylation of amino acid 81 of TDP1 does not facilitate its interaction with DNA 
ligase 3α in mitochondria and that there most probably no direct link between these 
enzymes in this organelle, unlike that found in the nucleus. 
This data indicates that there is still potential for identification of more enzymes that are 
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Chapter 1. Introduction 
 
1.1 General aspects of mitochondria 
Mitochondria are organelles present in almost all eukaryotes that have a vital role in 
normal cellular functioning (Attardi and Schatz, 1988). One of the main responsibilities 
of mitochondria is producing the vast majority of cellular energy in the form of 
adenosine-triphosphate (ATP) through oxidative phosphorylation, although 
mitochondria have a number of other roles in cells (Bonawitz and Shadel, 2007). 
Examples of these include biosynthesis of amino acids, phospholipids, and nucleotides, 
which are produced as a result of a close interplay with the nucleus (Attardi and Schatz, 
1988). 
Aberrant mitochondrial function can cause a wide variety of severe incurable diseases 
and is also implicated in the ageing process (Bonawitz and Shadel, 2007). In recent 
years the profile of mitochondrial research has been increased significantly due to its 
importance in cells and the potential consequences that can occur as a result of 
dysfunction in this organelle (Martin, 2012). Mitochondria require precise regulation to 
prevent negative effects arising from abnormalities in these highly organised organelles. 
Such organisation includes a double membrane structure, a distinct genome from that in 
the nucleus (mitochondrial DNA (mtDNA)), as well as a vast proteome that controls an 
extensive network of processes occurring in mitochondria (Bonawitz and Shadel, 2007).   
Encompassed in this thesis are the findings from a project focussed on the molecular 
mechanisms of mtDNA damage and repair, however, it is important to first review 
general aspects of mitochondria to provide an understanding of the activities within this 




1.1.1 Mitochondrial evolution 
For many years it has been proposed that mitochondria originated in eukaryotes as a 
result of endosymbiosis; a theory termed the serial endosymbiosis theory (Gray et al., 
1999). This theory attests that almost all modern day eukaryotic cells were formed when 
archaeal and eubacterial cells were unified in anaerobic symbiosis before the 
incorporation of mitochondria (Margulis, 1996). An exception to this is Giardia 
intestina that does not contain mitochondria, and instead incorporates a less developed 
form of mitochondria known as mitosomes (Henze and Martin, 2003, Tovar et al., 
2003). In contrast to mitochondria, mitosomes are not involved in producing ATP, and 
instead are relied upon for producing iron-sulfur FeS clusters used in ATP production in 
this organism (Henze and Martin, 2003, Tovar et al., 2003). Hydrogenosomes are 
another form of mitochondria related organelle (found in Trichomonas vaginalis, 
Giardia lamblia, Nyctotherus ovalis, Neocallimastix frontalis, and Psalteriomonas 
lantern), which contrast to mitosomes in that they produce ATP through substrate-level 
phosphorylation, but they are also similar to mitosomes as they produce FeS clusters 
and are less developed than mitochondria (Shiflett and Johnson, 2010). The relevance of 
FeS clusters in mitochondria is discussed later when reviewing the process of oxidative 
phosphorylation. Returning to the subject of mitochondrial evolution, much support for 
the serial endosymbiosis theory has come from the fact that mitochondria contain their 
own genome (mtDNA), which is suggestive that this organelle has its own evolutionary 
history (Gray et al., 1999). Sequencing the 16s ribosomal RNA (rRNA) gene within the 
mitochondrial genome suggested that mitochondria were derived from an ancestor of 
the alpha (α) subdivision of proteobacteria (Yang et al., 1985, Gray et al., 1999). The 
human mitochondrial genome is relatively small in comparison to its nuclear 
counterpart; encoding thirteen proteins involved in oxidative phosphorylation 
(Anderson et al., 1981). This suggests that, as part of the evolution of eukaryotic cells, 
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mtDNA has lost the vast majority of its protein encoding regions to the nuclear DNA 
(nDNA), as the mitochondrial proteome is far greater than that encoded by mtDNA 
(Gray et al., 1999, Henze and Martin, 2003). Despite this loss mitochondria are capable 
of performing a wide variety of activities as a result of the close relationship with the 
nucleus that ultimately provides a myriad of proteins to give mitochondria the required 
factors for these activities. 
1.1.2 Mitochondrial structure 
Electron microscopy has played a pivotal role in ascertaining the structure of 
mitochondria with seminal studies in the 1950s that identified mitochondria as being 
enclosed by a membrane, and containing protrusions that were named as cristae (Palade, 
1952, Sjostrand, 1953). Soon after these findings a model was developed for 
mitochondrial structure that is widely accepted today as being the true basic structure of 
mitochondria, which is illustrated in figure 1.2 (Palade, 1953). 
 
Figure 1.1. Basic structure of mitochondria (adapted from Palade, 1953). 
 
From the work carried out by Palade it has since been established that the structure of 
mitochondria can impact on metabolism depending on the condensation/swelling of this 
organelle that can affect diffusion of metabolites and subsequently production of ATP 
from oxidative phosphorylation (Hackenbrock, 1966, Scalettar et al., 1991). It has also 
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been found that mitochondria undergo fusion and fission processes to allow the 
transport of energy and metabolites throughout the cell and to ensure that mitochondria 
remain functional throughout environmental stresses (Palmer et al., 2011, Youle and 
van der Bliek, 2012). The maintenance of this network of mitochondria is vital for 
cellular homeostasis as any disruptions to this network can create a variety of 
complications to the many important processes within mitochondria, including that of 
oxidative phosphorylation (Palmer et al., 2011, Youle and van der Bliek, 2012). The 
processes of fission and fusion of mitochondria are mediated by guanosine 
triphosphatases (GTPases) that involve proteins such as dynamin related protein1 
(DRP1) that functions in fission, whereas the mitofusin’s 1 (Mfn1) and 2 (Mfn2) play a 
major role of fusion of mitochondria (Hoppins et al., 2007, Chen and Chan, 2005, 
Smirnova et al., 2001). Not surprisingly the structure of cristae in fusion and fission 
processes can be highly variable and therefore correct regulation and performance of 
these processes is vital in maintaining ATP production through oxidative 
phosphorylation (Mannella et al., 2001, Germain et al., 2005). 
1.1.3 Oxidative phosphorylation 
Oxidative phosphorylation (OXPHOS) is the process by which ATP is produced as a 
result of a number of reduction/oxidation (redox) reactions along the electron transport 
chain that are vital for cell survival (Papa et al., 2012). In mammalian cells more than 
80% of ATP is produced through OXPHOS that is then utilised to drive numerous 
processes in cells (Papa et al., 2012). During OXPHOS electrons are passed along the 
electron transport chain coupled with transfer of protons from the matrix to the inter-
membrane space that creates an electrochemical gradient that is then used in ATP 
production (Lemarie and Grimm, 2011). Figure 1.3 is a schematic of OXPHOS where 





Figure 1.2. A schematic of OXPHOS, which simply illustrates that electrons are passed 
along respiratory chain complexes I to IV whilst protons are moved across the inner 
mitochondrial membrane and subsequently used to produce ATP (adapted from 
Lemarie and Grimm, 2011). 
 
Figure 1.3 simply demonstrates that the electron transport chain is located on the inner 
mitochondrial membrane, however, the processes of electron transport and movement of 
protons across the membrane is far more complex than is illustrated in this figure (Papa 
et al., 2012, Lemarie and Grimm, 2011). 
The process of OXPHOS often begins with the oxidation of NADH to NAD
+
 with 
electrons being donated to flavin mononucleotide (FMN) in complex I (NADH 
dehydrogenase) (Hirst, 2005, Sled et al., 1994). Complex I has been established as a 
multi-subunit complex that has 14 core subunits that are present in all varieties of this 
enzyme, seven of which are encoded in the nucleus and the other seven in the 
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mitochondrial genome (Efremov and Sazanov, 2012, Heide et al., 2012). The subunits 
of this complex are assembled by multiple assembly factors (e.g. Acad9 and Ecsit) to 
enable adequate function of the complex within the membrane (Heide et al., 2012). 
Electron microscopy analysis outlined this complex in eukaryotes as being L-shaped 
and within the inner membrane with the protruding arm extending out to the 
mitochondrial matrix (Hofhaus et al., 1991). When NADH is oxidised by complex I at 
this protruding arm the electrons are passed to FMN that is then reoxidised by an FeS 
cluster and passed along eight FeS clusters before being used to reduce ubiquinone to 
ubiquinol (Hirst, 2005, Sheftel et al., 2010). These FeS clusters are relevant in many 
biochemical processes in the cell most probably due to the ability of the iron component 
to accept electrons, which makes these clusters particularly valuable to OXPHOS 
(Sheftel et al., 2010). When ubiquinone is reduced protons are translocated across the 
inner membrane, thus beginning the accumulation of the electrochemical gradient 
required for ATP production (Hirst, 2005). The reduced ubiquinol can then move 
through the inner membrane for further redox reactions later in OXPHOS (Hirst, 2005). 
In complex II (succinate dehydrogenase (SDH)) succinate from the citric acid cycle is 
oxidised to fumarate and the electrons generated from this are passed to flavin adenine 
dinucleotide (FAD) to form FADH2 which then passes the electrons through three FeS 
clusters (Rutter et al., 2010). The electrons are then used to reduce ubiquinone, but 
unlike the other complexes of the electron transport chain there is no transfer of protons 
across the inner membrane as a result of activities in SDH (Rutter et al., 2010). This 
complex consists of two main domains, one of which extends out into the matrix and 
the other bound in the inner membrane (Hagerhall, 1997). The domain extending to the 
matrix contains a dicarboxylate binding site for succinate as well as FAD and FeS 
clusters for electron transport in this complex (Hagerhall, 1997). These electrons are 
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then used by the membrane bound domain in oxidation and reduction of ubiquinone in 
the Quinone pool (Q pool) also present in the membrane (Hagerhall, 1997). 
Several redox reactions in complex III (cytochrome bc1 complex) make the process of 
electron transfer in this complex arguably the most complicated in the whole electron 
transport chain (Cramer et al., 2011). Complex III consists of intertwined dimers with a 
catalytic core made up of three subunits; cytochrome b, the FeS Rieske protein, and 
cytochrome c1 (Mulkidjanian, 2010). The electron transport in complex III is known as 
the Q cycle, which begins with oxidation of ubiquinol from the Q pool to ubiquinone 
one electron being passed to the Rieske FeS protein and then on to cytochrome c1 before 
being used to reduce the electron carrier cytochrome c (Mitchell, 1975, Mitchell, 1976). 
The other electron from the oxidation of ubiquinol reduces cytochrome b that passes 
across the membrane and is the used to reduce a molecule of ubiquinone to semiquinone 
(Mitchell, 1975, Mitchell, 1976). Another molecule of ubiquinol is then reduced once 
more, which passes another electron to the carrier cytochrome ci and then on to 
cytochrome c thereby reducing it, while the other electron is used to reduce the 
semiquinone molecule to fully reduced ubiquinol that re-enters the Q pool (Mitchell, 
1975, Mitchell, 1976). During this process further protons are translocated from the 
matrix into the inter-membrane space to increase the electrochemical gradient needed 
for the final production of ATP (Mulkidjanian, 2010). 
Complex IV, or cytochrome c oxidase, is the terminal oxidase of the electron transport 
chain (Yoshikawa et al., 2012). In this complex electron transfer begins with oxidation 
of cytochrome c that had been reduced in the Q cycle in complex III (Capaldi, 1990). 
Electrons are accepted by heme a and CuA before being used to reduce molecular 
oxygen to water in the mitochondrial matrix (Capaldi, 1990). During this process more 
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protons are translocated from the matrix to the inter-membrane space for the final step 
of ATP production by complex V (ATP synthase) (Capaldi, 1990). 
Generation of ATP by complex V involves the concerted action of two main subunits of 
this enzyme, F0 and F1, that function in a fascinating rotary manner to produce the 
molecules that are so vital to cells (Kinosita, 2012). The electrochemical gradient 
created by the transfer of protons from the matrix to the inter-membrane space, by 
complexes I, III, and IV  induces flow of protons through F0 subunit of complex V and 
results in this subunit rotating in a clockwise manner (Noji et al., 1997). Meanwhile the 
F1 subunit rotates anti-clockwise, which causes conformational changes  at three sites in 
this subunit that ultimately couples proton flow through F0 with production of ATP 
from ADP and Pi (Noji et al., 1997).  
The production of ATP is essential to cells; therefore production of the complexes that 
make up the electron transport chain is vital for cell survival. The vast majority of the 
proteins that form these complexes are encoded by nDNA, however, a small number are 
encoded by mtDNA and make-up an integral part of producing ATP through OXPHOS. 
1.1.4 Mitochondrial DNA 
For many years following the discovery and characterisation of DNA in the nucleus, 
mitochondria were postulated to contain their own DNA which was finally 
demonstrated in avian heart and liver (Rabinowitz et al., 1965). Following this 
discovery came great advances in DNA sequencing techniques, namely sequencing with 
chain-terminating dideoxynucleotides, which was used to sequence human mtDNA 
(Sanger et al., 1977, Anderson et al., 1981). From this Anderson et al reported mtDNA 
to contain two rRNA genes, twenty two transfer RNA (tRNA) genes, and five genes 
encoding subunits of the electron transport chain with a further eight predicted protein 
coding genes (Anderson et al., 1981). Later sequencing of the original placental mtDNA 
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sample used by Anderson et al with newer technology allowed revision of this sequence 
to remove any discrepancies that had originally been observed (Andrews et al., 1999, 
Anderson et al., 1981). The information provided from these sequencing experiments, in 
addition to sequencing of mouse mtDNA by Bibb et al, identified mammalian mtDNA 
as being highly organised with almost no non-coding nucleotides between coding 
sequences (Anderson et al., 1981, Bibb et al., 1981b). In the time since these 
publications it has been possible to establish the exact organisation of human mtDNA 
which is illustrated in figure 1.4.  
 
Figure 1.3. Organisation of the human mitochondrial genome (adapted from 
http://www.mitomap.org/MITOMAP/mitomapgenome.pdf). 
As can be seen in figure 1.4 the human mitochondrial genome is relatively small and it 
is also known to be maternally inherited and present in multiple copies in cells 
(Krishnan et al., 2007). The genome consists of two strands, the guanine rich heavy (H) 
strand and the guanine poor light (L) strand (Kasamatsu et al., 1971). It is understood 
that mtDNA molecules are clustered in DNA-protein structures known as nucleoids 
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where 2-10 copies of mtDNA are packaged by proteins (e.g. mitochondrial transcription 
factor A (TFAM)) that are also involved in mtDNA maintenance and gene expression 
(Spelbrink, 2010). Replication and transcription of mtDNA occurs independently of 
nDNA although all of the factors involved in regulating these processes are encoded by 
the nuclear genome (Krishnan et al., 2007, Shadel and Clayton, 1997).  
Replication of mtDNA was first proposed to occur in a strand uncoupled manner 
whereby leading strand replication was initiated from Ori H which continued around the 
genome with lagging strand replication initiated when the leading strand reached Ori L 
(Robberson et al., 1972). This mode for mtDNA replication was termed the strand-
displacement model and was developed as a result of electron microscopic analysis 
showing that replicating molecules of mtDNA had a single-stranded branch (Robberson 
et al., 1972). This form of replication was corroborated with the use of ethidium 
bromide/caesium chloride (EthBr/CsCl) gradients and in vivo labelling of mtDNA using 
radiolabelled thymidine (Berk and Clayton, 1974). These experiments helped to 
determine the relative densities of replicating molecules of mtDNA that supported 
previous experiments using electron microscopy and suggested mtDNA replication 
progressed in an asynchronous manner (Berk and Clayton, 1974). The use of 2-
dimensional agarose gel electrophoresis (2-D AGE) was utilised to contradict the 
strand-displacement model, and instead a bidirectional mode of replication from an 
origin downstream of Ori H was proposed (Bowmaker et al., 2003, Holt et al., 2000). 
However, the argument for unidirectional replication initiation was revitalised with the 
discovery of ribonucleotide incorporation throughout the lagging strand (RITOLS) that 
was proposed to supersede the bidirectional model (Yasukawa et al., 2006). To date the 
exact mechanism by which mtDNA is replicated remains to be elucidated, but work in 
the field is on going as is that involving the expression of genes encoded by mtDNA. 
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Transcription of human mtDNA is initiated at three points within the genome; the heavy 
strand promoter (HSP) 1 (H1), the HSP promoter 2 (H2), and the light strand promoter 
(LSP) (Falkenberg et al., 2007). Transcription from H1 results in the production of a 
bicistronic unit of mRNA for two rRNA molecules encoded in the genome (Falkenberg 
et al., 2007). Transcription initiation from H2 and LSP results in the production of a 
polycistronic mRNA unit from each strand that undergoes cleavage processes to 
produce the final mRNA molecules that can be used in translation (Falkenberg et al., 
2007, Montoya et al., 1981, Ojala et al., 1981). These cleavage processes are thought to 
take place immediately before and after tRNA sequences in the genome (Ojala et al., 
1981). Transcription initiation of mtDNA is dependent on the interaction of the 
mitochondrial RNA polymerase (POLRMT) with TFAM, B1 (TFB1M), and B2 
(TFB2M) (Falkenberg et al., 2002, McCulloch et al., 2002). To date the only 
transcription termination to be characterised is that from promoter H1 and involves the 
mitochondrial transcription termination factor (MTERF) with termination of the other 
mRNA units yet to be identified (Falkenberg et al., 2007, Kruse et al., 1989). Current 
knowledge of the processing of mitochondrial mRNA transcripts includes 
polyadenylation by the mitochondrial poly-A-polymerase (MTPAP) before synthesis of 
each of the 13 OXPHOS proteins encoded by mtDNA is performed on the inner 
mitochondrial membrane by the mitoribosome (Crosby et al., 2010, Sharma et al., 
2003). 
As mentioned earlier it has been established that there are multiple copies of mtDNA 
molecules in cells and that these are packaged in ‘nucleoids’ that can comprise many 
mtDNA molecules as well as proteins; most notably the TFAM (Kukat et al., 2011, 
Hallberg and Larsson, 2011). Despite mtDNA appearing to be very well organised, 
mitochondria still rely heavily on the nuclear encoded proteins and, as with all 
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biological systems, errors can be made and damage can develop in a variety forms that 
lead to an abundance of diseases as a result of mitochondrial dysfunction. 
1.1.5 Mitochondrial involvement in disease and ageing 
 
With mitochondria having a critical role in cells any dysfunction in this organelle can 
present in a number of diseases. These can be caused by mutations in mtDNA (primary 
causes), mutations in nuclear genes can also impact on many mitochondrial processes 
(secondary causes), and somatic damage to DNA/proteins during ageing can influence 
mitochondrial function (Schapira, 2012). Common mitochondrial diseases that result 
from mutations in mtDNA include neurogenic ataxia with retinitis pigmentosa (NARP) 
and Leber's hereditary optic neuropathy (LHON) whilst mutations in nuclear genes 
encoding proteins such as the mitochondrial DNA polymerase ƴ (POLG) and the 
mtDNA helicase twinkle can also cause mitochondrial disease in the form of chronic 
progressive external opthalmoplegia (CPEO) (Schapira, 2012). Mutations in either 
mtDNA or nDNA that affect components of the electron transport chain often present in 
infancy or early childhood and are frequently fatal, thus emphasising the importance of 
OXPHOS to cells and the whole body (Schapira, 2012). Mutations in the genes 
encoding Parkin and PTEN-induced putative kinase 1 (PINK1) are known to affect 
mitochondrial function which is related to the neurodegenerative disorder, Parkinson’s 
disease (PD) (Gegg and Schapira, 2011). Mitochondrial dysfunction has also been 
observed in patients with Alzheimer’s disease (AD) although a causative role for 
mitochondria in this disease has yet to be proven unequivocally (Howell et al., 2005). 
The diseases outlined are just a small collection of multiple disorders that involve 
mitochondrial dysfunction, but the exact role of mitochondria in ageing has yet to be 




In the 1950s it was proposed that oxidative damage caused by reactive oxygen species 
(ROS) accumulates in cells over time and that this results in impaired cell function 
which will eventually lead to death (Harman, 1956). This appears to be an attractive 
explanation for ageing with respect to mitochondria as increased ROS can be generated 
as a result of electron leakage from the electron transport chain (Lemarie and Grimm, 
2011). The increased levels of ROS could cause more damage to mitochondrial 
components that in turn could generate more ROS and therefore further damage that 
increases with time; a phenomenon described as the vicious cycle (Jang and Remmen, 
2009). However, mouse models in which mtDNA point mutations are greatly increased 
and lead to early onset of an ageing phenotype do not display increased ROS 
production, which provides evidence to contradict the vicious cycle of damage proposed 
for mitochondria (Trifunovic et al., 2004, Trifunovic et al., 2005, Park and Larsson, 
2011). Although this evidence would suggest that this vicious cycle of damage in 
mitochondria does not cause ageing it is clear that there are many negative effects that 
have been observed in mitochondria with increasing age, such as increased mtDNA 
mutation load and mtDNA deletion levels (Bender et al., 2006, Krishnan et al., 2007). 
These mtDNA mutations and deletions clonally expand with age, but whether this is 
just a sign of ageing or actually contributes to the ageing phenotype is unknown 
(Krishnan et al., 2007). An alternative hypothesis is that mtDNA mutations occur as a 
result of replication errors during embryogenesis, and subsequently expand during 
ageing suggesting that oxidative damage does not have a leading role in mtDNA 
mutation formation (Larsson, 2010). Even with this in mind it would be naïve to assume 
that oxidative damage does not affect the ability of mtDNA to provide subunits of the 
electron transport chain as there are a number of mechanisms by which mtDNA can be 
damaged (Boesch et al., 2011). The study of mtDNA damage is the main theme of this 
thesis and will be discussed in greater detail in the following sections. 
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1.2 Mitochondrial DNA damage and repair 
 
Damage to mtDNA can occur in a variety of forms and potentially have devastating 
effects in cells (Cline, 2012, Boesch et al., 2011). While knowledge for the potential 
mechanisms of mtDNA damage is well known, the actual study of how damaging 
agents affect mtDNA and its consequences in disease and ageing is much less 
characterised in comparison to the nucleus (Boesch et al., 2011). Although a significant 
proportion of research funding is directed to the study of nDNA damage and repair in 
comparison to the same subject for mtDNA there is a relative lack of knowledge in this 
field considering the advances that have been made in researching other areas of 
mitochondrial biology. Much attention in the area of mitochondrial damage has been 
devoted to studying the effects of ROS that can damage proteins and DNA within 
mitochondria (Roede and Jones, 2010). In this section attention will be given to known 
forms of mtDNA damage as well as the current knowledge surrounding repair of this 
damage and potential for further findings. 
 
1.2.1 Forms of mitochondrial DNA damage 
 
There are a number of agents that can cause DNA damage and with mitochondria 
producing a considerable amount of ROS this will be reviewed first with respect to 
mtDNA damage. As discussed previously ROS can be generated endogenously, but 
they can also be formed from exogenous factors such as pollution and ultra violet (UV) 
radiation (Boesch et al., 2011). As wells as generating ROS, UV radiation can cause 
DNA damage as the absorption spectrum of DNA matches the wavelength of UV 
radiation (100-400nm), which can lead to direct excitation of DNA and form pyrimidine 
dimers (Batista et al., 2009). This alteration can cause instability of DNA and/or 
15 
 
mutations in the nucleotide sequence (Boesch et al., 2011). Exogenously or 
endogenously generated ROS include superoxide (O2
-
), hydroxyl radicals (
.
OH), and 
hydrogen peroxide (H2O2) (Boesch et al., 2011). The 
.
OH radical is highly reactive 
towards DNA and can form damage as well as causing oxidation of unsaturated bonds 
in polyunsaturated fatty acids (PUFAs) present in the inner mitochondrial membrane 
(Halliwell and Gutteridge, 1984, Colbeau et al., 1971). The oxidation of PUFAs 
produces aldehyde products that are usually neutralised by enzymes such as aldehyde 
dehydrogenase and cause no problem (Esterbauer et al., 1991). However, in 
circumstances of increased ROS this neutralisation may not occur meaning that these 
reactive aldehydes are capable of damaging mtDNA (Schlame et al., 2005, Voulgaridou 
et al., 2011). In the case of O2
-
 approximately 0.15% of oxygen consumed by 
mitochondria forms this radical with complexes I and III being the main sites for its 
production (St-Pierre et al., 2002, Brand, 2010).
 
ROS can damage mtDNA by forming 
adducts such as thymine glycol and the well studied 8-hydroxyguanine (8-oxo-G), as 
well as forming strand breaks and abasic sites in mtDNA (Boesch et al., 2011, Ohno et 
al., 2009, Evans et al., 2004, Dizdaroglu et al., 2002). In addition to modifying bases 
within the backbone of mtDNA, oxidation of nucleotides in the deoxynucleotide 
triphosphate (dNTP) pool can occur which may then become incorporated within 
mtDNA by POLG upon replication (Boesch et al., 2011, Kamiya and Kasai, 1995). In 
addition to ROS reactive nitrogen species (RNS) can be formed as a result of a 
combination of O2
-
 and nitric oxide (NO
.
) which forms peroxynitrite (ONOO
-
) and is 
highly reactive, potentially being very damaging to mtDNA by oxidising bases and also 
generating abasic sites (Boesch et al., 2011, Burney et al., 1999). As well as adducts 
being formed in mtDNA by ROS and RNS it is also possible for adducts to be derived 
from alkylating agents produced endogenously and also from ultra violet (UV) light, 
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which forms thymine dimers within the DNA backbone (Boesch et al., 2011, Xiao and 
Samson, 1993).  
 
The various lesions described here are just some examples that can potentially be very 
detrimental to the cell and so mitochondria possess repair mechanisms to reverse these 
forms of mtDNA damage. 
 
1.2.2 Mitochondrial DNA repair pathways and potential for further identification 
 
In the mid-1970s a study was carried out to assess the capability of mitochondria to 
repair UV induced mtDNA damage in the form of pyrimidine dimers that would require 
the repair mechanism nucleotide excision repair (NER), but it was found that 
mitochondria did not have this capability (Clayton et al., 1974). From this many 
concluded that mitochondria did not contain any DNA repair capabilities for some time 
until this was disproven by demonstrating the existence of base excision repair (BER) in 
mitochondria (Bogenhagen, 1999, Mason et al., 2003). From this it has been found that 
mitochondria are able to repair various lesions in mtDNA, which is more than was 
initially anticipated (Yakes and Van Houten, 1997, Liu and Demple, 2010, Mason and 
Lightowlers, 2003).  
 
As described in the previous section ROS can be generated from exogenous factors such 
as pollution or endogenously from processes such as OXPHOS, which can result in 
many forms of DNA damage (Boesch et al., 2011). Defence against such damaging 
agents can come in the form of antioxidants such as superoxide dismutases and 
peroxidases that act to detoxify ROS before damage can occur (Foyer and Noctor, 2009, 
Turrens, 2003, Chaudiere and Ferrari-Iliou, 1999) However, there are occasions when 
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damaging ROS escape detoxification and cause a wide variety of DNA lesions that 
require various repair mechanisms to restore DNA to its original form and avoid any 
negative impact as a result of this damage (Boesch et al., 2011). 
 
Of the DNA repair pathways in mitochondria BER has been the most studied and was 
demonstrated to exist for both short-patch and long-patch versions of this pathway 
(Stierum et al., 1999, Liu et al., 2008). Figure 1.5 illustrates how both these forms of 












Figure 1.4. General characterisation of short-patch (SP) and long-patch (LP) BER 
mechanisms that repair mtDNA damage. The process is initiated when a damaged base 
is excised from the DNA backbone by a DNA glycosylase leaving an abasic (AP) site. 
The DNA backbone is then cleaved by an AP endonuclease followed by infilling of the 
abasic site by DNA polymerase in SP-BER. In some circumstances the 3’ end at the 
abasic site does not consist of OH following cleavage by the AP endonuclease, which 
then requires a flap endonuclease to remove 2-10 bases of DNA before infilling can be 
carried out by the DNA polymerase. Once the correct bases have been replaced a DNA 




Along with BER in mitochondria other repair mechanisms have been reported in 
mitochondria such as mismatch repair (MMR), and removal of oxidised dATP and 
dGTP from the dNTP pool (Mason et al., 2003, Nakabeppu, 2001b). Removal of these 
oxidised dNTPs (8-oxo-2′-dATP and 8-oxo-dGTP) is performed by MutT homolog 1 
(MTH1) as a protection of oxidised bases being incorporated within replicating mtDNA 
(Kang et al., 1995, Nakabeppu, 2001a). In cases where oxidised bases are incorporated 
during replication or when errors are made in this process MMR serves to remove errors 
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made in the nascent strand of replicating mtDNA by the enzyme YB-1 (Hsieh and 
Yamane, 2008, Mason et al., 2003, de Souza-Pinto et al., 2009). Direct repair (DR) of 
DNA without any cleavage of the DNA backbone has also been demonstrated to exist in 
mitochondria mediated by O
6
-methylguanine-DNA methyltransferase (MGMT), which 
removes methyl groups from modified guanine bases (Myers et al., 1988). Further 
repair mechanisms have been proposed to be present in mitochondria, such as double 
strand break repair (DSBR) by non-homologous end joining (NHEJ) and homologous 
recombination (HR); however these processes have not yet been unequivocally 
demonstrated in this organelle (Thyagarajan et al., 1996, Bacman et al., 2009, 
Lakshmipathy and Campbell, 1999a, Fukui and Moraes, 2009).  Despite this 
mitochondria potentially have a more developed repair network than initially anticipated 
and by turning to repair mechanisms for nDNA it was hoped that more information 
could be found for the repair capabilities for mtDNA. 
 
1.3 Tyrosyl-DNA-phosphodiesterase 1 
 
Tyrosyl-DNA-phosphodiesterase 1 (TDP1) is an enzyme involved in DNA repair in the 
nucleus (Yang et al., 1996). The repair of nDNA has been well studied when compared 
to that for mtDNA, and therefore repair in the nucleus is relatively well characterised in 
comparison to the mitochondrion (Boesch et al., 2011). Table 1.1 shows the DNA repair 
mechanisms that are known to exist in the nuclear and mitochondrial compartments of 
the cell. 
Table 1.1. DNA repair mechanisms in the nucleus and mitochondrion (adapted from 










Of the repair mechanisms in mitochondria single strand break repair (SSBR) had yet to 
be characterised at the beginning of this project. Experiments to determine whether 
SSBR existed in mitochondria were to be carried out by investigating the function of 
TDP1, which is involved in SSBR in the nucleus. 
 
1.3.1 Function of TDP1 enzyme in nucleus 
 
The discovery of TDP1 came in 1996 when it was found that cleavage complexes 
formed from type I topoisomerases could be resolved by the activity of TDP1 (Yang et 
al., 1996). This was established using cell extracts from Saccharomyces cerevisiae and a 
radiolabelled oligonucleotide with a 3’ phosphotyrosine to mimic the DNA-
topoisomerase 1 (TOP1) lesion that forms in vivo (Yang et al., 1996). Following this 
discovery a plethora of publications has arisen that provide further information on 
classification of this enzyme and the exact function of TDP1 in repairing DNA-TOP1 
lesions in the nucleus. Sequence comparison studies identified TDP1 as a member of 
phospholipase D (PLD) superfamily due to the presence of two histidine-lysine-aspartic 
acid (HKD) signature motifs that are characteristic of members of this family (Interthal 
et al., 2001). The HKD motifs in TDP1 are unusual in that they do not contain the 
aspartic acid (D) and in place there is an asparagine (N) that categorises TDP1 in a 
distinct class within the PLD family (Interthal et al., 2001). Other notable findings 
regarding TDP1 include the discovery that this enzyme can resolve other substrates than 
3’ phosphotyrosine, such as 3’ phosphoglycolate and 3’ phosphohistidine, which 
suggests an important role for TDP1 in cells (Interthal et al., 2005, Inamdar et al., 
2002). Also, it was found that in repairing DNA-TOP1 SSBs TDP1 acts in concert with 
other proteins including X-ray repair cross-complementing protein 1 (XRCC1), 
polynucleotide kinase (PNK), and DNA ligase IIIα (LIG3α) (Plo et al., 2003, El-
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Khamisy et al., 2005, Debethune et al., 2002). However, arguably the most important 
finding came with the identification that mutations in TDP1 (A1478G) are the causative 
factor in the autosomal recessive disorder spinocerebellar ataxia with axonal neuropathy 
1 (SCAN1) (Takashima et al., 2002). It was found that this mutation in TDP1 caused a 
change in the active site of the enzyme resulting in a loss of function that produces 
SCAN1 (Takashima et al., 2002, Raymond et al., 2004).  
 
1.3.2 Spinocerebellar ataxia with axonal neuropathy 1 
 
Identification of SCAN1 was established with the mutational analysis that characterised 
the A1478G mutation in TDP1 as being responsible for causing this disease in a large 
Saudi Arabian family (Takashima et al., 2002). Discovery of this mutation in TDP1 
came as a result of members of this family displaying a co-occurrence of 
spinocerebellar ataxia and peripheral neuropathy, but no indication of mutations in 
genes that had already been associated with ataxia and neuropathy (Takashima et al., 
2002). All members of the family with this disease had normal intelligence, but 
accompanying the ataxia and neuropathy was mild cerebellar atrophy with 
hypercholesterolemia and hypoalbuminemia (Takashima et al., 2002). As the number of 
diagnosed individuals was relatively low further studies surrounding this disease were 
limited, therefore when a Tdp1 -/- mouse was developed the opportunity for greater 
insight into the role of TDP1 in vivo was presented (Katyal et al., 2007). In these mice a 
mutation in the Tdp1 gene caused the subsequent protein to be unstable which 
effectively resulted in a loss of function (Katyal et al., 2007). Although the mutation in 
these mice was not exactly the same as in the SCAN1 patients the phenotype of these 
animals was very similar (ataxia, hypoalbuminemia etc.), which made them the ideal 
model for studying the role of TDP1 in vivo (Katyal et al., 2007). It was found that in 
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cerebellar neurons and primary astrocytes in these mice SSBs persisted and were 
unrepaired in comparison to wild type controls, which led to an age-dependent 
cerebellar atrophy as a consequence (Katyal et al., 2007). This demonstrates 
significance of DNA repair enzymes in normal cellular functioning and how a slight 
alteration in the interactions between enzymes associated with DNA can have drastic 
effects on the whole body level. 
 
1.3.3 Relationship with topoisomerase 1 
 
Although the function of TDP1 has been discussed the mechanism of formation of the 
DNA-TOP1 lesions has yet to be explained as has the history behind the identification 
of topoisomerases. The first topoisomerase, named protein ω at the time, was identified 
in Escherichia coli and was found to relax DNA from its superhelical structure in these 
organisms (Wang, 1971). From this a variety of topoisomerases have been characterised 
with several functions that alter the structure of DNA in preparation for transcription 
and replication (Vos et al., 2011). Although many different topoisomerases have been 
identified one characteristic that remains for all is that scission of DNA by these 
enzymes is mediated by a nucleophilic tyrosine (Vos et al., 2011). Furthermore, all 
topoisomerases are classified within two groups, type I and type II, and are subdivided 
within these groups into subtypes A, B, and C depending on sequence similarity 
between different topoisomerases and/or structural similarities that may exist between 
proteins (Vos et al., 2011). 
 
For type IA topoisomerases DNA is incised on one strand and the second strand is 
passed through the gap of this intermediate before the first strand is resealed, which 
altogether relaxes supercoiled DNA (Tse et al., 1980). In contrast type IB, in which 
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TOP1 belongs, and IC topoisomerases nick a strand of DNA and rotate this strand 
around the other before resealing takes place (Koster et al., 2005). The difference 
between type IB and IC topoisomerases comes in the structure of these enzymes and 
that type IC topoisomerases are not found in eukaryotes (Slesarev et al., 1993). Type 
IIA topoisomerases function in a similar way to type IA topoisomerases with the most 
notable difference being that in type IIA both strands of DNA are cleaved whereas in 
type IA only one strand is broken (Liu et al., 1980). A second class of type II 
topoisomerases exists (type IIB), however the exact mechanism by which this group of 
topoisomerases functions remains to be elucidated (Vos et al., 2011). 
 
The focus of this thesis involves TOP1, which has a relationship with TDP1 in that it is 
removed from DNA by this enzyme, as discussed earlier (Yang et al., 1996). Lesions 
where TOP1 becomes covalently bound to DNA can occur when TOP1 collides with 
DNA or RNA polymerases or when TOP1 incises DNA in close proximity to another 
form of DNA damage; resulting in this enzyme being covalently linked to the 3’ end of 
the DNA substrate (Caldecott, 2008). Figure 1.6 illustrates one mechanism by which 








Figure 1.5. The mechanism of formation of DNA-TOP1 lesions, and repair by TDP1. 
(A) DNA or RNA polymerases can collide with TOP1 resulting in the protein being 
covalently bound to the 3’ end of the DNA by a phosphotyrosine bond, which requires 
TDP1 to act in cleaving this bond seen in (B). Once the topoisomerase has been 
removed by TDP1 the status of the 3’ end of DNA at the (SSB) is 3’ phosphate, which 
requires action of a phosphatase (C) to restore the 3’ end to OH in preparation for re-
ligation by a DNA ligase (D) (adapted from Caldecott. 2008).  
 
Figure 1.6 demonstrates the importance of TDP1 to repair of DNA-TOP1 lesions and 
with the identification of a mitochondrial form of TOP1 (TOP1MT) the possibility that 
TDP1 may function in the mitochondrion was implied (Zhang et al., 2001). 
 
1.3.4 Mitochondrial topoisomerase 1 
 
The first indication of topoisomerase activity in mitochondria was discovered in rat 
liver mitochondria and the enzyme activity was found to be distinct from the activity of 
nuclear TOP1 (Fairfield et al., 1979). However, it was not for another twenty years 
before the actual gene encoding TOP1MT was found, which was established as a 
paralog of the nuclear TOP1 and contained a mitochondrial targeting sequence (Zhang 
et al., 2001, Zhang et al., 2007). With this finding it may have been assumed that much 
of the substrate specificity and mode of activity characteristics for TOP1MT were the 
same as for the nuclear TOP1; however this was proposed not to be true with a study 
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involving alternative localisation of both forms of the topoisomerase (Dalla Rosa et al., 
2009). In this study TOP1MT was overexpressed and targeted to the nucleus, and TOP1 
was overexpressed and targeted to mitochondria with controls including overexpression 
of each enzyme in their correct organelle (Dalla Rosa et al., 2009). The results showed 
that with expression of each enzyme to the opposite organelle the activity of both 
topoisomerases was not seen or greatly reduced, and when TOP1 was targeted to 
mitochondria mtDNA depletion was observed (Dalla Rosa et al., 2009). This suggests 
that the substrate specificity and/or structure of the catalytic subunit of each enzyme is 
different meaning that assumptions of TOP1MT activity based on information regarding 
TOP1 should be made with caution (Dalla Rosa et al., 2009). Despite this it has been 
possible to identify the binding sites of TOP1MT within the mitochondrial genome as 
including an area of the displacement loop (D-loop) and a region adjacent to this 







Figure 1.6. The binding sites of TOP1MT on mtDNA. This figure demonstrates that 
TOP1MT binds to a region of mtDNA adjacent to and including part of the D-loop 
(adapted from Zhang and Pommier, 2008, 
http://www.mitomap.org/MITOMAP/mitomapgenome.pdf). 
 
All together the results indicating that mitochondria contain their own topoisomerase 
illustrates how mechanisms surrounding the regulation of mtDNA are more intricate 
than initially thought, which leaves the possibility for finding further information on 
factors that are involved with this genome. 
 
1.4 Overall aims of study 
 
The overall aim of this study was to determine whether TDP1 was present and active in 
mitochondria and if so exactly what role this enzyme has in mtDNA repair, which was 
covered by asking the following questions: 
 Is TDP1 present and active in the mitochondrion? 
 Is TDP1 essential in mtDNA repair and cell survival? 





It was also determined that if TDP1 was found to be present and active in mitochondria 
the protein associations of this enzyme would be assessed by asking: 
 
 Does phosphorylation of amino acid 81 in TDP1 promote association with 
mitochondrial DNA ligase IIIα? 
 
 
It was anticipated that by using these questions as a basis to study TDP1 it would be 
possible to delineate the role of this enzyme in mitochondria, providing greater insight 





















Chapter 2. General materials and methods 
 
2.1 Materials  
2.1.1 Chemicals and reagents 
 
All reagents used for the experiments presented in this thesis were supplied by Sigma-
Aldrich
®
, unless stated otherwise. 
 
2.1.2 Bacterial strains 
 
 α-Select Competent Cells (Bioline): 
 
Bacterial strain used to transform cloned DNA into bacteria in preparation for 
experiments with mammalian cell lines. 
 
2.1.3 Mammalian cell lines 
 
 Flp-InTM T-RexTM HEK293 cells (life technologies): 
 
Mammalian cell line containing a Tet repressor and Flp Recombination Target (FRT) 
site that allows stable integration and tetracycline-inducible expression of a gene of 
interest, from a specific locus within the genome of the host. Stable integration of the 




 HEK293 host genome at the same location 





 FD105 M21 fibroblasts 
 
These cells were derived from an ataxia oculomotor apraxia-1 (AOA1) patient and 
immortalised using human telomerase reverse transcriptase (hTERT). The cells were 
then stably transfected with a plasmid encoding and expressing aprataxin (APTX); the 
protein involved in causing AOA1 when its function is compromised as a result of 
mutated APTX (El-Khamisy et al., 2009). 
 
 SCAN1 lymphoblastoids 
 
These cells were taken from a SCAN1 patient and immortalised using Epstein-Bar virus 
(EBV) (performed by Dr El-Khamisy). These cells contained the A1478G mutation in 
TDP1 that causes SCAN1 (Takashima et al., 2002). 
 
2.1.4 Mouse strains 
 
 Tdp1 -/- mice 
These mice were generated from C57 black 6 (C57BL/6) mice and contained a single 
substitution at nucleotide 1369 in Tdp1 causing premature termination of transcription 
and loss of stability of TDP1. Heterozygous Tdp1 +/- mice were kept on an outbred 


















(Clontech Laboratories Inc.) 
Contained the TOP1mt and TOP1mt
Y559A
 genes to be 




 HEK293 cells. 
Vector contained gene for resistance to Kanamycin. 










 HEK293 cells. Vector contained a gene for 
resistance to Ampicillin. 
pcDNA5/FRT/TO  
(life technologies) 
Vector was used for cloning with TOP1mt and 
TOP1mt
Y559A





 HEK293 cells. Vector contained a gene 
for resistance to Ampicillin. 
pOG44 
(life technologies) 





HEK293 cells along with pcDNA5/FRT/TO and desired 




Vector contained a gene for mitochondrially targeted 
PARN. The PARN gene was removed by restriction 
digest, leaving the mitochondrial presequence from 
ATP9 of Neurospora crassa behind. This would then be 










 HEK293 cells. The vector also contained a gene 




2.1.6 DNA oligonucleotides 
 
























pcDNA5 (F) GTTTAGTGAACCGTCAGATCG N/A Plasmid 
sequencing 




B2M (F) CCAGCAGAGAATGGAAAGTCAA N/A qRT-PCR 










ND1 (F) CCCTAAAACCCGCCACATCT  N/A qRT-PCR 


















































































*Bases in bold represent restriction sites introduced by the primers into each gene. With exception to 
probes for qRT-PCR all oligonucleotides were supplied by Eurogentec.  
 
2.1.7 siRNA duplexes 
 






















*Supplied by OriGene. All contained 2x dT 3’ end overhangs. 
 
 
2.2 General methods 
 
 
2.2.1 Bacterial culture 
 
i) Transformation of chemically competent cells 
 
α-select bacterial cells (Bioline Reagents Ltd.), kept in 200µl aliquots at -80oC, were 
thawed on ice and 40µl was transferred to pre-chilled 1.5ml reaction tubes per 
transformation reaction. Any remaining cells from the aliquot were replaced at -80
o
C, 
but freeze-thaw cycles never exceeded more than 1 per aliquot. Between 1-4µl of 
ligation reaction for molecular cloning, or 10ng for purified plasmid DNA was added to 
40µl α-select bacterial cells for each sample and incubated on ice for 30 mins. During 
this time Super Optimal Broth with Catabolite repression (SOC) media was pre-warmed 
to 37
o
C. Cells were heat pulsed at 42
o
C for 45 secs before being incubated on ice for 2 
mins, followed by addition of 900µl SOC to each sample and incubation for 1 hour at 
37
o
C with rotary shaking. The cell suspension was then plated on agar plates with the 
desired antibiotic resistance and incubated overnight at 37
o
C. Plates displaying colonies 




10mM  NaCl  
2.5mM KCl  
10mM  MgCl2  
10mM  MgSO4  
20mM  Glucose 
0.5%  Yeast Extract  
2%  Tryptone 
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ii) Plasmid DNA isolation from bacteria 
 
Bacterial cells containing a desired plasmid for purification were grown overnight at 
37
o
C in 5ml Luria Bertani broth (LB) medium containing the correct antibiotic 
resistance. Cells suspensions were centrifuged at 1500xg for 15 mins and supernatant 
discarded before plasmid purification was performed using the GeneJET™ Plasmid 
Miniprep Kit (Fermentas) and the manufacturer’s instructions.  
 
LB medium 
1.0%  NaCl 
1.0%  Tryptone 
0.5%  Yeast Extract 
Adjust to pH 7.0 with NaOH 
 
 
2.2.2 Tissue culture 
 
i) Cell storage 
Cells were incubated at 37
o
C with humidified 5% CO2 in sterile conditions in filter-
topped flasks or 6-well plates. 
 
ii) Cell maintenance 
 
When cells reached 80-90% confluence during general culturing (i.e. not an experiment 
to gather data) growth media was removed and cells were removed from their 75cm
2
 
flask using 5ml PBS/1mM EDTA, or 5ml PBS/1mM EDTA+1x trypsin in the case of 
fibroblasts. The cell suspension was neutralised with an equal volume of pre-warmed 
supplemented growth media before being centrifuged at 260xg for 4 mins. The 
supernatant was discarded and the cell pellet was resuspended in 1ml pre-warmed 
supplemented growth media before 100µl (at least 200µl for fibroblasts) of the 
suspension was replaced in its original flask with 15ml supplemented growth media. 
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Once split three times cells were placed in a fresh 75cm
2





 HEK293 cells the correct concentrations of 
hygromycin (life technologies) and/or blasticidin (Melford) were added. 
 
iii) Freezing cells for long term storage 
 
To freeze cells for long term storage cell lines were grown to 70-80% confluence in 
75cm
2
 flasks and harvested using 5ml PBS/1mM EDTA or 5ml PBS/1mM EDTA+1x 
trypsin for fibroblasts. The cell suspension was neutralised using and equal volume of 
supplemented growth media before being centrifuged at 260xg for 4 mins. The 
supernatant was discarded and the cell pellet carefully resuspended in 1ml 10% DMSO 
in FBS before being transferred to a 2ml cryovial and placed a -80
o
C in a freezing 
container with isopropanol for 24 hours. After this time the cells could be transferred to 
a container with liquid nitrogen.  
 
iv) Thawing cells from long term storage 
 
Cells stored in liquid nitrogen were removed and thawed in their cryovials in a 37
o
C 
water bath. The 1ml cell suspension was then transferred to 5ml pre-warmed 
supplemented growth media and centrifuged at 260xg for 4 mins. The cell pellet was 
then resuspended in 1ml pre-warmed supplemented growth media and transferred to a 
75cm
2
 flask with 15ml pre-warmed supplemented growth media. Cells were incubated 






v) Cell counting 
 
Cell counting was performed using an improved Neubauer Haemocytometer 
(Hawksley) using 100µl cell suspension mixed with 100µl 50% Trypan Blue/PBS. Cells 
that were unstained by the Trypan Blue were counted in each quadrant of one side of the 
cell counter. The total number was then divided by 4 (for each quadrant) and then 
multiplied by 2 (to account for dilution in 50% Trypan Blue/PBS). This number was 
then multiplied by 10000 to give the total number of cells per ml of cell suspension. The 
process of counting was then repeated using the quadrants on the opposite side of the 
cell counter to verify that the number of cells were the same on either side. 
 
vi) Mycoplasma testing and treatment 
 
Every 6 weeks mycoplasma testing was carried out using MycoAlert™ Mycoplasma 
Detection Kit (Lonza) as per the manufacturer’s guidelines. If mycoplasma was present 
treatment with Plasmocin
TM
 (InvivoGen) was carried out for 2 weeks or until 
undetectable. 
 
vii) Transformation of Flp-InTM T-RexTM HEK293 cells 
 





 HEK293 system (life technologies) was used. Cells were seeded 
at 3x10
5
 cells in wells of a 6-well plate in 2ml supplemented DMEM for the desired 
plasmid, and a negative and positive control (pcDNA5/FRT/TO without any gene 
integration through cloning). Once cells were adhered to the well surface 500µl DMEM 
was mixed carefully with 1µl pOG44 (1µg), 1µl of the desired plasmid (100ng), and 
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10µl SuperFect Transfection Reagent (Qiagen) in 1.5ml reaction tubes. The same 
reaction was also set up with pcDNA5/FRT/TO alone as a positive control, and another 
reaction without any pcDNA5/FRT/TO vector was also set up. The reactions were 
incubated at room temperature for 10 mins before being applied to the cell containing 
wells once the 2ml supplemented DMEM had been removed. Cells were incubated as in 
2.2.2 (i) for 2.5 hours before the vector/DMEM mix was removed and replaced with 
2ml supplemented DMEM. Cells were then incubated for 48 hours before selection of 
successfully transformed cells began with the use of hygromycin B (life technologies) at 
100ng/ml final concentration and blasticidin S (Melford) at 10ng/ml final concentration. 
 
viii) Poly-L-ornithine treating flasks 
 
To aid in adhering cells the surfaces of 25cm
2
 flasks for use in transient siRNA 
transfections 1.5ml Poly-L-ornithine was added to each flask required for the 
experiment and then incubated as in 2.2.2 (i) for 30 mins. After this time the Poly-L-
ornithine was removed and flask surfaces were washed with 2ml PBS before 5ml 
supplemented growth media was added along with the desired cell number. 
 
2.2.3 Protein manipulation 
 
i) Isolation of cytoplasmic protein from human cell lines 
 
Cells grown in 6-well plates or 25cm
2
 flasks were harvested using 0.5ml and 2ml 
PBS/EDTA, respectively, before being neutralised in an equal volume of supplemented 
growth media. Cells were centrifuged at 260xg for 4 mins and the resulting supernatant 
was discarded. Cell pellets from 6-well plates were resuspended in 50µl pre-chilled lysis 
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buffer, and cell pellets from 25cm
2
 flasks were resuspended in 150µl pre-chilled lysis 
buffer. Samples were then vortexed for 30 secs and centrifuged at 2000xg for 4 mins at 
4
o
C. The supernatant was then transferred to fresh pre-chilled 1.5ml reaction tubes and 
used to quantify protein concentration by Bradford analysis, or snap frozen in liquid 












1x Protease inhibitor mix (Roche Applied Science)* 
 




ii) Isolation of mitochondria from human cell lines 
 
Cells were grown in 300cm
2
 flasks (1-6 flasks depending on quantity of mitochondria 
required) until 80-90% confluent, and were harvested by removing growth media 
followed by addition of 15ml 1mM EDTA/PBS or 15ml 1mM EDTA/PBS+1x trypsin 
for fibroblast cells. The cell suspension was neutralised with supplemented growth 
media and centrifuged at 260xg for 4 mins before the subsequent pellet was 
resuspended in 2ml ice cold homogenisation buffer. All steps from this point were 
carried out at 4
o
C. The cell suspension was then transferred to a 2ml glass/teflon 
homogeniser (Glas-Col) for HEK293 cells or glass/glass homogeniser for fibroblast 
cells. The cell suspension was subjected to 20 homogenisation passes before being 
centrifuged at 400xg for 10 mins. The supernatant was transferred to a new tube and the 
pellet was resuspended in 2ml homogenisation buffer for the homogenisation and 
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centrifugation steps to be repeated twice more. All supernatants were centrifuged at 
12000xg for 10 mins and supernatants discarded. Pellets were combined in 100µl 
homogenisation buffer and centrifuged at 12000xg once again. This pellet was 
resuspended in 500µl homogenisation buffer to wash and centrifuged at 12000xg for 
another 10 mins. The pellet could then be snap frozen in liquid nitrogen and stored at -
80
o
C, or resuspended in 100-500µl homogenisation buffer (without BSA or PMSF) if 
purification was desired. 
Homogenisation buffer 
0.6M Mannitol 
10mM Tris-HCl pH 7.4 
1mM EGTA 
1mM PMSF 
0.1% BSA  
 
 
iii) Isolation of mitochondria from mouse brain 
 
Once the mouse brain was harvested it was placed immediately in a beaker containing 
20ml isolation medium. Using pre-chilled scissors the brain was cut into small pieces 
that were then washed by carefully decanting the isolation medium followed by addition 
of another 10ml isolation medium. The brain suspension was then transferred to a 40ml 
Dounce homogeniser (Fisher Scientific) and subjected to 8 homogenisation passes 
before being transferred to a pre-chilled SS34 centrifuge tube and centrifuged for 3 mins 
at 2000xg using the Sorvall RC-5C. The supernatant was decanted into a clean pre-
chilled SS34 tube and centrifuged at 12500xg for 10 mins. The supernatant was 
removed and the pellet resuspended in 1ml 3% ficoll medium using a pre-chilled glass 
rod being careful not to disturb any blood spot in the pellet. The suspension was then 
carefully layered onto 10ml 6% ficoll medium and centrifuged at 11500xg for 15 mins. 
The supernatant was decanted sharply and the remaining pellet was resuspended in 
10ml isolation medium before being centrifuged at 11500xg for a further 10mins. The 
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pellet could then be snap frozen in liquid nitrogen and stored at -80
o
C or could be 
purified if desired. 
Isolation medium    Ficoll medium 
250mM Sucrose    240mM Mannitol 
10mM   Tris-HCl pH 7.4   60mM   Sucrose 
0.5mM  EDTA    50µM    EDTA 
      10mM   Tris-HCl pH 7.4 
6% or 3% Ficoll (added immediately                  
before use) 
 
iv) Mitochondrial purification 
 
Mitochondrial purification was carried out in order to remove any nuclear and/or 
cytosolic contaminants following mitochondrial isolation from human cells or from 
mouse brain. This was performed by initially treating with 1U RNase free DNaseI 
(Epicentre®) per 5mg mitochondrial protein at room temperature for 15 mins 
supplemented with 10mM MgCl2. Following this 20µg RNase free Proteinase K (Life 
Technologies) was added per 5mg mitochondrial protein and incubated on ice for 30 
mins. The reaction was stopped with addition of 1mM PMSF (final concentration) 
before being centrifuged at 12000xg for 10 mins. Mitochondria were washed with 500µl 
homogenisation buffer containing 1mM PMSF and centrifuged as previous. 
v) Mitochondrial localisation assay 
 




 HEK293 system (life 
technologies) were localised to mitochondria a localisation assay was performed using 
Proteinase K (life technologies). Mitochondria that had been isolated from appropriate 
cell lines as described in 2.2.3 (ii) were quantified by Bradford analysis as in 2.2.3 (vi) 
and transferred in homogenisation buffer to 3 1.5ml reaction tubes for each cell line in 
100µg per tube. The following reactions were set up with a total volume of 50µl: 
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Table 2.4. Reaction set up for mitochondrial localisation assay. 
 
 Untreated Proteinase K 
alone 
Proteinase K + Triton X-
100 
Mitochondria 100µg 100µg 100µg 
Proteinase K - 4µg 4µg 
Triton X-100 - - 1% 
 
 
The Proteinase K was stopped using 5µl 10mM PMSF and then mixed with an equal 
volume of 2x dissociation buffer, snap frozen in liquid nitrogen, and stored at -80
o
C to 
be used for SDS-PAGE and western blot analysis. The use of 4µg Proteinase K would 
prove to be too much and so this experiment was repeated for the 
HEK293/TOP1mt/FLAG and HEK293/TOP1mt
Y559A
/FLAG cell lines with 0.5µg and 





/FLAG cell lines. 
 
2x dissociation buffer  
0.125M Tris-HCl, pH 6.8   
4%    SDS      
0.15M   DTT    
15%    Glycerol    
0.01%    Bromophenol blue 
0.01%    Benzonase (Novagen) 
 
 
vi) Protein quantification through Bradford assay 
 
The Bradford assay was used to quantify protein within samples and this was performed 








Table 2.5. Reaction set up to make standard curve for Bradford analysis on the 
microplate reader Elx 800 (BIO-TEK). 
 
 BSA (µg) 
 0 2 5 10 15 20 




200µl 200µl 200µl 200µl 200µl 200µl 
BSA 
(1µg/µl) 
- 2µl 5µl 10µl 15µl 20µl 
 
 
Once this had been set up, 1µl of each sample for protein quantification was then mixed 
in 799µl H2O and 200µl Bradford reagent before 200µl of all reactions were added to 
two wells of a 96-well plate for each sample. The plate was then put into the microplate 




To prepare samples for western blotting protein was separated by SDS-PAGE. Protein 
samples were transferred to 1.5ml reaction tubes in the desired concentration and then 
mixed with and equal volume of 2x dissociation buffer. Each reaction was then heated 
at 95
o
C for 3 mins before being centrifuged at 12000xg for 2 mins and loaded onto the 
gel. For the results outlined in this thesis either 10% or 12% polyacrylamide resolving 
gels were used along with a 4% stacking gel in every case. The following tables 














Table 2.6. 4% SDS-PAGE stacking gel reagents and volumes. 
 




0.625ml 1.25ml 1.875ml 2.5ml 
0.5M Tris-HCl pH 6.8 1.25ml 2.5ml 3.75ml 5ml 
H2O 3.025ml 6.05ml 9.075ml 12.1ml 
10% SDS 50µl 100µl 150µl 200µl 
TEMED 5µl 10µl 15µl 20µl 
10% APS 50µl 100µl 150µl 200µl 
 
 
Table 2.7. 10% SDS-PAGE resolving gel reagents and volumes. 
 




1.665ml 3.33ml 4.995ml 6.66ml 
3.75M Tris-HCl pH 
8.5 
0.5ml 1ml 1.5ml 2ml 
H2O 2.725ml 5.45ml 8.175ml 10.9ml 
10% SDS 50µl 100µl 150µl 200µl 
TEMED 5µl 10µl 15µl 20µl 
10% APS 50µl 100µl 150µl 200µl 
 
 
Table 2.8. 12% SDS-PAGE resolving gel reagents and volumes. 
 




1.998ml 3.998ml 5.994ml 7.992ml 
3.75M Tris-HCl pH 
8.5 
0.5ml 1ml 1.5ml 2ml 
H2O 2.392ml 4.784ml 7.176ml 9.568ml 
10% SDS 50µl 100µl 150µl 200µl 
TEMED 5µl 10µl 15µl 20µl 
10% APS 50µl 100µl 150µl 200µl 
 
 
Once samples had been loaded onto the gel the were electrophoresed at 80V in 1x 
running buffer until the samples reached the resolving gel in which the voltage was set 
to 120V. A molecular weight marker (Thermo Scientific) was also run to determine the 
rate at which protein was moving through the gel and when it should be stopped. Once 
complete the gel could then be used for its desired purpose.  
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2x dissociation buffer  1x running buffer  
125mM Tris-HCl, pH 6.8  192mM Glycine   
4%    SDS    25mM   Tris-HCl pH 7    
0.15M    DTT    0.1%   SDS  
15%    Glycerol    
0.01%    Bromophenol blue   





viii) Western blotting 
 
Once SDS-PAGE was complete the gel was removed and transferred to 20ml 1x 
transfer buffer and incubated at room temperature with rocking for 10 mins to 
equilibrate. During this time a section of Immobilon transfer membrane (Millipore) was 
cut to an appropriate size to cover the SDS-PAGE gel, and then activated with 
incubation in 15ml Methanol for 30 secs with agitation. Once activated the membrane 
was placed in 20ml 1x transfer buffer and incubated with rocking until the 10 min 
incubation for the SDS-PAGE gel was complete. At this point 2 sections of 3mm 
chromatography paper (Whatman
TM
) were cut to an appropriate size in comparison to 
the gel/membrane and placed in a transfer cassette, followed by addition of the gel on 
top, then the transfer membrane, and lastly 2 more sections of 3mm chromatography 
paper. The cassette was then closed and placed into the transfer unit (Hoefer
®
 or Bio-
Rad), making sure the gel end of the cassette was closest to the cathode, and ≈1.5L 1x 
transfer buffer was added. The transfer unit was then placed in 4
o
C with a magnetic 
stirrer to aid circulation of the buffer before the transfer from gel to membrane was 
mediated at 100V or 500mA for 1.5 hours, or if 2 gels were run, 2 hours. Once the 
transfer was complete the membrane the membrane was washed in 1x TTBS for 10 
mins at room temperature with rocking before being blocked in 5% milk/TTBS for 1 
hour or overnight at 4
o
C with rocking. After blocking, membranes were washed 3 times 
in 1x TTBS and then exposed to the primary antibody, washed 3 times in 1x TTBS, and 
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then secondary antibodies (after another washing step) at the indicated concentration 
and indicated times as shown in tables 2.7 and 2.8. 
 
Table 2.9. Primary antibodies used for western blotting. 
 
Antibody Source Dilution in 5% 
milk/TTBS  














α β-Actin Mouse 1:10,000 1 20 42 
α COX I 
(Abcam) 
Mouse 1:1000 1 20 40 
α COX II 
(Abcam) 
Mouse 1:1000 1 20 24 





Rabbit 1:1000 overnight 4 51 
α NDUFA9 
(Abcam) 
Mouse 1:1000 1 20 35 
α Neu N 
(Cell 
Signalling) 
Rabbit 1:1000 overnight 4 46 
α TDP1 
(Abcam) 
Rabbit 1:1000 overnight 4 70 
α TOM 20 
(Santa Cruz 
Biotechnology) 
Rabbit 1:750 overnight 4 17 
α Porin 
(Abcam) 




Rabbit 1:1000 overnight 4 82 
 
 
Table 2.10. Secondary antibodies used for western blotting. 
 
Antibody Source Dilution in 5% 
milk/TTBS  









α mouse  
(Dako) 
Rabbit 1: 2000 1 20 
α rabbit  
(Dako) 






Once incubation with the secondary antibody was complete the membrane was washed 
3 time in 1x TTBS before being exposed to ECL Plus (GE Healthcare) for 5 mins 
followed by scanning and imaging using the Storm 850. The blot could then be analysed 
by using ImageQuant. 
1x transfer buffer   1x TTBS 
25mM Tris-HCl (pH 7.6)  50mM Tris-HCl (pH 7.6) 
192mM glycine   150mM NaCl 
20% methanol    0.05% Tween-20 
0.03% SDS 
 
2.2.4 DNA manipulation 
 
i) DNA amplification by polymerase chain reaction 
 
In order to amplify desired regions of DNA for cloning or to prepare samples for 
sequencing polymerase chain reaction (PCR) was carried out. This was performed by 
setting up PCR reactions in 0.2ml reaction tubes using the KOD polymerase kit 
(Novagen) in the following manner (negative and positive reactions were also set up): 
Table 2.11. Reagents of a standard PCR. 
 
Plasmid DNA (10ng) 1µl 
10x PCR Buffer 
20 mM Tris-HCl pH7.5 
0.5 mM DTT 
50 μg/ml BSA 
5µl 
10x dNTPs (2mM each) 5µl 
MgSO4 (25mM) 2µl 
Forward primer (10µM) 1µl 
Reverse primer (10µM) 1µl 
H2O 34µl 











Table 2.12. General PCR programme. 
 
Step Time Temperature (
o
C) Cycle number 











Final extension 10 mins 70 1 






Once the PCR programme was complete the samples could then be subjected to gel 
electrophoresis as described in 2.2.4. (iv). 
 
ii) Real-time polymerase chain reaction (qRT-PCR) to assess mtDNA copy 
number 
The copy number of mtDNA was assessed using qRT-PCR following 
expression/knockdown experiments in mammalian cells as described in chapter 4. In 
order to attain this data 10ng whole cell DNA from each experiment was mixed with the 
following reagents and oligonucleotides (table 2.13) in a 96-well plate in triplicate, and 
subjected to the qRT-PCR programme (table 2.14) in the StepOnePlus™ Real-Time 
PCR System. For validity of results samples using 100ng, 10ng, 1ng, 100pg, and 10pg 
DNA were also added to the reagents in table 2.13 in triplicate so that a standard curve 









Table 2.13. Reagents and oligonucleotides used per qRT-PCR reaction. 
 
Reagent Volume (µl) 
Taqman
®
 Universal Master Mix II (life 
technologies) 
10 
B2M (F) primer (10µm) (Eurogentec) 0.6 
B2M (R) primer (10µm) (Eurogentec) 0.6 
ND1 (F) primer (10µm) (Eurogentec) 0.6 
ND1 (R) primer (10µm) (Eurogentec) 0.6 
B2M FAM probe (life technologies) 0.4 








C) Time Cycle number 
50 2 mins 1 










Once the data had been gathered by the StepOnePlus™ Real-Time PCR System it was 
transferred to a Microsoft Excel 2010 folder where the critical threshold (CT) values 
from ND1 were subtracted by the CT value from B2M. The relative number of reads of 
ND1 to B2M could then be assessed by using 2
ΔΔCT
 on the ND1 minus B2M value. 
 
iii) Restriction digests of DNA 
 
Restriction digests were performed in molecular cloning to prepare PCR amplified 





 HEK293 cells. Restriction digests for experiments in this thesis were 
conducted using 1U BamHI, XhoI, NotI, and BssHII (all from New England Biolabs), 
which were incubated at 37
o
C overnight with the appropriate vector/DNA fragment. 
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Enzymes were inactivated by heat treating reactions at 70
o
C for 15 mins once digest 
was complete. 
iv) DNA ligation 
For ligation of vectors with these specific inserts ligation was carried out in 10µl 
reactions containing 50ng vector: 100ng insert. In these 1µl T4 DNA Ligase (New 
England Biolabs) was used with 1µl 10x ligase buffer (50mM Tris-HCl pH 7.5, 10mM 




v) Gel electrophoresis of DNA 
To separate products of DNA to determine whether PCR or restriction digest reactions 
were successful, samples were subjected to gel electrophoresis. For this gels were cast 
at 0.8% molecular grade agarose (Bioline) in 1x TAE containing 50ng/ml ethidium 
bromide. When DNA was to be extracted from the gel following electrophoresis, gels 




 agarose (Lonza) in 1x TAE containing 50ng/ml 
ethidium bromide. Samples were then loaded onto the appropriate gel with 5µl 1kb 
DNA ladder (New England Biolabs) and electrophoresis was carried out by applying 
70V for 45 mins. Images of the gel could then be taken and any further manipulations 







vi) Phenol/chloroform extraction of DNA constructs from agarose 
  
Following some PCR and restriction digest reactions it was necessary to remove DNA 
of the correct molecular weight for further experiments. This was achieved by cutting 




 agarose (Lonza) (described above), 
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transferring it to a 1.5ml reaction tube, and melting it a 68
o
C. An equal volume of TE 
buffer was then added followed by addition of an equal volume of phenol pH 7.9 and 
vortexing for 30 secs. The sample was then centrifuged at maximum speed in a 
microcentrifuge for 3mins before the upper aqueous phase was transferred to a fresh 
1.5ml reaction tube. An equal volume of phenol was added and the vortexing/centrifuge 
step was repeated with the upper aqueous phase being transferred to a new 1.5ml 
reaction tube again. An equal volume of 1:1 phenol: chloroform (24 parts chloroform, 1 
part isoamyl alcohol) was then added and the vortexing/centrifuge step was repeated 
before an equal volume of chloroform was added followed by vortexing/centrifuging 
once more. The upper aqueous phase was taken and placed into a fresh 1.5ml reaction 
tube and incubated on ice for 15 mins, and then centrifuged at 16,000xg for 15 mins at 
4
o
C. The upper aqueous phase was transferred to a new 1.5ml reaction tube with 10% 
3M NaOAc, 1µl linear acrylamide, and 2 volumes of 100% ethanol. This reaction was 
then incubated overnight at -20
o
C before being centrifuged at 16,000xg for 30 mins, the 
supernatant discarded and tube air dried, followed by the DNA being resuspended in 
20µl H2O. 
TE buffer 
10mM Tris-HCl pH 8 
1mM EDTA 
 
vii) Phenol/chloroform extraction of DNA from mammalian cells in culture 
 
To extract DNA from mammalian cells in culture the cells were harvested with 
PBS/EDTA and centrifuged at 260xg before the supernatant was discarded. The cell 
pellet was then resuspended in 200µl TE buffer, 20µl 20% SDS, and 25µl Proteinase K 
(20µg/µl) (life technologies). The reaction was then incubated overnight at 37
o
C with 
shaking, followed by addition of 245µl phenol pH 7.9, vortexing for 30 secs and 
centrifuging at maximum speed in a microcentrifuge for 3 mins. The upper aqueous 
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phase was transferred to a fresh 1.5ml reaction tube and an equal volume of phenol was 
added and the vortexing/centrifuge step was repeated with the upper aqueous phase 
being transferred to a new 1.5ml reaction tube again. An equal volume of 1:1 phenol: 
chloroform (24 parts chloroform, 1 part isoamyl alcohol) was then added and the 
vortexing/centrifuge step was repeated before an equal volume of chloroform was added 
followed by vortexing/centrifuging once more. The upper aqueous phase was taken and 
placed into a fresh 1.5ml reaction tube and 10% 3M NaOAc, 1µl linear acrylamide, and 
2 volumes of 100% ethanol were added. This reaction was then incubated overnight at -
20
o
C before being centrifuged at 16,000xg for 30 mins, the supernatant discarded and 
tube air dried, followed by the DNA being resuspended in 20µl H2O. 
 
viii) Nucleic acid quantification 
 
Quantification of DNA was performed using a ND1000 spectrophotometer (Labtech) at 
OD260 for duplex DNA (50µg/OD260) following the manufacturer’s guidelines. Using 




ix) DNA sequencing 
 





 HEK293, sequencing was carried out. This service was kindly provided 






Chapter 3. Is TDP1 present and active in the mitochondrion? 
3.1 Introduction 
As outlined in 1.3.2 the mutation in TDP1 (A1478G) causes a conversion of amino acid 
493 from histidine to arginine, thus modifying the active site of TDP1 resulting in a 
loss-of-function (Takashima et al., 2002). This mutation affects cerebellar neurons 
which is manifested in SCAN1; a rare autosomal recessive neurodegenerative disorder 
(Takashima et al., 2002). A common feature of mitochondrial disorders is 
spinocerebellar ataxia, alluding to the possibility that a loss of function mutation in 
TDP1 could have an effect in mtDNA repair and contribute to the phenotype observed 
in patients (Stumpf and Copeland, 2011).  
The observation that TDP1 resolves DNA-TOP1 complexes independently of DNA 
replication demonstrated the importance of TDP1 in neurons as they are post-mitotic 
(El-Khamisy et al., 2005). Generation of Tdp1 -/- mice showed that TDP1 was required 
in neural homeostasis and that these mice displayed a very similar phenotype to that 
observed in SCAN1 patients (Katyal et al., 2007). In order to investigate whether TDP1 
was present and active in mitochondria a collaboration was set up between our own 
group and a group leader at the University of Sussex; Dr SF El-Khamisy. Being an 
author on several papers regarding TDP1, and having access to SCAN1 patient cell 
lines as well as the Tdp1 -/- mice, it was anticipated that this collaboration would help in 
our shared objective.  
Activity assays were used as a means to determine whether TDP1 was present and 
active in mitochondria from fibroblasts, a SCAN1 patient cell line, and from Tdp1 -/- 
mouse brain. Once these experiments had been conducted it was hoped that a sound 
conclusion could be made to the question:    
52 
 
Is TDP1 present and active in the mitochondrion?   
3.2 Methods 
3.2.1 In vitro activity assay using mitochondrial extracts 
 
To determine whether TDP1 was active in mitochondria an in vitro assay was used with 
mitochondrial extracts from both human cells and mouse brain. The assay employs a 
duplex DNA substrate composed of three oligonucleotides of which one (18mer) is 
radiolabelled and has a 3’ phosphotyrosine. This phosphotyrosine is intended to mimic 
the covalent bond in vivo that is formed between DNA and TOP1. Under this 
circumstance TDP1 cleaves the phosphotyrosine bond, thus removing TOP1 from the 3’ 
end of DNA allowing further processing by a phosphatase before re-ligation can 
commence. In this in vitro assay the phosphotyrosine bond of the 18mer is cleaved, 
removing tyrosine and resulting in a 3’ phosphate. If the duplex substrate is then 
subjected to denaturing gel electrophoresis the radiolabelled 18mer oligonucleotide 
without tyrosine has increased electrophoretic mobility, which then allows exposure to a 
phosphorscreen and scanning by Storm 8500 to confirm this result. Therefore, if TDP1 
is present and active within a sample the tyrosine should be cleaved which lowers the 
molecular weight of the substrate resulting in further migration on the denaturing gel. 
 
Mitochondria from human cells were isolated as described in 2.2.3 (ii), and from mouse 
brain as in 2.2.3 (iii). Both human and mouse mitochondrial extracts were purified as in 
2.2.3 (iv) before the activity assay was performed. Three oligonucleotides were used for 
this assay: 
18-mer  5’-TCCGTTGAAGCCTGCTTT-P-Y-3’ 
25-mer  5’-GACATACTAACTTGAGCGAAACGGT-3’  
43-mer  3’-TAGGCAACTTCGGACGAAACTGTATGATTGAACTCGCTTTGCC-5’ 
 
(25-mer complimentary to nucleotides 18-43 of 43-mer, and 18-mer complimentary to nucleotides 1-18 of 43-




The 18-mer (Midland Scientific), with a 3’-phosphotyrosine terminus (18-Y) to imitate 
DNA lesion in vivo, was radiolabelled by phosphorylation using T4 PNK (New England 
Biolabs) in 25µl reactions containing 5µCi (γ-32P) ATP at 7000Ci/mM for 1 hour at 
37
o
C. T4 PNK was inactivated by incubation at 68
o
C for 10 mins. Following removal of 
unincorporated nucleotides the three oligonucleotides were annealed in equimolar 
concentrations at 55
o
C and then kept on ice. Mitochondrial samples were lysed using 1x 
lysis buffer on ice for 15 mins before being centrifuged at 10,000xg for 5 mins at 2
o
C 
before the supernatant was transferred to a clean reaction tube. Mitochondria and 
control whole cell extract containing nuclear protein were quantified by Bradford 
analysis as described in 2.2.3 (vi). In 10µl reactions the desired amount of protein 
extract was incubated with 25nM substrate for 1 hour at 37
o
C in 1x reaction buffer. 
Reactions were stopped with addition of 1x loading buffer before being heated at 90
o
C 
for 10 mins and fractionated by denaturing electrophoresis. Once ran, the gel was 
exposed to a phosphorscreen and results visualised using the Storm 8500 and 
ImageQuant to assess relative conversion rates of 3’-phosphotyrosine to 3’-phosphate. 
 
1x lysis buffer  1x reaction buffer  1x loading buffer 
20mM Tris-HCl pH7.5 25mM Hepes pH8  44% deionized formamide 
10mM EDTA   130mM KCl   2.25mM Tris-borate 
1mM EGTA   1mM DTT   0.05mM ETDA 
100mM NaCl       0.01% xylene cyanol 
1% Triton X-100      1% bromophenol blue 




3.3.1 TDP1 is present and active in fibroblast mitochondrial extracts 
Mitochondria isolated from FD105 M21 fibroblasts were used for the activity assay 
described in 3.2.1 as well as whole cell extract containing nuclear protein as a control. 
Reasons for using this cell line are outlined in the discussion of this chapter. The results 






Figure 3.1. Activity assay to assess TDP1 presence and activity in fibroblast 
mitochondria. Mitochondria were prepared from FD105 M21 fibroblasts as described in 
2.2.3 (ii) and purified as in 2.2.3 (iv), and whole cell protein was isolated as in 2.2.1 (i). 
Whole cell lysate containing nuclear protein (CL) and mitochondrial protein (M) 
(10µg) were incubated with radiolabeled duplex substrate and subsequent repair 
products fractionated by denaturing electrophoresis then exposed to phosphorscreen as 
described in 3.2.3. Duplex substrate without any protein addition (-) was also 
fractionated as a control. (A) Schematic to demonstrate the radiolabeled duplex 
substrate used in the assay as described in 3.2.3. (B) Substrate following denaturing 
electrophoresis to indicate whether TDP1 is active in both mitochondrial and nuclear 
protein. The 18-Y and 18-P to the right of B describe 18-mer with 3’-phosphotyrosine 
terminus and 3’-phosphate terminus, respectively. 
 
The results shown in figure 3.1 B demonstrate TDP1 presence and activity in 
mitochondria, which can be seen in lane 3 by the increased electrophoretic mobility of 
the 18mer oligonucleotide after incubation with mitochondrial extracts from FD105 
M21 fibroblasts. This result is verified in lane 2 as there is similar migration of the 
substrate following incubation with control whole cell lysate containing nuclear protein 
in which TDP1 is certainly present. In lane 1, substrate without any protein addition was 
also fractionated on the gel to illustrate the electrophoretic mobility of the 18mer 







3.3.2 TDP1 is active in LCL mitochondrial extracts 
 
Having established TDP1 was present and active in FD105 M21 fibroblasts it was then 
decided to repeat the same activity assay using extracts from wild type and SCAN1 
patient lymphoblastoid cell lines. The aim of this experiment was to determine the 
relative activity of TDP1 in mitochondria in comparison to whole cell lysate and to also 
confirm that the A1478G mutation in TDP1 affected activity in mitochondria; thus 
demonstrating TDP1 in mitochondria is encoded by the same gene as TDP1 in the 
nucleus. As earlier the same activity assay was carried out (described in 3.2.1) using the 
same duplex substrate, which is illustrated in figure 3.2 A. Mitochondrial and whole cell 
lysate containing nuclear protein were isolated for this experiment with the results being 















Figure 3.2. Activity assay to assess TDP1 presence and activity in LCL mitochondria. 
Mitochondrial protein was prepared as described in 2.2.3 (ii) from SCAN1 patient and 
wild type lymphoblastoid cell lines. Following purification as described in 2.2.3 (iv) 
mitochondrial and whole cell lysate containing nuclear protein (10µg) were incubated 
with radiolabeled duplex substrate and subsequent repair products were fractionated by 
denaturing electrophoresis then exposed to phosphorscreen as described in 3.2.3. (A) 
Schematic to demonstrate the radiolabeled duplex substrate used in the assay as 
described in 3.2.3. (B) Substrate following denaturing electrophoresis to indicate 
whether TDP1 is active in both mitochondrial and nuclear protein. The 18-Y and 18-P 
to the right of B represent 18-mer with 3’-phosphotyrosine terminus and 3’-phosphate 
terminus respectively. (C) Percentage conversion of 3’-phosphotyrosine to 3’-phosphate 
from both mitochondrial (M) and whole cell lysate containing nuclear protein (CL) 
from lanes 2 and 4 of B, as determined by ImageQuant. Error bars represent the 
difference observed from two independent experiments for the activity assay. (D) 
Whole cell and mitochondrial protein (20µg) separated by SDS-PAGE as described in 
2.2.3 (vii) followed by western blot analysis as in 2.2.3 (viii) to determine purity of 
mitochondrial protein used in the assay. 
 
Figure 3.2 B confirms TDP1 presence and activity in human mitochondria similar to 
that observed in 3.3.1. In B lanes 2 and 4 suggest cleavage of tyrosine from the 
radiolabelled 18mer constituent of the duplex substrate resulting in further migration on 
electrophoresis. Extracts from the SCAN1 patient cell line show no TDP1 activity in 
lanes 3 and 5 of B, consistent with the control reaction in lane 1 without any protein 
addition to the duplex substrate. The graph in C illustrates the relative conversion of 3’ 
phosphotyrosine to 3’ phosphate from lanes 2 and 4 of B. The graph demonstrates that 
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there is greater cleavage of tyrosine using whole cell lysate (column 2) in comparison to 
mitochondrial extract alone (column 1). Western blot analysis in D demonstrates that 
there was no nuclear contamination in the mitochondrial extract used in the assay as the 
nuclear protein XRCC1 is detected in whole cell extract (lane 1), but not in 
mitochondrial extract (lane 2).  
 
3.3.3 TDP1 is active in mouse brain mitochondrial extracts 
 
Having demonstrated TDP1 presence and activity in in mitochondria from human cell 
lines in 3.3.1 and 3.3.2, it was decided to determine whether this was also true in mouse 
mitochondria. Using mitochondria isolated from wild type and Tdp1 -/- mouse brain 
mitochondria the activity assay described in 3.2.1 was performed with the duplex 
substrate illustrated in figure 3.3 A. Whole cell lysate containing nuclear protein was 
also prepared and used in the assay for which the results are shown in figure 3.3 B, C, 














Figure 3.3. Activity assay to assess TDP1 presence and activity in mouse brain 
mitochondria. Mitochondrial protein was isolated from Tdp1 -/- and Tdp1 +/+ mouse 
brain as described in 2.2.3 (iii) and purified as in 2.2.3 (iv). Once purified, 
mitochondrial and whole cell lysate containing nuclear protein (5µg and 10µg) were 
incubated with the radiolabelled duplex substrate followed by fractionation using 
denaturing electrophoresis and exposure to phosphorscreen as described in 3.2.3. (A) 
Schematic to demonstrate the radiolabeled duplex substrate used in the assay as 
described in 3.2.3. (B) Substrate following denaturing electrophoresis to indicate 
whether TDP1 is active in both mitochondrial and whole cell lysate containing nuclear 
protein. The 18-Y and 18-P to the right of B represent 18-mer with 3’-phosphotyrosine 
terminus and 3’-phosphate terminus respectively. (C) Percentage conversion of 3’-
phosphotyrosine to 3’-phosphate using mitochondrial (M) and whole cell lysate (CL) 
from mouse brain at both 5µg and 10µg concentration. These conversion are with 
reference to those observed in lanes 2, 3, 6, and 7 of B and were calculated using 
ImageQuant. Error bars represent the difference observed from two independent 
experiments for the activity assay. (D) Whole cell (lanes 1) and mitochondrial (lanes 2) 
protein (20µg) from Tdp1 +/+ and Tdp1 -/- mouse brain separated by SDS-PAGE as 
described in 2.2.3 (vii) followed by western blot analysis as in 2.2.3 (viii) to determine 
purity of mitochondrial protein used in the assay. 
 
Figure 3.3 B demonstrates TDP1 presence and activity in mouse brain mitochondria by 
the increased electrophoretic mobility of the radiolabelled 18mer component of the 
duplex substrate used for this assay. This indicates that the tyrosine from the substrate 
was cleaved by TDP1 using 5µg and 10µg mitochondrial and whole cell extract 
containing nuclear protein from wild type mouse brain (shown in lanes 2, 3, 6, and 7). 
Activity was not observed in mitochondrial and whole cell extract from Tdp1 -/- mouse 
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brain (shown in lanes 4, 5, 8, and 9). In C the percentage conversion from 3’ 
phosphotyrosine to 3’ phosphate is shown for each amount of protein (5µg and 10µg) 
for both mitochondrial (M) and whole cell lysate (CL). This result shows that using 5µg 
whole cell lysate on 25nM of substrate for the assay was almost enough to cause 
complete conversion from 3’ phosphotyrosine to 3’ phosphate, which was in contrast to 
the mitochondrial extract where only ≈40% conversion was observed at the same 
concentration. This suggests that the amount of TDP1 in the whole cell lysate is 
considerably higher than in the mitochondrial extract alone. A consideration for future 
could be to increase the concentration of substrate used in the assay so that similar 
increases in conversion may be seen on doubling the concentration of protein used in 
the assay for both whole cell lysate and mitochondrial extract. Western blot analysis, 
shown in D, excludes nuclear contamination of mitochondrial extracts used in the assay 
by the absence of Lamin and NeuN in mitochondrial protein (lanes 2) in contrast to 
whole cell protein (lanes 1) for wild type and Tdp1 -/- mice. Equal loading was 
demonstrated using antibodies to the mitochondrial proteins porin and NDUFA9. 
 
3.4 Discussion and conclusions 
 
In assessing the role of TDP1 in mtDNA repair, it was necessary to establish that TDP1 
was present and active in mitochondria. At this stage of the project there had been no 
previous reports of TDP1 in mitochondria, and therefore the decision to investigate 
TDP1 presence and activity in mitochondria was based on three basic principles, which 
are that: 
 
 Mammalian mitochondria have their own DNA (Anderson et al., 1981, Bibb et 
al., 1981a) 
 Mitochondria have mechanisms to repair their DNA (Boesch et al., 2011), and 
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 Mutations in TDP1 can cause cerebellar ataxia; a common feature of 
mitochondrial disease (Takashima et al., 2002, Stumpf and Copeland, 2011) 
 
With this in mind the assays undertaken in this chapter to examine TDP1 presence and 
activity in the mitochondrion has provided convincing data from which a sound 
conclusion can be drawn.  
 
Presence and activity of TDP1 in human mitochondria 
 
Activity of TDP1 in mitochondrial samples from human cell lines was first 
demonstrated using FD105 M21 fibroblasts. These cells had been isolated from an 
ataxia with oculomotor apraxia type 1 (AOA1) patient and been immortalised by our 
collaborators who also stably transformed these cells with a plasmid encoding and 
expressing aprataxin (APTX). Mutations in APTX are responsible for causing AOA1 
and these ‘corrected’ cells were originally intended to aid in determining whether APTX 
was present and active in mitochondria. This project was discontinued when another 
group reported presence and activity of APTX in mitochondria; thus explaining the lack 
of any data regarding APTX in this thesis (Sykora et al., 2011). Despite mitochondria 
from FD105 M21 fibroblasts originally intended for experiments investigating APTX, 
some of the mitochondrial extract could also be used to determine whether TDP1 was 
present and active in mitochondria as there were no mutations in the TDP1 gene in these 
cells. Figure 3.1 shows TDP1 activity in mitochondrial extract from FD105 M21 
fibroblasts as there is increased electrophoretic mobility of the radiolabelled 18mer 
component of the duplex substrate used in the assay. This increased electrophoretic 
mobility was generated as a result of TDP1 removing tyrosine from the DNA substrate 
as it would in vivo where the phosphodiester linkage between DNA and TOP1MT is 
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broken allowing re-ligation of DNA to its normal conformation (Zhang et al., 2001). 
The activity seen from mitochondria is similar to that from whole cell extract containing 
nuclear protein in which TDP1 activity has already been characterised (Yang et al., 
1996). This provided preliminary data supporting the hypothesis that TDP1 is present 
and active in mitochondria, and once this had been established a more comprehensive 
investigation into TDP1 presence and activity in human and mouse mitochondria was 
begun. 
 
With the data in figure 3.1 suggesting TDP1 presence and activity in fibroblast 
mitochondria it was decided to assess whether this was also true in lymphoblasts. Our 
collaborators had a SCAN1 patient lymphoblast cell line as well as wild type control 
cells that were used in the same in vitro assay as earlier. Figure 3.2 demonstrates that 
the tyrosine was cleaved from the DNA substrate and increased its electrophoretic 
mobility as a result of TDP1 activity in mitochondrial extract from wild type cells 
similar to whole cell extract containing nuclear protein from the same cell line. In the 
SCAN1 patient cell line the A1478G mutation in TDP1 causes a change in the active 
site of the protein converting amino acid 493 from histidine to arginine, which disrupts 
the symmetrical arrangement of the active site and results in a loss-of-function 
(Takashima et al., 2002). Crystal structure characterisation of TDP1 identified the 
histidine at amino acid residue 493 as a vital component of two symmetrical domains in 
the active site of the enzyme, which explains why there is no detectable activity from 
either mitochondrial or whole cell extracts from the SCAN1 cell line (Davies et al., 
2002b). Figure 3.4 illustrates the proposed reaction mechanism for TDP1 when 
processing DNA-TOP1 cleavage complexes, and demonstrates the importance of 




Figure 3.4. Proposed mechanism for TDP1 activity on mtDNA-TOP1MT substrate in 
(A), which leads to its conversion to 3’ phosphate seen in (B). The process of removing 
TOP1MT from the 3’ end of mtDNA begins with nucleophilic attack from His 263 of 
TDP1 as in (C) leading to covalent attachment of this amino acid to the mtDNA 
molecule and release of TOP1MT that is also protonated by His 493 of TDP1 as 
illustrated in (D). In (E) His 493 activates a water molecule that then hydrolyses the 3’ 
phosphohistidine thus releasing and regenerating the active site of TDP1 and leaving 
behind 3’ phosphate (F) for further processing by a phosphatase (adapted from Davies 
et al., 2002a).  
 
The His493 residue is conserved between species which highlights its importance for 
normal enzyme function and offers an explanation as to the lack of cleavage of tyrosine 
from the DNA substrate used in the activity assays in this chapter (Davies et al., 2002b, 
Interthal et al., 2001). This result also demonstrates that the mutation in TDP1 in 
SCAN1 patients affects function in the mitochondria as well the nucleus, which 
suggests that TDP1 is encoded by the same gene for activity on nDNA and mtDNA 




Possible mechanisms for TDP1 import into mitochondria 
 
Based on the data in this chapter that appears to suggest TDP1 is encoded by the same 
gene, it is therefore necessary to discuss some the possible mechanisms by which TDP1 
gains entry to the mitochondrion. For many years import into mitochondria was thought 
to be carried out through two general pathways involving a mitochondrial targeting 
sequence (MTS) (Becker et al., 2012). Many proteins have an N-terminal mitochondrial 
targeting sequence (MTS) that is usually cleaved by mitochondrial processing peptidase 
(MPP) upon entry into the mitochondrion (Bolender et al., 2008, Zhang et al., 2001). An 
example of a protein of significance to TDP1 that enters mitochondria by this 
mechanism is TOP1MT, where the mitochondrial isoform is encoded by a separate gene 
to the nuclear TOP1 (Zhang et al., 2001). In other instances, such as for several inner 
mitochondrial membrane proteins, there is no N-terminal targeting sequence, and 
alternatively there are internal targeting sequences throughout the polypeptide chain 
(Becker et al., 2012). In these cases the mitochondrial proteins are bound to cytosolic 
chaperones, which are recognised by the outer membrane protein, Tom70, and passed 
across the membrane on the way to their final destination (Becker et al., 2012). 
However, TDP1 does not appear to contain a predicted MTS which opens the 
possibility that it is transported into mitochondria through an alternative mechanism 
(Das et al., 2010).  
 
In some other cases, such as for 8-oxoG DNA glycosylase (OGG1) and 2-OH-
A/adenine DNA glycosylase (MYH), proteins are encoded in the same genes as their 
nuclear counterpart and are instead spliced for localisation to mitochondria (Nakabeppu, 
2001b, Zhang et al., 2001). Another well characterised example where alternative 
splicing acts as the mechanism for targeting a DNA repair enzyme to mitochondria is 
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that of uracil-DNA glycosylase (UNG) (Nilsen et al., 1997, Otterlei et al., 1998). This 
protein has two isoforms UNG1 (mitochondrial) and UNG2 (nuclear) are transcribed 
from distinct transcription initiation sites and are spliced for targeting to their chosen 
organelle (Nilsen et al., 1997). Each isoform has a targeting sequence, which is a classic 
strong mitochondrial targeting sequence for UNG1, whereas the nuclear targeting 
sequence (NTS) for UNG2 was found to be unusually long and complex (Otterlei et al., 
1998). Although such mechanisms for import exist for some mtDNA repair enzymes 
there are no such alternatively spliced isoforms found for TDP1 (Das et al., 2010).  
 
In more rare circumstances, as for the mitochondrial DNA ligase (LIG3α), an upstream 
initiation site for translation controls targeting to mitochondria where the targeting 
sequence is then cleaved meaning that the resulting polypeptide in mitochondria has 
approximately the same molecular weight as LIG3α in the nucleus (Lakshmipathy and 
Campbell, 1999b). However, TDP1 does not contian an upstream translation initiation 
site and so it is unlikely that this mechanism causes its localisation to mitochondria, but 
it is important to consider these more rare targeting mechanisms in relation to TDP1 
(Das et al., 2010). Another interesting observation was made in yeast (Saccharomyces 
cerevisiae) where an uncharaterised protein (Pir1p) interacts with the C-terminal end of 
AP endonuclease 1 (Apn1p) to initiate localisation to mitochondria (Vongsamphanh et 
al., 2001). Although this mechanism for import has yet to be identified in humans it acts 
to demonstrate the variety of possible mechanisms for protein entry into mitochondria.  
 
Despite not comprehending the exact way in which TDP1 is imported into 
mitochondria, an interesting point from the data presented in this chapter is that TDP1 is 
present and active in mitochondria in unstressed conditions, whereas many dual 
localised repair proteins (e.g. AP-endonuclease 1 (APE1)) are recruited to mitochondria 
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upon stress (Mitra et al., 2007, Boesch et al., 2011). This would suggest that TDP1 is 
continuously localised to mitochondria due to DNA-TOP1MT lesions occuring on a 
regular basis during initiation of mtDNA replication and transcription (Zhang et al., 
2001). While the data in figures 3.1 and 3.2 show clear actvity of TDP1 in 
mitochondrial extracts from human cells, this protein had not yet been identified in 
mitochondria of other mammalian organisms; therefore this was to be evaluated. 
 
Presence and activity of TDP1 in mouse mitochondria 
 
Our collaborators developed a Tdp1 -/- mouse for use in their own research, which has 
been shown to exhibit a very similar phenotype (e.g. cerebellar atrophy and ataxia) to 
that observed in SCAN1 patients (Katyal et al., 2007). The Tdp1 -/- mice were 
generated using a mutated form of Tdp1 which contained a single substitution at 
nucleotide 1369 causing premature termination of transcription (Katyal et al., 2007). 
The resulting polypeptide is unstable and its function is therefore lost as it lacks a 
significant section of TDP1 including the His493 residue vital to the active site of the 
protein (Katyal et al., 2007). These mice with wild type controls were utilised to detect 
TDP1 presence and activity in mouse mitochondria, and to determine whether the Tdp1 
gene encoded nuclear and mitochondrial forms of TDP1 as in humans. Figure 3.3 shows 
increased electrophoretic mobility of the DNA substrate following treatment with 
mitochondrial and whole cell protein from wild type mouse brain, suggesting that the 
tyrosine was cleaved from the substrate similar to previous experiments. However, 
mitochondrial and whole cell extracts from Tdp1 -/- mouse brain did not cleave the 
tyrosine from the DNA substrate suggesting that TDP1 in mice is encoded by the same 
gene for nuclear and mitochondrial localisation similar to in humans. This provides 
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further evidence of TDP1 presence and activity in mitochondria of higher eukaryotes; a 
phenomenon yet to be reported at the time of these experiments. 
 
Discovery of this novel mtDNA repair enzyme has many interesting implications for 
discerning the extent of the mtDNA repair machinery and how much disrupting this 
contributes to ageing and disease. It could be postulated that impaired mtDNA repair 
due to the loss of function of TDP1 is a contributing factor to progression of SCAN1 
along with dysfunctional nDNA repair; although unequivocal experimental data for this 
does not exist and would be very difficult to attain (Takashima et al., 2002). However, 
in discovering that this enzyme is present and active in mitochondria as well as 
previously identified repair proteins, there is confirmation that mtDNA repair 
mechanisms do exist and may be more intricate than initially thought (Cline, 2012, 
Boesch et al., 2011, Clayton et al., 1974). Delineating the involvement and role of more 
repair enzymes and more repair mechanisms in mitochondria may prove difficult. 
Despite this, the identification of more enzymes involved in mtDNA repair is increasing 
and so it was decided to perform more experiments relating to this field of 
mitochondrial research for which there is relatively little known (Boesch et al., 2011, 
Cline, 2012). The focus of this thesis was to determine the extent to which DNA-
TOP1MT lesions form and what role TDP1 has in repairing this damage. 
 
Altogether, the data shown in this chapter provide compelling evidence of TDP1 
presence and activity in the mitochondrion. This was demonstrated using a variety of 
human and mouse samples, therefore strengthening this conclusion and developing a 









The results in chapter 3 provide very strong evidence that TDP1 is present and active in 
human and mouse mitochondria. The next step in investigation was to answer the 
question: 
  
Is TDP1 essential in mtDNA repair and cell survival? 
  
While attempting to address this question another group reported the presence and 
activity of TDP1 in mitochondria. In this publication the group used 
immunofluorescence on cells (MCF-7 breast carcinoma cells), and subcellular 
fractionation with a Proteinase K protection assay to demonstrate TDP1 presence in 
mitochondria. Mouse embryonic fibroblasts (MEFs) with Tdp1 knockout were also used 
to demonstrate absence of TDP1 activity in comparison to controls similar to the 
experiments conducted in chapter 3 using Tdp1 -/- mice and SCAN1 patient cells. An in 
vitro repair assay was also utilised to show an association between TDP1 and DNA 
Ligase IIIα (LIG3α), and to show that TDP1 can remove 3’ phosphoglycolate using 
mitochondrial lysates in contrast to those with TDP1 immunodepletion. Further 
investigation into the involvement of TDP1 in mtDNA repair was carried out using a 
long-range quantitative PCR based assay following hydrogen peroxide (H2O2) treatment 
in cells with or without Tdp1 knockout. The data from this suggested the loss of TDP1 
caused dramatically more mtDNA damage with H2O2 treatment in comparison to 
controls. From this the group concluded that mitochondrial base excision repair 
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(mtBER) was dependent on TDP1, implying that this enzyme was a critical member of 
the mtDNA repair network (Das et al., 2010). 
 
Although the data from this paper shows clearly that TDP1 is present and active in 
mitochondria, similar to our previous observations, the conclusion that mtBER depends 
on this enzyme is a conclusion that does not appear to be true based on our own 
observations (Das et al., 2010). If mtBER depended on TDP1 it would be reasonable to 
assume the mtDNA mutation rate would be relatively high, yet the phenotype of 
SCAN1 patients and Tdp1 -/- mice is relatively mild in comparison to patients and mice 
with high mtDNA mutation load (Stumpf and Copeland, 2011, Trifunovic et al., 2004). 
It has also been shown that other enzymes involved in mtBER, namely LIG3, play a 
critical role in maintaining the integrity of mtDNA and also show very severe 
phenotypes in mice, which contrasts to Tdp1 -/- mice (Simsek et al., 2011, Gao et al., 
2011). Also, demonstrating that TDP1 can resolve 3’ phosphoglycolate in mitochondria 
corroborates that already observed in the nucleus, but this in itself does not demonstrate 
that TDP1 can resolve all DNA lesions involved in BER (Das et al., 2010, Interthal et 
al., 2005). The authors neglected the possibility that other 3’ damaged termini are likely 
to exist in mtDNA other than 3’ phosphotyrosine and 3’ phosphoglycolate; not to 
mention 5’ damaged termini that require repair such as 5’ adenine monophosphate and 
5’ hydroxyl, to name just two (Caldecott, 2008). Experience of the principal supervisor 
of this project (Professor R.N.Lightowlers), with regard to the long range quantitative 
PCR assay used to assess mtDNA damage in the publication, revealed that this assay 
can be highly variable and any results provided using this should be viewed with 
caution. With this in mind it was decided to continue with the aim of trying to determine 
whether TDP1 was essential for mtDNA repair and cell survival to either confirm or 




Approaching this began with analysis of Tdp1 -/- mouse brain to determine whether 
there was any mitochondrial dysfunction detectable through COX/SDH histochemistry. 
This would determine whether there is any severe mtDNA damage resulting in COX 
deficiency in the cerebellum of these mice. Our collaborators had also observed 
increased retinal degeneration in Tdp1 -/- mice with methylmethane sulfonate (MMS) 
treatment, and so it was intended to assess mitochondrial involvement in this as there is 
mounting evidence for mitochondrial dysfunction in retinal diseases (Barot et al., 2011).  
 
Experiments were also conducted using mammalian cells in culture. Some of these 
included transient siRNA transfections to knockdown TDP1 and determine whether this 
provided any data on the involvement of TDP1 in mtDNA repair. Our collaborators had 
also generated a mutant form of the mitochondrial topoisomerase (TOP1mt
Y559A
) to be 
used in the cell culture experiments. This construct contains a mutation changing amino 
acid 559 from tyrosine to alanine (Y559A), thus affecting the active site of the enzyme 
causing it to remain covalently bound to mtDNA upon nicking (Redinbo et al., 1998, 
Zhang et al., 2001). This would then require TDP1 for removal, therefore expressing 
TOP1mt
Y559A
 in cells in culture was intended to provide more information on the role of 




4.2.1 Ionizing radiation treatment of mice 
 
In order to generate mtDNA damage in the brain that would require TDP1 for repair 
mice were treated with ionizing radiation (IR). This was achieved in a 7 day experiment 
by dosing 1.5 years Tdp1 -/- and wild type mice with 3Gy caesium 137 on day 1 and 
day 4, and 10Gy on day 7 with brain being harvested 3 hours after the last exposure. 
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This dose is similar to that given to human patients receiving radiotherapy in treatment 
of brain tumours (10Gy/week). Radiation was delivered using a Cammael 1000 source. 
 
4.2.2 Methylmethane sulfonate (MMS) treatment of mice 
 
Treatment using MMS was carried out to stall mtDNA replication forks in Tdp1 -/- and 
wild type mice that may then require TDP1 for repair, with particular focus being on the 
retina of these mice. This was undertaken by intraperitoneal injection of 6-8 week-old 
mice with 75mg/kg MMS and collecting tissue after 5 days. Mice were kept under daily 
observation following MMS treatment and were culled humanely if found to be in any 
discomfort. 
 
4.2.3 Cytochrome c oxidase (COX)/succinate dehydrogenase (SDH) histochemistry 
To assess whether significant mtDNA damage was occurring in mice dual COX/SDH 
histochemistry was performed. The principal behind using this technique is that there 
are three subunits of COX encoded in the mitochondrial genome and therefore damage 
to mtDNA may cause reduced expression of these proteins, which consequently affects 
the activity of COX. In contrast SDH is fully encoded in nDNA and its activity should 
not be affected by mtDNA damage. This technique uses cytochrome c which is reduced 
when mixed with DAB, but is then oxidised when placed on the tissue section if COX is 
active. A brown colour is then produced as DAB donates more electrons to cytochrome 
c as it is oxidised by COX. A second reaction medium is then used on the section of 
tissue which contains sodium succinate, sodium azide, NBT and PMS. The NBT acts as 
a final electron acceptor following dehydrogenation of sodium succinate by SDH 
followed by transport of electrons by PMS to NBT, and the sodium azide inhibits COX 
to ensure no further activity is seen from this complex. As the NBT is reduced it 
produces a blue colour that will only be seen if there is reduced COX activity from the 
previous staining procedure (Old and Johnson, 1989). 
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For this thesis sections of mouse brain and eye that had been cut to 10µm using a 
cryostat (Leica Biosystems) were firstly incubated in 100µl COX reaction medium for 
the following times for each tissue type at 37
o
C (See appendix for optimisation of 
incubation times): 
 Mouse brain – 35 mins 
 Mouse eye – 30 mins 
Following this incubation sections were washed three times in 100µl PBS for 5 mins 




 Mouse brain – 40 mins 
 Mouse eye – 35 mins 
Washing was repeated a further three times using 100µl PBS for 5 mins each time. For 
mouse eye sections counterstaining with 100µl Vector Methyl Green (Vector 
laboratories) was carried out for 10 mins at 65
o
C to help distinguish retinal morphology 
before sections were washed three times in 100µl PBS for 5 mins each time and then 
dehydrated in the following percentages of EtOH in H2O for the indicated times: 
 70% EtOH – 5 mins 
 95% EtOH – 5 mins 
 100% EtOH – 5 mins 
 100% EtOH – 10 mins 
Sections were allowed to air dry for 5 mins before being mounted using DPX
TM
 and a 
coverslip, followed by image acquisition using a light microscope (Zeiss).    
COX reaction medium   SDH reaction medium 
100µM Cytochrome c    1.3M      Sodium succinate   
4mM  DAB     1.875mM NBT 
0.2M  Phosphate buffer pH 7  2mM      PMS 
      100mM    Sodium azide 
      0.2M      Phosphate buffer pH 7 
 
4.2.4 TOP1mt/FLAG and TOP1mt
Y559A
/FLAG expression experiments 
 







 HEK293 cells as described in 2.2.2. (vii) it was necessary to determine 
72 
 
whether clones exhibiting resistance to antibiotics blasticidin S and hygromycin B 
expressed the desired proteins upon induction. This was accomplished by seeding 5x10
5
 
cells  in 2ml supplemented DMEM in 2 wells of a 6-well plate for each clone of both 
HEK293/TOP1mt/FLAG and HEK293/TOP1mt
Y559A
/FLAG and adding 1µg/ml (final 
concentration) tetracycline in one well for each clone leaving the other without 
tetracycline as a control. Cells were incubated as outlined in 2.2.2 (i) for 18 hours before 
cytoplasmic protein was isolated as described in 2.2.3 (i). In order to determine whether 
expression of TOP1mt/FLAG and TOP1mt
Y559A
/FLAG was successful in each clone 
SDS-PAGE (2.2.3 (vii)) and western blotting (2.2.3 (viii)) were performed using the 
cytoplasmic isolate for each sample. 
 
Once successful expression of each protein had been established (figure 4.5), clone D 
for HEK293/TOP1mt/FLAG and clone A for HEK293/TOP1mt
Y559A
/FLAG were 
selected for further experimentation as these clones appeared to produce the strongest 
signal on western blot analysis using the M2 anti-FLAG antibody in comparison to 
other clones for each cell line. Expressing both proteins for 6 days would enable 
analysis of whether TOP1mt
Y559A
/FLAG had any significant effect on cell growth, 
mtDNA encoded protein levels, or levels of mtDNA copy number in comparison to 
TOP1mt/FLAG. To facilitate this each cell line was seeded in triplicate at 5x10
4
 cells in 
2 poly-L-ornithine treated 25cm
2
 flasks with 5ml supplemented DMEM to allow 
unrestricted growth. Tetracycline at 1µg/ml final concentration was added to one flask 
for both cell lines in each of the three replicates and incubated as described in 2.2.2 (i) 
for 72 hours. After this period media was removed from each flask and replaced with 
fresh supplemented DMEM containing 1µg/ml tetracycline and incubated for a further 




Cells were harvested using 1ml PBS/1mM EDTA, transferred to a 2ml reaction tube, 
and neutralised using 1ml supplemented DMEM. Samples were centrifuged at 260xg 
for 4mins, supernatant discarded, and cells carefully re-suspended in 1ml PBS. From 
this 100µl cell suspension was mixed with 100µl 50% Trypan Blue/PBS and used for 
cell counting with an improved Neubauer Haemocytometer (Hawksley) to determine 
any impact on cell growth. The remaining cell suspension was centrifuged once more at 
260xg for 4mins, supernatant discarded, and cytoplasmic protein isolated as described 
in 2.2.3 (i) before SDS-PAGE (2.2.3 (vii)) and western blotting (2.2.3 (viii)) were 
carried out to detect levels of mtDNA encoded proteins (COXI and COXII) in the 
absence of TDP1 compared to controls. 
 
This experiment was repeated with exception to the cytoplasmic protein isolation 
followed by SDS-PAGE and western blotting. On this occasion the remaining cell 
suspension was used for whole cell DNA extraction as described in 2.2.4 (vii) and used 
for qRTPCR analysis as in 2.2.4 (ii). 
 
4.2.5 siRNA transfection optimisation 
 
With the intention of performing TDP1 knockdown experiments it was necessary to 
determine if the Trisilencer-27 siRNA kit (OriGene) was capable of reducing the levels 
of TDP1 that would then be undetectable by western blot analysis. If TDP1 was not 
detected by western blot analysis then it could be assumed that the protein was no 
longer present in these cells. To assess this, 3 concentrations (0.1nM, 1nM, and 10nM 
final) of each siRNA construct provided in the kit were used including a negative 
control (non-targeted) to determine whether the highest concentration of a non-specific 
siRNA had any impact on the levels of TDP1. In 1.5ml reaction tubes 4µl lipofectamine 
(life technologies) was mixed with 500µl Opti-MEM RNAiMAX (life technologies) 
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and 1.25µl stock siRNA. For each siRNA construct used, including the negative control, 
3 stocks had been prepared for each final concentration desired: 
 
 
 Stock      0.2µM  2µM  20µM 
 Final concentration  0.1nM  1nM  10nM 
 
An untransfected control reaction was also prepared using the same reagents with 
exception to addition of any siRNA construct. Each reaction was incubated for 15mins 






 HEK293 cells in 6-
well plates with 2ml supplemented DMEM and incubated for 72 hours as described in 
2.2.2 (i). Cytoplasmic protein was then isolated as described in 2.2.3 (i) and TDP1 
levels determined by SDS-PAGE (2.2.3 (vii)) and western blotting (2.2.3 (viii)). 
 







With siRNA transfection optimisation completed as described in 4.2.4 it was concluded 
that siRNA would be used at 10nM final concentration with constructs B and C 
reducing the levels of TDP1 to the extent that it was not detectable by western blot 





 HEK293 cells to determine whether there were any effects on cell growth, 
mtDNA encoded protein levels, or mtDNA copy number in the absence of TDP1. This 
was undertaken by mixing 8µl lipofectamine (life technologies) with 1ml Opti-MEM 
RNAiMAX (life technologies) and 2.5µl 20µM construct C siRNA in a 1.5ml reaction 
tube. The same reaction was set up replacing construct C siRNA with 2.5µl 20µM non-
targeted siRNA as a negative control. A reaction without any siRNA was also prepared 
and all reactions were made in triplicate. Reactions were incubated for 15mins at room 











 flasks with 4ml supplemented DMEM to allow for unrestricted 
cell growth. Cells were incubated for 72 hours as described in 2.2.2 (i) before the 
siRNA transfection was repeated and cells incubated for a further 72 hours.  
 
Cells were counted, and protein and DNA extracted and analysed as in 4.2.3. This 
experiment was also repeated for further cell counting and isolation of DNA. 
 
 





In an attempt to generate a greater degree of mtDNA-TOP1 lesions to investigate TDP1 
function in mtDNA repair an experiment combining TDP1 knockdown with expression 
of TOP1mt/FLAG and TOP1mt
Y559A
/FLAG was conducted. From this it would be 
possible to observe whether there was a greater impact on cell growth, levels of mtDNA 
encoded proteins, or mtDNA copy number when the specific damage that TDP1 is 
responsible for repairing was being generated in the absence of this enzyme. Using 
HEK293/TOP1mt/FLAG clone D and HEK293/TOP1mt
Y559A
/FLAG clone A cell lines 
cells were seeded at 5x10
4
 in poly-L-ornithine treated 25cm
2
 flasks in 5ml 
supplemented DMEM for unrestricted growth. The same siRNA transfection as in 4.2.5 
was carried out for each cell line in triplicate and cells had expression of 
TOP1mt/FLAG and TOP1mt
Y559A
/FLAG induced as in 4.2.3. 
 
After the experiment was complete cells were counted, and protein and DNA extracted 









In order to determine whether there was severe mtDNA damage occurring in Tdp1 -/- 
mice COX/SDH histochemistry was carried out on mouse brain and eye. The rationale 
for using this technique was that severe mtDNA damage can cause reduced production 
of mRNA encoding COX proteins and thus reduce COX activity, which can be detected 
upon histochemical analysis. 
 
i) No COX negativity in Tdp1 -/- mouse brain 
 
Dual COX/SDH histochemistry was performed on wild type and Tdp1 -/- mouse brain 
sections with particular attention to the granule and Purkinje cell layers of the 
cerebellum. The reason for this was that SCAN1 causes defects in the cerebellum in 
patients which is also observed in Tdp1 -/- mice (Katyal et al. 2007). The results from 




Figure 4.1. COX/SDH histochemistry (described in 4.2.3) of mouse brain cerebellum. 
Sections cut to 10µm. 
GCL – Granule cell layer 
PCL – Purkinje cell layer 
(A and B) Tdp1 +/+  




The images in figure 4.1 C and D show no sign of COX deficiency and therefore 
demonstrate that there was no severe mtDNA damage occurring in Tdp1 -/- mouse brain 
cerebellum. There are no blue coloured cells visible in C or D similar to that in the wild 
type mouse brain in A and B, suggesting that any mtDNA damage in cells without 
TDP1 was not enough to cause a biochemical defect. 
 
 
ii) No COX negativity in Tdp1 -/- mouse brain following ƴ-irradiation 
 
Following the results observed in 4.3.1 (i) ƴ-irradiation was used as a means to generate 
increased mtDNA damage that would potentially have a greater impact in Tdp1 -/- mice. 
Once this had been performed COX/SDH histochemistry was carried out on wild type 
and Tdp1 -/- mouse brain sections to determine whether there were any COX deficient 
cells in any sections that would suggest severe mtDNA damage. Results for this 




Figure 4.2. COX/SDH histochemistry (described in 4.2.3) of mouse brain cerebellum 
following ƴ-irradiation (described in 4.2.1). Sections cut to 10µm. 
GCL – Granule cell layer 
PCL – Purkinje cell layer 
(A and B) Tdp1 +/+  




Images C and D in figure 4.2 demonstrate that in the absence of TDP1 there is no 
severe mtDNA damage that is visible by COX/SDH histochemistry in the cerebellum 
following ƴ-irradiation. These images are similar to those observed in A and B for the 
wild type control. However, Tdp1 -/- mice did show an early onset of ataxia following 
γ-irradiation, which would suggest that this treatment did have an effect in mice lacking 
TDP1. 
 
iii) No COX negativity in Tdp1 -/- mouse eye 
 
Analysis by COX/SDH histochemistry was carried out in wild type and Tdp1 -/- mouse 
eye sections as our collaborators had observed greater retinal degeneration under a 
particular treatment (MMS), and mitochondrial involvement in this was to be 
investigated. Firstly, COX/SDH histochemistry was performed on eye sections taken 
from wild type and Tdp1 -/- mice without any treatment. The results from this are 




Figure 4.3. COX/SDH histochemistry and methyl green counterstaining (described in 
4.2.3) of mouse eye retina. Sections cut to 10µm. 
R - Retina  
(A and B) Tdp1 +/+  




The images shown in figure 4.3 demonstrate that without stress there is no severe 
mtDNA damage in the absence of TDP1 that would cause a biochemical defect leading 
to blue coloured cells following COX/SDH histochemistry (C and D). These results are 
the same as for eye sections taken from wild type mice with the blue layer of cells 
(photoreceptors) visible in all images being as a result of counterstaining with methyl 
green to aid in determining eye morphology. There is also no noticeable retinal 




iv) No COX negativity in Tdp1 -/- mouse eye following MMS treatment 
 
Using MMS to stall replication forks in mice and thus potentially cause severe mtDNA 
damage leading to COX deficiency was the next step in analysing the role for TDP1 in 
mtDNA repair. Treatment using MMS was carried out in wild type and Tdp1 -/- mice 
before COX/SDH histochemistry was performed to determine whether there was 
increased retinal degeneration and/or COX deficiency in mice lacking TDP1. Results 






Figure 4.4. COX/SDH histochemistry and methyl green counterstaining (described in 
4.2.3) of mouse eye retina following MMS treatment (described in 4.2.2). Sections cut to 
10µm. 
R - Retina   
(A and B) Tdp1 +/+  
(C and D) Tdp1 -/- 
 
 
The images in figure 4.4 C and D show no blue cells that would suggest COX 
deficiency due to increased mtDNA damage in Tdp1 -/- mouse retina following MMS 
treatment. However, there is dramatic retinal degeneration visible in C and D in 
comparison to that in A and B suggesting that there is a severe effect in Tdp1 -/- mice as 
a result of MMS treatment, but that the majority of this was probably due to DNA 
damage/replication stalling in the nucleus which explains the cell loss observed in C 
and D. 
4.3.2 Expression of TOP1mt/FLAG and TOP1mt
Y559A
/FLAG following stable 
transfection 
 
With COX/SDH histochemical analysis in 4.3.1 not providing any evidence for severe 
mtDNA damage with various treatments in Tdp1 -/- mice it was decided to concentrate 
further studies for the role of TDP1 in mtDNA repair using cells in culture. This began 




 HEK293 cells with a FLAG-tagged 
wild type form of TOP1MT (TOP1mt/FLAG) and a mutant form of the gene 
(TOP1mt
Y559A
/FLAG). The mutant form of the gene has a mutation changing amino acid 
559 from tyrosine to alanine, thus altering the active site of the enzyme and causing it to 
remain covalently bound to mtDNA upon nicking, which does not detach like the wild 
type form of the protein. This would then require TDP1 for removal, and therefore by 




 HEK293 cells it was predicted that a 











HEK293 cells was completed and results for successfully expressing clones are shown 




   A 
 




Figure 4.5. Analysis of TOP1mt/FLAG and TOP1mtY559A/FLAG expression. Western 
blot analysis as described 2.2.4 (viii) using 20µg cytoplasmic protein isolated as 





 HEK293 cells as described in 2.2.2 (vii). Expression 
of each protein was induced with addition of 1µg/ml (final concentration) tetracycline 
from 5x10
5
 cells in 2ml supplemented DMEM in 6-well plates, followed by incubation 
for 18 hours in conditions outlined in 2.2.2 (i). A separate well containing 5x10
5
 cells 
for each clone in 2ml supplemented DMEM was left without tetracycline as controls 
(A) Analysis of 4 clones following transfection of TOP1mt/FLAG. (B) Analysis of 6 




Western blot analysis in figure 4.5 A shows successful expression of TOP1mt/FLAG in 
4 clones following the transfection and induction with tetracycline (lanes 2, 4, 6, and 8). 
The uninduced controls (lanes 1, 3, 5, and 7) show no signal as anticipated. Also, 
western blot analysis in B illustrates successful expression of TOP1mt
Y559A
/FLAG from 
6 clones following transfection and induction with tetracycline (lanes 2, 4, 6, 8, 10, and 
12); whereas the uninduced controls (lanes 1, 3, 5, 7, 9, and 11) show no signal. Equal 
loading for each western blot was proven using α-porin antibody. Following this it was 





/FLAG would be used for further experiments as they appeared to show the 
strongest expression based on the western blots in figure 4.5. 
 
4.3.3 Localisation of TOP1mt/FLAG and TOP1mt
Y559A
/FLAG to mitochondria 
 
Once successful expression of TOP1mt/FLAG and TOP1mt
Y559A
/FLAG had been 
established in 4.3.2, it was necessary to confirm that each of the clones selected for 
further experiments (clone D for HEK293/TOP1mt/FLAG and clone A for HEK293/ 
TOP1mt
Y559A
/FLAG) had expression of their respective proteins targeted to 
mitochondria. This was achieved using a Proteinase K (life technologies) protection 
assay described in 2.2.3 (v) for which the results are shown in figure 4.6. 
   A 
 
 
   B 
                       
 
Figure 4.6. Analysis of TOP1mt/FLAG and TOP1mtY559A/FLAG mitochondrial 
localisation. Western blot analysis as described 2.2.3 (ix) using 10µg mitochondrial 
protein isolated as described in 2.2.3 (ii) to determine mitochondrial localisation of both 
TOP1mt/FLAG and TOP1mt
Y559A





 HEK293 cells as described in 2.2.2 (vii). Expression of each protein was induced 
in each cell line with addition of 1µg/ml (final concentration) tetracycline followed by 
incubation for 18 hours in conditions outlined in 2.2.2 (i). Localisation of both proteins 
was assessed by addition of 0.5µg, 2µg, and 4µg Proteinase K (life technologies) with 
or without Triton X-100 as described in 2.2.3 (v). (A) Analysis of TOP1mt/FLAG clone 
D (B) Analysis of TOP1mt
Y559A
/FLAG clone A. 
 
Successful localisation of both proteins is demonstrated in figure 4.6. In A and B 2µg 
was the optimal concentration of Proteinase K (life technologies) to show that both 
TOP1mt/FLAG and TOP1mt
Y559A
/FLAG were protected by the mitochondrial outer 
membrane in samples without Triton X-100 (lanes 5 in A and B), whereas those 
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samples with this detergent added showed no signal for the expressed protein using the 
M2 α-FLAG antibody (lanes 6 in A and B). It was found in optimising this assay that 
0.5µg Proteinase K was not enough to cause degradation of either TOP1mt/FLAG or 
TOP1mt
Y559A
/FLAG with Triton X-100 addition (lanes 3 in A and B), and that 4µg was 
too much and caused widespread degradation of proteins including porin (lane 8 in A 
and lanes 8 and 9 in B). Nevertheless, based on the results using 2µg Proteinase K it 
was concluded that on expression of TOP1mt/FLAG or TOP1mt
Y559A
/FLAG these 
proteins were both localised to mitochondria, and could then be used in further 
experiments. 
4.3.4 No decreased cell growth, reduction of mtDNA encoded proteins, or reduction in 




With the knowledge that TOP1mt/FLAG or TOP1mt
Y559A
/FLAG were expressed and 
localised to mitochondria in HEK293/TOP1mt/FLAG and HEK293/ 
TOP1mt
Y559A
/FLAG, respectively, it was decided to express each protein within their 
cell line for 6 days to determine whether this had any impact on cell growth, levels of 
mtDNA encoded proteins, or mtDNA copy number in comparison to uninduced 











       
Figure 4.7. Expression of TOP1mt/FLAG and TOP1mt
Y559A
/FLAG for 6 days by 
addition of 1µg/ml (final concentration) tetracycline at the 0 hours and 72 hours of 




 flasks in triplicate in 
5ml supplemented DMEM without any limiting factors on cell growth. (A) Cell counts 
(mean +/- SEM from each triplicate) performed using an improved Neubauer 
Haemocytometer (Hawksley) upon expression (+) of both TOP1mt/FLAG (wt) and 
TOP1mt
Y559A
/FLAG (mut) in comparison to non-expressed (-) controls. Dashed line 
indicates approximate starting number of cells (5x10
4
 cells). (B) Real-time PCR (qRT-
PCR) as described in 2.2.4 (ii) to determine mtDNA copy number by the ratio of ND1 
reads in comparison to reads of a nuclear control B2M (mean +/- SEM from each 
triplicate). For this, whole cell DNA extraction as described in 2.2.5 (x) was performed 
following expression (+) of both TOP1mt/FLAG (wt) and TOP1mt
Y559A
/FLAG (mut) in 
comparison to non-expressed (-) controls. (C) Western blot analysis as described 2.2.3 
(viii) using 20µg cytoplasmic protein isolated as described in 2.2.3 (i) to determine 
levels of mtDNA encoded proteins (COXI and COXII) upon expression (+) of both 
TOP1mt/FLAG (wt) and TOP1mt
Y559A
/FLAG (mut) in comparison to non-expressed (-) 
controls. 
 
The graph in figure 4.7 A shows that there was no significant decrease in cell growth 
with expression of TOP1mt
Y559A
/FLAG for 6 days in comparison to uninduced controls. 
As expected, the results upon expression of TOP1mt/FLAG for the same time period 
showed no reduction in cell growth. When analysis by qRT-PCR was carried out using 
DNA isolated from these cells there was no significant reduction in mtDNA copy 
number with expression of TOP1mt
Y559A
/FLAG in comparison to controls. Not 
surprisingly, when cytoplasmic protein was isolated and western blotting performed in 
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C, there was no reduction in the levels of mtDNA encoded proteins (COXI and COXII) 
with expression of TOP1mt
Y559A
/FLAG (lanes 4, 8, and 12) in comparison to expression 
of TOP1mt/FLAG and uninduced controls. Both COXI and COXII have a half-life of 
six days and so it may have been expected that if this treatment caused severe mtDNA 
damage the transcript levels of corresponding mRNAs could have been reduced 
resulting in 50% reduction of signal on western blot analysis, but this was not observed. 
This suggested that expression of TOP1mt
Y559A
/FLAG alone over 6 days was not 
enough to cause severe mtDNA damage and affect cell growth, mtDNA encoded 
protein levels, or mtDNA copy number. 
 
4.3.5 TDP1 siRNA transfection optimisation 
 
 
With expression of TOP1mt
Y559A
/FLAG alone not leading to any detectable mtDNA 
damage or negative effect in cells, alternative methods for evaluating the role of TDP1 





 HEK293 cells using siRNA and evaluate its effect in a similar way as in 4.3.4. 
To begin this line of experiments the TDP1 siRNA constructs (OriGene) were required 
to be tested to measure their effectiveness at different concentrations. This was 
implemented with a 3 day knockdown using siRNA constructs A, B, and C at 0.1nM, 
1nM, and 10nM final concentration whilst also using a non-targeted siRNA control at 
the same concentration to determine whether there was any off target knockdown of 













 HEK293 cells. Western 
blot analysis as described 2.2.3 (viii) using 20µg cytoplasmic protein isolated as 





 HEK293 cells as described in 4.2.4. Three TDP1 siRNA constructs 
(A, B, and C) and a non-targeted (NT) control were used over 3 days at 0.1nM, 1nM, 
and 10nM final concentration in parallel with untransfected cells (UT). 
 
Figure 4.8 establishes that TDP1 siRNA constructs B and C knockdown TDP1 to levels 
that are undetectable by western blot analysis at 1nM and 10nM concentration. 
Construct A shows no knockdown of TDP1 similar to the non-targeted control and 
untransfected cells. Equal loading of protein on the blot was proven using the α-porin 
antibody. Based on this data construct C would be used alongside the non-targeted 
siRNA at 10nM final concentration in further experiments.  
 
4.3.6 No decreased cell growth, reduction in mtDNA encoded proteins, or reduction in 




 HEK293 cells 
 
 
Using TDP1 siRNA construct C TDP1 was knocked down over a 6 day period at 10nM 




 HEK293 cells to determine whether 
there were any negative effects detectable with reference to cell growth, levels of 
mtDNA encoded proteins, or mtDNA copy number. The results from this experiment 





















 flasks in triplicate in 5ml supplemented 
DMEM without any limiting factors on cell growth. Knockdown was performed at 
10nM siRNA final concentration and repeated after 72 hours from experiment start. (A) 
Cell counts (mean +/- SEM from each triplicate) performed using an improved 
Neubauer Haemocytometer (Hawksley) in untransfected (UT), non-targeted (NT), and 
siRNA construct C cells after 6 days. Dashed line indicates approximate starting 
number of cells (5x10
4
 cells). (B) Real-time PCR (qRT-PCR) as described in 2.2.4 (ii) 
to determine mtDNA copy number by the ratio of ND1 reads in comparison to reads of 
a nuclear control B2M (mean +/- SEM from each triplicate). Whole cell DNA extraction 
as described in 2.2.4 (vii) was performed from in untransfected (UT), non-targeted 
(NT), and siRNA construct C cells after 6 days (* = P<0.05). (C) Western blot analysis 
as described in 2.2.3 (viii) using 20µg cytoplasmic protein isolated as described in 2.2.3 
(i) to determine levels of mtDNA encoded proteins (COXI and COXII) in untransfected 
(UT), non-targeted (NT), and siRNA construct C cells after 6 days. 
 
The results in figure 4.9 A show no significant decrease in cell growth despite 
knockdown of TDP1 over 6 days. In B qRT-PCR shows no reduction in mtDNA copy 
number with loss of TDP1 over the same time period, and in C western blotting 
demonstrates that there is no reduction in the levels of COXI or COXII with TDP1 
knockdown (lanes 3, 6, and 9). The statistically significant result showing reduced 
mtDNA copy number in non-targeted cells is most probably an anomalous result as 






4.3.7 Significantly decreased cell growth with TDP1 knockdown and expression of 
TOP1mt/FLAG and TOP1mt
Y559A
/FLAG, but no reduction in mtDNA encoded proteins, 
or reduction mtDNA copy number 
 
 
The experiments conducted in 4.3.4 and 4.3.6 indicate that expressing 
TOP1mt
Y559A
/FLAG and knocking down TDP1, as separate treatments, are not enough 
to cause severe mtDNA damage that presents in decreased cell growth, reduction in 
levels of mtDNA encoded proteins, or lowered mtDNA copy number. With this in mind 
it was decided to knockdown TDP1 and express TOP1mt
Y559A
/FLAG for 6 days to 
determine whether combining these treatments had a negative impact on cells, which 
may aid in realising the exact role for TDP1 in mtDNA repair. Knockdown of TDP1 
with expression of TOP1mt/FLAG was also performed as a control, as well as cells 
without TDP1 knockdown but expression of both TOP1mt/FLAG and 
TOP1mt
Y559A







Figure 4.10. Analysis of TDP1 knockdown and TOP1mt/FLAG and TOP1mt
Y559A
/FLAG 
for 6 days. siRNA transfection at 10 nm (final concentration) and expression of 
TOP1mt/FLAG and TOP1mt
Y559A
/FLAG by addition of 1µg/ml (final concentration) 
tetracycline over 6 days in HEK293/TOP1mt/FLAG and HEK293/TOP1mt
Y559A
/FLAG 




 flasks in triplicate. The siRNA transfection 
and addition of tetracycline was repeated after 72 hours from experiment start. (A) Cell 
counts (mean +/- SEM from each triplicate) performed using an improved Neubauer 
Haemocytometer (Hawksley) for untransfected (UT), non-targeted (NT), and siRNA 
construct C cells with expression of both TOP1mt/FLAG (wt) and TOP1mt
Y559A
/FLAG 
(mut) after 6 days. Dashed line indicates approximate starting number of cells (5x10
4
) 
(* = P<0.05). (UT/NT vs C) (B) Real-time PCR (qRT-PCR) as described in 2.2.4 (ii) 
measuring the ratio of ND1 reads in comparison to reads of the nuclear control B2M to 
determine mtDNA copy number (mean +/- SEM from each triplicate). Whole cell DNA 
extraction as described in 2.2.4 (vii) was performed from untransfected (UT), non-
targeted (NT), and siRNA construct C cells with expression of both TOP1mt/FLAG 
(wt) and TOP1mt
Y559A
/FLAG (mut) after 6 days. (C) Western blot analysis as described 
2.2.3 (viii) using 20µg cytoplasmic protein isolated as described in 2.2.3 (i) to determine 
levels of mtDNA encoded proteins (COXI and COXII) in untransfected (UT), non-
targeted (NT), and siRNA construct C cells with expression of both TOP1mt/FLAG 
(wt) and TOP1mt
Y559A
/FLAG (mut) after 6 days. 
 
In figure 4.10 A cell counting revealed that over 6 days there was significantly less cell 
growth in cells that had TDP1 knocked down, and TOP1mt/FLAG and 
TOP1mt
Y559A
/FLAG expressed. This suggests that there is sufficient mtDNA damage 
occurring in these cells to have a negative impact on cell proliferation, which is not 
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observed in control cells for the experiment. This was unexpected for cells expressing 
TOP1mt/FLAG, but it must be that lesions occur more often than originally thought 
when TOP1mt/FLAG is expressed and TDP1 would then be required for repair. 
Western blotting in B indicates that in spite of the decreased cell growth there was no 
reduction in either COXI or COXII in protein from cells that had TDP1 knocked down, 
and that were expressing TOP1mt/FLAG or TOP1mt
Y559A
/FLAG (lanes 3, 6, 9, 12, 15, 
and 18). Similarly there was no decrease in mtDNA copy number in these cells (C), 
suggesting that the damage to mtDNA was not enough to cause a reduction in mtDNA 
levels or the levels of mtDNA encoded proteins despite a reduction in cell growth. 
There was a slight increase in mtDNA copy number in cells that had been transformed 
with TOP1mt
Y559A
/FLAG in comparison to cells with the wild type form of this protein. 
However when comparing mtDNA copy number in HEK293/TOP1mt
Y559A
/FLAG cells 
between the TDP1 knockdown, and non-targeted and untreated controls there does not 
appear to be any discernible cause for this with regard to mtDNA damage as a result of 





With TDP1 presence and activity being demonstrated in chapter 3 and verified by 
another group, the experiments in this chapter were designed to assess whether TDP1 is 
essential to mtDNA repair and cell survival (Das et al., 2010). By using Tdp1 -/- mice 
and mammalian cell lines it was anticipated our experiments would aid in confirming or 
counteracting the argument that: 




If this was true TDP1 would be a significant member of the mtDNA repair network, and 
therefore our line of experiments would help to interpret how essential TDP1 is to 
mitochondria. 
Impact of TDP1 loss in mice 
From their inception Tdp1 -/- mice have been utilised to study the impact of TDP1 loss 
with regard to nDNA. It was established that these mice were very similar in phenotype 
to SCAN1 patients in terms of their neurological (e.g. cerebellar atrophy and ataxia) and 
extraneurological (e.g. hypoalbuminemia) symptoms. Therefore using various 
mechanisms to generate specific TOP1-DNA damage through camptothecin (CPT) and 
topotecan (TPT), as well as more general single strand break (SSB) and double strand 
break (DSB) damage using γ-irradiation, it was possible to find that TDP1 was crucial 
to SSB repair (SSBR) of nDNA in primary neural cells. From this the cerebellar atrophy 
observed in the mice and patients was attributed to the unrepaired SSBs as a result of 
loss of function of TDP1 (Katyal et al., 2007). 
In light of these findings and the claim that mtBER is dependent on TDP1 it is 
important to make clear the distinction between SSBR and BER (Katyal et al., 2007, 
Das et al., 2010). In SSBR the DNA backbone can be broken and form a lesion (e.g. 3’ 
phosphotyrosine and 5’ AMP) but the base at that particular position may or may not be 
damaged in addition (Caldecott, 2008). This is different to BER that has many steps 
including one for SSBR (Boesch et al., 2011). In brief, the process begins with the 
removal of a damaged base by a DNA glycosylase, incision of the DNA backbone by an 
apurinic/apyrimidinic (AP) endonuclease, infilling of the abasic site by a DNA 
polymerase, before DNA is finally restored to its original conformation with ligation of 
the backbone by a DNA ligase (Boesch et al., 2011). Although the final ligation step in 
this process involves SSBR by a DNA ligase, it does not necessarily involve the activity 
of TDP1 as the specific substrate required for this enzyme (3’ phosphotyrosine) does 
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not match the 3’ hydroxyl present before the final ligation takes place (Boesch et al., 
2011, Caldecott, 2008). By researching previous studies performed in mice that 
investigated mtDNA repair, it may be possible to determine the some of the expected 
outcomes of our own experiments if mtBER depends on TDP1. 
Mouse knockouts of enzymes with specific involvement to mtBER (e.g. oxoguanine 
DNA glycosylase (OGG1) and thymine glycol-DNA glycosylase (NTH1)) have shown 
relatively mild to no observable phenotype, but have reduced mtDNA repair capacity 
(de Souza-Pinto et al., 2001, Karahalil et al., 2003). The phenotype observed in Tdp1 -/- 
mice, in comparison, is more severe and based on this it would appear that this would 
support the argument that mtBER depends on TDP1 (Katyal et al., 2007). However, 
when Tdp1 -/- mice are compared to other mouse models with knock-outs for enzymes 
that are known to be involved in all mtBER, the consequences of TDP1 loss appear to 
be relatively mild. The mitochondrial DNA ligase (LIG3α) is involved in all mtBER 
and mitochondrial SSBR, and in this case Lig3α -/- mice displayed a very severe 
phenotype including mtDNA loss and debilitating ataxia (Gao et al., 2011). Although 
TDP1 does not have the same function as LIG3α there would surely be a more 
significant phenotype in Tdp1 -/- mice and SCAN1 patients if mtBER was dependent on 
TDP1 as the mutation rate of mtDNA would be relatively high, which can have a 
dramatic effect at the molecular and whole organism level (Hirano, 2008, Trifunovic et 
al., 2004). In the case of the well reported mtDNA mutator mouse, an alteration in the 
mitochondrial DNA polymerase ƴ (POLG) to affect the proof reading capability of the 
enzyme caused increased mtDNA mutation rate and early ageing onset (Trifunovic et 
al., 2004). Such dramatic changes on the whole organism level are not seen in Tdp1-/- 
mice, which potentially questions the dependency of mtBER on TDP1. However, data 
was required to illustrate this so by assessing the activity of complexes of the electron 
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transport chain, with subunits encoded in mtDNA, it was hoped that more information 
could be provided on the role of TDP1 in mtDNA repair. 
The results in figure 4.1 and 4.2 show no sign of severe mtDNA damage in the 
cerebellum of Tdp1 -/- mice in comparison to wild type controls despite introducing 
more DNA damage through γ-irradiation. Although γ-irradiation is used to generate 
DSBs in DNA, the vast majority (>95%) of DNA damage using this technique is SSBs 
(Katyal et al., 2007). This does not necessarily cause the specific DNA-TOP1 lesion, 
but it should lead to these lesions as they can be formed when TOP1 incises DNA at the 
site of an already damaged nucleotide (Caldecott, 2008). In the absence of TDP1 the 
delivery of DNA damage through γ-irradiation has already been shown to have an effect 
in mice with regard to nDNA, and so it was believed that lesions of DNA-TOP1MT 
would occur in the mitochondrion using this method (Katyal et al., 2007). However, 
with COX/SDH histochemistry there is no evidence to suggest that there is severe 
mtDNA damage in the cerebellum of Tdp1 -/- mice indicating that any mtDNA damage 
is not occurring at a high enough rate in the absence of TDP1 to have an effect on the 
expression of COX subunits encoded in this genome. This suggests that TDP1 is not 
critical to general SSB repair of mtDNA as a result of γ-irradiation. 
Studies using Tdp1 -/- mice were continued with investigation using COX/SDH 
histochemistry in the retina as our collaborators observed retinal degeneration with a 
particular treatment, and mitochondrial dysfunction has been associated with retinal 
diseases (Barot et al., 2011). In unstressed conditions there did not appear to be any 
retinal degeneration or mitochondrial dysfunction in Tdp1 -/- mice as a result of 
increased mtDNA damage due to TDP1 loss; as was expected. Further experiments 
were carried out using the alkylating agent methylmethane sulfonate (MMS) that adds 
methyl groups to DNA bases, which would then require BER enzymes for repair (Wyatt 
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and Pittman, 2006). If mtBER was dependent on TDP1 it may be the case that mtDNA 
damage would be severe enough to be detected by COX/SDH histochemistry in Tdp1 -/- 
mice. However, there is quite dramatic retinal degeneration in Tdp1 -/- mice that can be 
seen in figure 4.4 with no sign of mitochondrial dysfunction. One possible explanation 
for this could be that the DNA damage occurring in these mice in the absence of TDP1 
is mainly within the nucleus, thus accounting for the cell loss observed in figure 4.4. 
This method of generating DNA damage is most probably not the best mechanism to 
investigate mtDNA repair and so no definitive conclusions could be made. 
One criticism of using COX/SDH histochemistry to detect mtDNA damage is that it 
may not be very sensitive to observe this phenomenon in mice. In humans it has been 
shown that immunohistochemistry using antibodies against subunits of complex I of the 
respiratory chain allows for a more sensitive analysis of respiratory chain defects (Lax 
et al., 2012). With many complex I subunits in mtDNA it would appear as though this 
would be perfect for analysis of mtDNA damage in mice. However, this was attempted 
in relation to a separate project by a member of the Mitochondrial Research Group 
(Dr.N.Lax) with much experience in immunohistochemistry, and unfortunately it was 
not possible to optimise this technique for mouse brain as there was too much 
background signal produced when using this tissue. Investigating the involvement of 
TDP1 in mtDNA was then continued with further experiments using mammalian cells 
in culture. 
Investigations in mammalian cell lines 
In order to attempt to delineate the exact role of TDP1 in mtDNA repair, mammalian 
cells (HEK293) were manipulated to gain a greater understanding of the importance of 
TDP1 on the molecular level. Using cells in culture has many practical advantages over 
experiments involving mice and so this would aid in producing more data for analysis. 
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One of the challenges of studying mtDNA damage in cells in culture and in mice is to 
generate DNA damage that is specific to the mitochondrial genome as many other 
methods (e.g. γ-irradiation, MMS, and H2O2) impact on nDNA as well as mtDNA. In 





system (life technologies) was utilised in order to gain cell 
lines that had been transformed with a wild type form of TOP1MT (TOP1mt/FLAG) 
and a mutant form (TOP1mt
Y559A
/FLAG). The mutant form of the protein has an altered 
active site, which causes it to remain covalently bound to mtDNA upon nicking and 
does not become detached as the wild type form would; meaning that TDP1 is then 
required for removal. This mutant was designed based on previously studied mutants for 
the nuclear TOP1, and in consideration of this the active amino acid residue at position 
559 in the mitochondrial topoisomerase was changed from tyrosine to alanine to cause 
altered function (Redinbo et al., 1998, Zhang and Pommier, 2008). Expressing the 
FLAG-tagged TOP1mt
Y559A
 was intended to increase DNA damage specific to mtDNA 
that would then require TDP1 for repair, and help to understand the exact role of this 
repair enzyme in mtDNA repair. However, when this mutant was expressed for a six 
day period there was no indication of a negative impact in cells as a result, which can be 
seen in figure 4.7. This may not be too surprising given that TDP1 was still present and 
active in the mitochondria of these cells meaning that it could repair any damage formed 
as a result of this expression. Knockdown of TDP1 was also performed to determine 
whether there would be any negative effects on cells with the loss of TDP1. Figure 4.9 
demonstrates that there was no negative impact in cells with the loss of TDP1.  
Although the cells with TDP1 knockdown were not stressed, mtDNA damage would 
likely still occur in these cells suggesting that TDP1 is not a critical member of mtDNA 
repair as when vital mtDNA repair enzymes are lost, such as the mitochondrial DNA 
ligase (LIG3α), cells cannot survive (Simsek et al., 2011). This is also similar for other 
96 
 
enzymes specific to mtBER, such as apurinic/apyrimidinic endonuclease 1 (APE1), 
which causes apoptosis when the enzyme is lost, but when overexpressed to 
mitochondria apoptosis is reduced (Hegde et al., 2012, Li et al., 2008). Only when 
combining TDP1 knockdown with expression of either TOP1mt/FLAG or 
TOP1mt
Y559A
/FLAG was any impact in cells seen. The reduction in cell number in 
figure 4.10 indicates that there was reduced cell growth due to TOP1MT being bound to 
mtDNA in the absence of TDP1, but interestingly this did not have any impact on the 
levels of mtDNA encoded proteins or mtDNA copy number. This implies that mtDNA 
integrity is still maintained and can produce mtDNA encoded proteins over a six day 
period despite these lesions occurring and causing a reduction in cell growth. The 
reduced cell growth with TDP1 knockdown and TOP1mt/FLAG expression was slightly 
unexpected in this experiment, but it must be the case that expression of this protein 
caused these lesions occur more often than initially expected in the absence of TDP1 
which resulted in less cell growth. The presence of TDP1 in mitochondria in unstressed 
conditions, as demonstrated in chapter 3, also supports the assumption that these lesions 
occur within mitochondria under normal circumstances that requires TDP1 for repair, 
and would help explain the unexpected result in this case. 
The significance of these findings is that TDP1 is confirmed to be involved in mtDNA 
repair, but based on this data it would be careless to assume that mtBER is dependent on 
this enzyme or that it is essential for cell survival. It may have been possible to observe 
reduction in the levels of mtDNA encoded proteins or mtDNA copy number if the 
length of experiments had been longer, but these data do still show that TDP1 is in some 
part involved in mtDNA repair. Further analysis of exact mtDNA mutation load through 
deep sequencing would provide a greater depth of analysis to assess the consequences 
of losing TDP1. Using DNA samples from the expression/knockdown experiments 
would help to determine whether mtDNA mutation load was increased with TDP1 loss 
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as would be expected if mtBER was dependent on this enzyme (Boesch et al., 2011, 





























Chapter 5. Does next generation sequencing aid in discovering the 
exact role of TDP1 in mtDNA repair? 
 
5.1 Introduction 
The results presented in chapters 3 and 4 suggest that TDP1 is present and active in 
mitochondria, but the exact role of TDP1 in mtDNA repair remained unclear although it 
is unlikely that mtBER is dependent on this enzyme as Das et al concluded (Das et al., 
2010). In order to delineate the role of TDP1 in mtDNA repair next generation 
sequencing was utilised as it was anticipated this would provide insight into the exact 
mutation rate in mtDNA as a result of the expression/knockdown experiments described 
in chapter 4.  
For this Ion Torrent
TM
 technology (life technologies) was used to sequence mtDNA 
using DNA samples from the experiments described in chapter 4. One of the main 
advantages of Ion Torrent
TM
 technology is the ability to perform sequencing at a 
relatively low cost in comparison to traditional Sanger sequencing methods and 
machines that are typically used in this line of experimentation. Although the coverage 
of DNA using Ion Torrent
TM
 technology is not as extensive as with other Next-
Generation sequencing platforms (≤1Gb compared to ≤120Gb using SOLiDTM 
technology previously used for sequencing mtDNA) it was decided that this was not an 
issue for the study of the mitochondrial genome as it is relatively small and would allow 
for sufficient coverage to detect significant mutation levels in mtDNA if the mutations 
were present (Rothberg et al., 2011, Ameur et al., 2011, Liu et al., 2012).  
The principle behind this form of sequencing technology is that pH changes can be 
measured and used to determine the sequence of DNA as a result of proton release 
following incorporation of nucleotides by a DNA polymerase in a growing nucleotide 
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chain. More specifically, when a nucleotide is incorporated into a nascent strand of 
DNA by polymerase a single proton is released as a result of hydrolysis of the entering 
dNTP. For sequencing using Ion Torrent
TM
 technology the DNA sample is loaded onto 
a chip that is then flooded sequentially with the four dNTPs that, when incorporated into 
DNA, release a proton that alters the pH in the solution surrounding that particular area. 
The change in pH is then detected by the chip, converted to a voltage, and processed so 
that it is recorded by the software. This allowed for the sequencing of mtDNA in a 
library following a library preparation protocol that briefly consisted of an initial long-
range PCR (LR-PCR) to generate two ≈8kb regions of mtDNA that were combined, 
fragmented into smaller sections, ligated to adapters, and then clonally amplified onto 
beads. Once this had been complete the samples could be analysed by loading the 
clonally amplified libraries on beads onto a chip that contained wells for each bead to 
lie in whilst the chip was flooded with each dNTP. Figure 5.1 illustrates how flooding 
of a chip with a dNTP leads to incorporation of a nucleotide into nascent DNA that is 







Figure 5.1. Detection of an incorporated nucleotide using Ion Torrent
TM
 technology. 
The chip is flooded with a dNTP that passes over wells and is incorporated into a 
nascent strand of DNA on a bead if complementary to the parental strand. This 
incorporation causes the release of a proton that is detected by the chip and recorded by 
the machine to determine the sequence of the parental strand of DNA (adapted from 
Rothberg et al., 2011).  
It was anticipated that using this form of sequencing technology that it would be 
possible to determine: 
The exact role of TDP1 in mtDNA repair. 





) that was designed for sequencing analysis from the Ion 
Torrent
TM
 and would provide data on the number of mtDNA mutations generated as a 
result of the expression/knockdown experiments described in chapter 4. 
5.2 Methods 
5.2.1 mtDNA sequencing using Ion Torrent
TM
 
In order to determine the mutation rate in mtDNA following the expression/knockdown 
experiments conducted in chapter 4, it was necessary to perform deep sequencing. This 
was accomplished using Ion Torrent
TM
 technology (life technologies) with sequencing 







The process of generating samples for sequencing began with a LR-PCR step to 
generate two ≈8kb mtDNA fragments with primers Human mtDNA A (F and R) and 
Human mtDNA B (F and R) using 500ng DNA extracted following 
expression/knockdown experiments described in chapter 4. A control sample of mouse 
mtDNA cloned into the vector pAM1 was a kind gift form the lab of Professor 
N.G.Larsson which was previously sequenced by Bibb et al to discover the sequence 
and gene organisation of mouse mtDNA (Bibb et al., 1981a). This plasmid was 
considered to be the correct control to be used to determine the error rate of the 
sequencing technique as mtDNA from control human cells will contain a natural 
mutation rate that are not mutations generated as a result the sequencing technology. As 
with the DNA from human cells two DNA fragments of ≈8kb were generated through 
LR-PCR with primers Mouse mtDNA A (F and R) and Mouse mtDNA B (F and R) 
using 50ng plasmid DNA. LR-PCR reactions were performed in 25µl in 0.2ml reaction 
tubes with the following reagents (TaKaRa) and put through the following PCR 
programme: 
Table 5.1. LR-PCR reagents and programme used to generate mtDNA fragments 
(≈8kb) in preparation for deep sequencing. 
LR-PCR reagents  LR-PCR programme 
4µl dNTPs (2.5mM 
each) 






2.5µl 10x LR-PCR 
buffer 
25 mM TAPS (pH9.3 at 25℃) 
50 mM KCl 
2 mM MgCl2 













98 10 secs  
 




60 30 secs 
0.5µl LA Taq DNA 
polymerase 
 Extension 68 10 mins 







1 1µl DNA 
500ng for human cell DNA 











 agarose gel (Lonza) for 45 mins at 70V. Following this mtDNA fragments at the 
correct molecular weight (≈8kb) were excised from the gel and mtDNA was purified by 
phenol/chloroform extraction as described in 2.2.4 (vi). Quantification of DNA 
concentration was then determined as described in 2.2.4 (viii) and then 50ng of each 
mtDNA fragment (A and B from the LR-PCR) were combined at equal molarity in 35µl 
H2O in 1.5ml LoBind
®
 reaction tubes (eppendorf). 
Samples were then incubated at 37
o
C for 40 mins after 5µl Ion Shear
TM
 Plus 10x 
Reaction Buffer (life technologies) had been added. Once complete samples were then 
purified by firstly transferring them to 2ml LoBind
®
 reaction tubes (eppendorf) for 





 XP Reagent (Beckman Coulter) were added to each sample 
followed by a pulse spin and incubation at room temperature for 5 mins. Samples were 
then subjected to another pulse spin before being placed in the DynaMag™-2 magnetic 
rack (life technologies) and incubated for 3 mins. The supernatant was then discarded 
and 500µl freshly prepared 70% EtOH was added in each tube whilst still in the rack. 
Samples were incubated for 30 secs and each reaction tube was turned twice in the rack 
during this time. The supernatant was then discarded and this wash step was repeated. 
To remove residual EtOH samples were subjected to a pulse spin and replaced in the 
magnetic rack for 30 secs before any leftover EtOH was removed and samples 
incubated with open lids for ≥5 mins. Once this incubation was complete 25µl Low TE 
(life technologies) was added to each pellet and samples were then vortexed for 10 secs 
before being subjected to a pulse spin and incubated in the magnetic rack for 1 min. 




In order for final sequencing in later stages it was necessary to ligate barcoded adapters 
for identification of each sample when final analysis of the sequencing data was 
required. To ligate barcoded adapters the following reactions were set up with different 
barcode numbers, and subjected to the following programme:  
Table 5.2. Components and programme to ligate barcoded adapters to sheared DNA. 
All reagents were supplied by life technologies. 
Ligation reaction component Volume  Ligation programme 





10x ligation buffer 10µl  25 15 
Ion P1 adapter  2µl  






dNTP mix 2µl  
H2O 49µl  
DNA ligase 2µl  




Once the ligation programme was complete reactions were transferred to 2ml LoBind
®
 
reaction tubes (eppendorf) and 180µl AMPure
®
 XP Reagent (Beckman Coulter) was 
added before purification was carried out as described earlier. The purified DNA (now 
in 20µl Low TE (life technologies)) was then used for size selection of DNA of 150bp 
length as per the manufacturer’s instructions using the E-Gel® iBase™ unit and E-Gel® 
Safe Imager™ transilluminator combo kit with a 2% E-Gel® SizeSelect™ 2% Agarose 
Gel. 
 
Once DNA fragments of the correct length had been selected it was then necessary to 
amplify these in preparation for sequencing. This was performed by setting up the 





Table 5.3. Reagents and PCR programme to amplify 150bp DNA fragments in 




Volume  PCR programme 




























Once the PCR programme was complete samples were transferred to 2ml LoBind 
reaction tubes (eppendorf) and DNA was purified using 195µl AMPure
®
 XP Reagent 
(Beckman Coulter) as described earlier. Following purification the DNA was quantified 
using the 2100 Bioanalyzer (Agilent Technologies) as per the manufacturer’s 
instructions, and then DNA from all samples were combined to 26pM concentration to 
form a combined library for the final sequencing steps. This was kindly performed by 
Dr. Helen Tuppen. Briefly, the combined library was subjected to another PCR step to 
enrich the samples using the Ion OneTouch
TM
 system (life technologies) before the 




) sequencer (life 





) with insertion/deletion (INDEL) mutations 
discounted from analysis as the Ion Torrent
TM




The results in chapter 4 demonstrate that cell growth was reduced as a result of 
expression of both TOP1mt/FLAG and TOP1mt
Y559A
/FLAG with knockdown of TDP1. 
However, the levels of mtDNA encoded proteins and mtDNA copy number were not 
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affected; therefore it was decided to perform deep sequencing to determine whether 
there was an increase mtDNA mutation load with this treatment. As a control to 
determine the error rate of the sequencing procedure mouse mtDNA was used. This had 
been cloned into pAM1 and originally used to sequence the mitochondrial genome of 
the house mouse (Mus musculus), and therefore the resulting data should have been 
exactly the same as the reference sequence available on GenBank (accession number 
J01420.1) that had been published from this paper (Bibb et al., 1981a). Using this as a 
control would help to distinguish errors made as a result of the sequencing procedure, 
and those resulting from a natural mtDNA mutation load that would have occurred 
when the HEK293/TOP1mt/FLAG and HEK293/TOP1mt
Y559A
/FLAG cells were being 
cultured in normal conditions. The reference sequence used for human mtDNA was 
provided by Andrews et al (accession number NC 012920) (Andrews et al., 1999). 
Completion of this sequencing was anticipated to aid in determining whether mtBER 
was dependent on TDP1. 
5.3.1 Sequence data from expression/knockdown experiments 
As described in chapter 4 the expression/knockdown experiments had provided little 
data on the molecular level that could help to provide information of the exact role of 
TDP1 in mtDNA repair. Deep sequencing data is provided for the 
expression/knockdown experiments, which to remind included expression of 
TOP1mt/FLAG and TOP1mt
Y559A
/FLAG for six days (results shown in table 5.2), 




 HEK293 cells for six days (results 
shown in table 5.3), and expression of TOP1mt/FLAG and TOP1mt
Y559A
/FLAG with 
siRNA knockdown of TDP1 for six days (results shown in table 5.4). Insertion/deletion 





(life technologies) is prone to introducing these mutations. Explanations for headings in 
the tables are as follows: 
 
 Sample = DNA sample from each of the expression/knockdown experiments 
 Number of matched bases = Number of bases from sequencing data that were aligned to the 
reference sequence 
 Number of unmatched bases = Number of bases that were considered mutations by the 
NextGENe
®
 software (Softgenetics) 
 Ratio matched bases: unmatched bases = Ratio of number of matched bases to  number of 
mutations detected 
 Reference length (bp) = Length of the reference sequence in base pairs 
 Number of bases covered from reference (bp) = Number of bases from the reference sequence 
that were read during sequencing (slightly less for the control mouse mtDNA due to the 
availability of primers that did not include any of the pAM1 vector DNA). 
 
 
Table 5.4. Deep sequencing data of the control mouse mtDNA in pAM1 and human 
DNA samples following expression of TOP1mt/FLAG and TOP1mt
Y559A
/FLAG for six 
days as in chapter 4. 
 




















Mouse mtDNA 3115820 11520  3.697261 16295  16023  
WT - 4094734 24478 5.977922 16569 16569 
WT + 3563289 21643 6.073883 16569 16569 
MUT - 4065604 24109 5.929992 16569 16569 
MUT + 3034723 20325 6.697481 16569 16569 
*Sequencing was carried out as described in 5.2.1 with sample labelling’s as follows: 
Mouse mtDNA = mouse mtDNA cloned into pAM1 (control) 
WT - = HEK293/TOP1mt/FLAG cells without expression of TOP1mt/FLAG 
WT + = HEK293/TOP1mt/FLAG cells with expression of TOP1mt/FLAG 
MUT - = HEK293/TOP1mt
Y559A
/FLAG cells without expression of TOP1mt
Y559A
/FLAG 
MUT + = HEK293/TOP1mt
Y559A




Table 5.5. Deep sequencing data of human DNA samples following siRNA knockdown 
of TDP1 for six days as in chapter 4. 
 




















UT 5245914 28766 5.483506 16569 16569 
NT 3964357 23429 5.909912 16569 16569 
C 4713751 27560 5.846724 16569 16569 
*Sequencing was carried out as described in 5.2.1 with sample labelling’s as follows: 
UT = untransfected 
NT = non-targeted siRNA 




Table 5.6. Deep sequencing data of human DNA samples following siRNA knockdown 
of TDP1 and expression of TOP1mt/FLAG and TOP1mt
Y559A
/FLAG for six days as in 
chapter 4. 
 




















WT-UT 4572540 25401 5.555118 16569  16569  
WT-NT 5145911 30055 5.84056 16569 16569 
WT-C 6623268 34649 5.231405 16569 16569 
MUT-UT 5209559 29125 5.590684 16569 16569 
MUT-NT 4753097 25922 5.453707 16569 16569 
MUT-C 4798886 26657 5.554831 16569 16569 
*Sequencing was carried out as described in 5.2.1 with sample labelling’s as follows: 
WT-UT = Expression of TOP1mt/FLAG without any siRNA transfection 
WT-NT = Expression of TOP1mt/FLAG with transfection using non-targeted siRNA 
WT-C = Expression of TOP1mt/FLAG siRNA with transfection using construct C 
MUT-UT = Expression of TOP1mt
Y559A
/FLAG without any siRNA transfection 
MUT-NT = Expression of TOP1mt
Y559A
/FLAG with transfection using non-targeted siRNA 
MUT-C = Expression of TOP1mt
Y559A
/FLAG with transfection using siRNA construct C 
 
The data in tables 5.4, 5.5, and 5.6 do not appear to indicate a higher mutation load with 
any of the treatments in the cell lines used for these experiments as described earlier. 
Even in cells that displayed reduced cell growth with knockdown of TDP1 and 
expression of TOP1mt/FLAG and TOP1mt
Y559A
/FLAG for six days there was no 
indication of a significant increase in mtDNA mutation load in comparison to controls. 
One observation to note in table 5.4 is that the overall mutation ratio (ratio bases read: 
unmatched bases) is lower for the control mouse mtDNA than the controls from the 
human cell lines when compared to the reference sequence. Although there is a 
difference in the levels of mutations between the control mouse mtDNA and the other 
samples the difference is not so high and raises questions as to the sensitivity of using 







5.4 Discussion and conclusions 
The data outlined in this chapter does not appear to show an increased mtDNA mutation 
load with the expression/knockdown experiments described in chapter 4. This 
information has aided in the attempt to determine: 
 The exact role of TDP1 in mtDNA repair. 
Although the data indicates that there are no significant changes in mtDNA mutation 
load from cells that had shown decreased growth with knockdown of TDP1 and 
expression of TOP1mt it is possible to make assertions as to the exact function of this 
enzyme in mtDNA repair. However, a critical discussion of the techniques used to 
assess mtDNA mutation load must first be carried out before any definitive conclusions 
about the role of TDP1 in mtDNA repair will be made.  
Next generation sequencing to assess de novo mtDNA mutations 
The decision to use next generation sequencing to assess mtDNA mutations was taken 
as the experiments in chapter 4 suggested a negative impact on cell growth with TDP1 
knockdown and expression of TOP1mt, but western blot analysis and qRT-PCR did not 
suggest a severe impact in these cells with this treatment. It was anticipated that using 
Ion Torrent
TM
 technology (life technologies) would provide a more sensitive 
mechanism to determine the exact effect of this treatment as increased mtDNA mutation 
load would potentially be detected. However, before samples could be sequenced they 
firstly underwent a preparation phase. This began with a LR-PCR step to amplify two 
≈8kb regions so that full coverage of the mitochondrial genome was achieved. There 
were two additional PCR steps in this protocol when fragmented DNA with ligated 
adapters is amplified, and when these products are then clonally amplified onto beads 
before being loaded onto a chip for sequencing. These PCR steps all have the potential 
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to introduce mutations into DNA that may then be recorded as mutations that had 
occurred due to knockdown of TDP1 and expression of TOP1mt/FLAG 
TOP1mt
Y559A
/FLAG. Despite this all samples were treated with the same library 
preparation protocol and so any mutations arising from this preparation would have 
occurred in a similar amount in all samples and would have been taken into account in 
the analysis of final mutation numbers. 
 
Ultra-deep sequencing of the mtDNA mutator mouse using the SOLiD
TM
 sequencing 
platform (life technologies) indicated that there were significant increases in mtDNA 




 in comparison to heterozygous and 
wild type controls (a total of 10 samples were loaded onto the chip for sequencing in 
this instance) (Ameur et al., 2011). Although this may have been expected for the 
homozygous mutant, the heterozygous mice also displayed a higher ratio of mutations 
despite being phenotypically similar to wild type mice (Ameur et al., 2011, Trifunovic 
et al., 2004). This suggests that even under circumstances where a strong phenotype is 
not seen mutation levels are increased and detectable using deep sequencing technology 
(Ameur et al., 2011). This relates to our own studies as the deep sequencing of mtDNA 
from cells that showed a decreased growth rate would surely have produced detectable 
levels of mtDNA mutations using Ion Torrent
TM
 technology. However, this was not the 
case and there did not appear to be any notable differences in mutation levels in mtDNA 
from the cells used in the expression/knockdown experiments. It could be argued that 
the error rate generated from the library preparation and sequencing using the Ion 
Torrent
TM
 was too high to detect any mutations arising in mtDNA as a result of TDP1 
knockdown and expression of TOP1mt/FLAG and TOP1mt
Y559A
/FLAG. Although the 
mutation rate is lower in the control mtDNA (≈3.7x10-3) than in the samples from 
expression/knockdown experiments (≈5.2-6.7-3) these differences are not significant 
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enough to suggest that they are a result of a natural mutation rate occurring in the cells 





(Larsson, 2010, Vermulst et al., 2007, Vermulst et al., 2008). This suggests that Ion 
Torrent
TM
 technology and/or the NextGENe
®
 may not be capable of detecting high 
levels of random mtDNA mutations that may have occurred as a result of the 




 mutator mouse 
were reported to be ≈1.1-1.3x10-3 using SOLiDTM sequencing platform, mentioned 
earlier, which adds to the argument that the Ion Torrent
TM
 was not sensitive enough for 
our purposes (Ameur et al., 2011). These mice accumulate a greater number of mtDNA 
mutations due to their proof-reading deficient form of PolgA (Trifunovic et al., 2004). 
In our experiments even the control mtDNA sample had a mutation rate higher than that 
of the mutator mouse suggesting a very high error rate of the Ion Torrent
TM
 sequencing 
platform (Ameur et al., 2011). Despite this, the data provided in previous chapters offers 
the potential for further discussion of the role of TDP1 in mtDNA repair. 
 
Although the data presented in this chapter does not provide any conclusive data the 
results in chapter 4 suggest it would be fair to conclude that mtBER is not dependent on 
TDP1 as Das et al (Das et al., 2010) suggested for the following reasons:  
 Tdp1 -/- mice did not show signs of mtDNA damage despite various treatments 
to induce this. 
 
 There were no signs of severe mtDNA damage with knockdown of TDP1 in 
human cells. 
 
 There are a wide variety of DNA lesions that can occur within the mitochondrial 
genome that TDP1 is not capable of repairing (e.g. 5’ adenine monophosphate 
repaired by APTX). 
 
Therefore, what role does TDP1 have in mtDNA repair? The observation in chapter 4 
that there was no decrease in mtDNA copy number or levels of mtDNA encoded 
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proteins with TDP1 knockdown and expression of TOP1mt/FLAG and 
TOP1mt
Y559A
/FLAG may suggest that either TDP1 is not involved in mtDNA to a great 
degree or that there are mechanisms present that can compensate for this loss. The 
reduction in cell growth with TDP1 knockdown and expression of TOP1mt/FLAG and 
TOP1mt
Y559A
/FLAG would imply that there is some negative impact in mitochondria in 
these cells such as reduced levels of mitochondrial mRNA transcripts that could then 
affect ATP production from OXPHOS resulting in reduced cell growth. Another 
possibility could be that this treatment stalled mtDNA replication that then affected cell 
growth also, but which was not accompanied by mtDNA depletion in 6 days of this 
treatment as our results demonstrated in chapter 4. However, these theories are purely 
speculative at this point and it is necessary to discuss further how this treatment may 
have been detrimental in cells on the molecular level and whether there are other means 
of repairing any damage caused by this treatment. 
The first inference that other repair mechanisms existed to compensate for the loss of 
TDP1 was made in S. cerevisiae where RAD1 and MUS81 were able to repair DNA-
TOP1 lesions in the nucleus in the absence of TDP1 (Liu et al., 2002). It was proposed 
that these enzymes excised a section of DNA surrounding the CPT generated DNA-
TOP1 lesion, which acted as a compensatory mechanism for repairing this type of 
damage without the preferred TDP1 (Liu et al., 2002). Another study that involved our 
collaborators identified tyrosyl-DNA-phosphodiesterase 2 (TDP2) to be involved in 
repairing DNA-TOP1 lesions in the absence of TDP1 (Zeng et al., 2012). Despite the 
main function of TDP2 being repair of lesions involving double strand breaks where 
topoisomerase 2 (TOP2) is covalently bound to the 5’ end of DNA at this lesion it can 
still function to repair TOP1 mediated damage (Cortes Ledesma et al., 2009, Zeng et al., 
2012). The data presented in this thesis suggests that there is some detrimental impact 
with loss of TDP1 and expression of TOP1mt/FLAG or TOP1mt
Y559A
/FLAG shown by 
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a reduction in cell growth. However, mtDNA depletion and a reduction in the levels of 
mtDNA encoded proteins may have been prevented with compensatory repair of these 
lesions by TDP2. Although TOP2 and TDP2 have yet to be identified in mitochondria 
this evidence demonstrates that there are alternative mechanisms that could exist to 
repair mtDNA-TOPMT lesions when TDP1 is not present. This could explain why the 
impact of losing TDP1 in mice and in human cells is not so severe on the molecular 
level as claimed previously (Das et al., 2010).  
This leads to the conclusion that mtBER is not dependent on TDP1 as proposed by Das 
et al using H2O2 treatment and a questionable semi-quantitative PCR based assay, and 
that this enzyme is predominantly responsible in repairing lesions involving TOP1MT 
bound to mtDNA in mitochondria (Das et al., 2010). The potential for this enzyme to be 
involved in other repair pathways as with TDP2 cannot be determined based on the data 
presented in this thesis, but it can be concluded that TDP1 is not essential for mtDNA 
repair based on our observations. Although TDP1 may not be essential to mtDNA repair 
it may be possible that the DNA repair machinery in mitochondria is more intricate than 
we think. This then leads us to ask whether there are more proteins involved in DNA 
repair in mitochondria, and what associations do current proteins involved in this 
subject have with each other and how are these associations mediated? The latter 
question is reviewed in the next chapter with reference to TDP1 and the mitochondrial 







Chapter 6. Does phosphorylation of amino acid 81 in TDP1 promote 
association with mitochondrial DNA ligase IIIα? 
 
 
6.1 Introduction  
 
The data previously described within this thesis has identified TDP1 as a novel DNA 
repair enzyme in mitochondria. Whilst investigating the exact role of TDP1 in mtDNA 
repair it was also decided to explore some other factors that may influence TDP1 
function in mitochondria, and/or provide a greater comprehension of how the mtDNA 
repair network operates to protect against mtDNA damage. More specifically, the 
association between TDP1 and another protein involved in mtDNA repair, namely DNA 
ligase IIIα (LIG3α), would be scrutinised to determine whether these two proteins have 
a direct link with each other in mitochondria, and if so the exact mechanism that 
facilitates their association. 
 
Our collaborators reported that the association between TDP1 and LIG3α in the nucleus 
was mediated by phosphorylation of amino acid 81 in TDP1 using both yeast 
(Saccharomyces cerevisiae) and MEFs. Phosphorylation of this amino acid (serine, 
S81) was shown to promote the association between TDP1 and LIG3α in A549 cells by 
using expression of a mutant form of TDP1 with a change in amino acid 81 from serine 
to alanine. This change prevented phosphorylation at this site, which inhibited the 
interaction between TDP1 and LIG3α. This inhibition of interaction between the two 
proteins reduces the stability of TDP1 which could be as a result of either a 
conformational change in TDP1 that affects its tertiary structure rendering it unstable, or 
more simply, a need for LIG3α association for stability and function. Subsequently cell 
survival was reduced when DNA-TOP1 lesions were induced using camptothecin 
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(CPT), which suggests the interaction of TDP1 with LIG3α is important to repair of 
these specific lesions in the nucleus. This data provides an intriguing example of the 
intricacies underlying post-translational modifications in relation to DNA repair in the 
nucleus, and based on this it was decided to try and find whether a similar association 
existed in mitochondria (Chiang et al., 2010). 
 
In consideration of this and given that TDP1 had been identified in having a role in 
mtDNA repair, this strand of the project was set about to determine whether: 
 
Phosphorylation of amino acid 81 in TDP1 promotes the association with 
mitochondrial DNA ligase IIIα. 
 
This was accomplished by using protein complex immunoprecipitation (Co-IP) with 
two mitochondrially targeted variants of TDP1; a phosphomimetic version 
(mtTDP1
S81E
/FLAG) and a non-phosphorylatable form (mtTDP1
S81A
/FLAG). If this 
association was found it would open many possibilities as to the depth of the mtDNA 




















/FLAG had been completed (as 
described in 2.2.2 (vii) it was necessary to determine whether clones for each cell line 
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/FLAG upon induction. This was carried out by 
seeding 5x10
5
 cells for each cell line in 2ml supplemented DMEM in 2 wells of a 6-well 
plate for each clone. Tetracycline was then added at 1µg/ml final concentration in 1 well 
for each clone and all cells were incubated as described in 2.2.2 (i) for 18 hours before 
being harvested with 0.5ml PBS/1mM EDTA, neutralised in 0.5ml supplemented 
DMEM, and centrifuged for 4 mins at 200xg. Cytoplasmic protein was then isolated as 
described in 2.2.3 (i) to allow analysis by SDS-PAGE as in 2.2.3 (vii) and western 
blotting as in 2.2.3 (viii) to determine which clones for each cell line expressed their 
respective protein.  
 







To assess the association between the mitochondrial DNA ligase (LIG3α) and TDP1 a 
Co-IP was carried out following expression of a phosphomimetic form of TDP1 
(mtTDP1
S81E
/FLAG) and a non-phosphorylatable form (mtTDP1
S81A
/FLAG), as well as 




 expression system (life technologies); a 
mitochondrially targeted FLAG-tagged luciferase (mtLUC/FLAG). This mtLUC/FLAG 
should not associate with LIG3α and would act as a control by helping to rule out any 





system in HEK293 cells. The resulting samples would then analysed by mass 
spectrometry to determine whether phosphorylation of amino acid 81 of TDP1 was 
responsible for its association with LIG3α in the mitochondrion similar to that observed 









/FLAG were grown in 3x 300cm
2
 flasks each with 50ml 
supplemented DMEM. Expression of each protein was induced with addition of 1µg/ml 
tetracycline and cells were incubated as described in 2.2.2 (i) for 48 hours. Cells were 
harvested using 20ml PBS/1mM EDTA and neutralised in 20ml supplemented DMEM 
before being centrifuged at 200xg for 4 mins followed by mitochondrial isolation and 
purified as in 2.2.3 (ii) and 2.2.3 (iv), respectively. Mitochondrial protein was quantified 
by Bradford analysis and up to 5mg mitochondrial protein from each cell line was 
resuspended in 500µl lysis buffer in separate 1.5ml reaction tubes. Each sample was 
incubated at 4
o
C while being rotated for 30 mins before samples were centrifuged at 
12000xg for 10 mins at 4
o
C. The supernatant from each sample was then transferred to 
new 1.5ml reaction tubes and protein quantified by Bradford analysis as in 2.2.3 (vi). 
 
Then up to 3mg of each sample was transferred to separate 1.5ml hydrophobic reaction 
tubes with 40µl ANTI-FLAG M2 affinity gel that had already been washed 3x in 1x 
washing buffer, and samples were then incubated with rotation at 4
o
C for 3 hours. Each 
sample was then centrifuged at 5000xg for 30 secs before the supernatant was removed 
and discarded. Each sample was washed 3x using 1ml 1x washing buffer and 
centrifuging at 5000xg for 30 secs for each wash. Once the supernatant had been 
discarded following the final wash step 5µl of 3xFLAG peptide (5µg/µl) was added 
with 100µl 1x washing buffer and added to the ANTI-FLAG M2 affinity gel now 
encompassing bound protein from each sample. Samples were then incubated at 4
o
C for 
45 mins with rotation. Once incubation was complete the supernatant from each sample 
was carefully removed and transferred to fresh 1.5ml reaction tubes for analysis of 
protein associations by silver staining and mass-spectrometry. The beads were also 




Lysis buffer      10x washing buffer 
50mM Tris HCl, pH 7.4,     0.5M Tris HCl, pH 7.4  
150mM NaCl       1.5M NaCl 
1mM EDTA      10mM MgCl2 
10mM MgCl2      1mM PMSF 
1mM PMSF      10U SUPERase•In™ (life 
technologies) 
60U SUPERase•In™ (life technologies)  1 protease inhibitor tablet* (Roche) 
1% Triton X-100 
  
*Added at the time of dilution of 1ml 10x washing buffer with 9ml DEPC treated H2O 
 
 
6.2.3 Silver staining 
 





/FLAG following Co-IP and to provide some 
preliminary data as to the association of TDP1 with LIG3 and/or any other proteins in 
the mitochondrion. This was performed by first mixing 5µl of each elution sample with 
5µl 2x dissociation buffer, and 2µl each beads sample with 2µl 2x dissociation buffer. 
Each sample was then denatured at 95
o
C for 3 mins before being run on a 10% SDS-
PAGE as described in 2.2.3 (vii). Once molecular weight marker 40kDa subunit had 
reached the bottom of the gel the gel was carefully removed and washed for 1 hour in 
50% NaOH. Both TDP1 (≈70kDa) and LIG3α (≈113kDa) should still be in the gel at 
this point so any association should be seen, and any other proteins would be identified 
on mass-spec analysis. During this time the silver stain was prepared. After 1 hour the 
50% NaOH was discarded and the gel was stained with the silver stain solution with 
rocking for 15mins. The silver stain was then discarded and the gel was washed 3x for 5 
mins in H2O before being developed with 50ml developer solution with agitation until 
protein bands could be seen (≈ 3 mins). The gel was then fixed in fixing solution 
overnight before being washed for 10 mins in 30% EtOH followed by washing for 10 
mins in H2O and an image taken. 
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2x dissociation buffer Silver stain (100ml)  Developer solution 
(200ml) 
0.125M tris-HCl, pH 6.8 21ml 0.36% NaOH  1ml 1% citric acid 
4% SDS   1.4ml NH4OH   300µl 37% formaldehyde 
0.15M DTT   77.6ml H2O   198.7ml H2O 
15% glycerol   0.8g AgNO3 in 4ml H2O* 
0.01% bromophenol blue 
0.01% benzonase 
 
*Added last in a drop by drop manner with agitation until liquid becomes slightly darker 
 
 
6.2.4 Preparation of samples for mass-spectrometry analysis 
In order for Co-IP samples to be analysed by mass-spectrometry the samples needed to 





/FLAG as described in 6.2.2 were 
mixed with 20µl 4x dissociation buffer. Each sample was denatured at 95
o
C for 3 mins 
and samples were separated on a 12% SDS-PAGE as described in 2.2.3 (vii) at 60V 
until ≈1cm into the resolving gel. The gel was then removed and each lane for each 
sample was cut out and transferred to separate 1.5ml reaction tubes before 1ml 
acetonitrile was added in each tube and incubated for 30 mins at room temperature. The 
acetonitrile was removed and a small hole was created in the lid of each reaction tube 
before the lid was closed and samples incubated overnight at room temperature to allow 
the acetonitrile to evaporate. Each sample was then sent for mass-spectrometry analysis 
at: 
 
Nijmegen Proteomics Facility/Nijmegen Centre for Mitochondrial Disorders 
Department of Laboratory Medicine  
Radboud University Nijmegen Medical Centre 
 
 
4X Dissociation buffer 
0.25M tris-HCl, pH 6.8  
8% SDS     
0.3M DTT     
30% glycerol    
0.02% bromophenol blue   









/FLAG following stable 
transfection 
 









 HEK293 cells as described in 2.2.2 (vii) and the expression experiments 





/FLAG were being expressed in their cell lines. 
Figure 6.1 illustrates the results from expression of each protein. 
 
   A 
 
   B 
 




/FLAG expression. Western 
blot analysis as described 2.2.3 (viii) using 20µg cytoplasmic protein isolated as 





 HEK293 cells as described in 2.2.2 (vii). Expression 
of each protein was induced with addition of 1µg/ml (final concentration) tetracycline 
from 5x10
5
 cells in 2ml supplemented DMEM in 6-well plates, followed by incubation 
for 18 hours in conditions outlined in 2.2.2 (i). A separate well containing 5x10
5
 cells 
for each clone in 2ml supplemented DMEM was left without tetracycline as controls 
(A) Analysis of 3 clones following transfection of mtTDP1
S81E
/FLAG. (B) Analysis of 4 










were successfully expressed in each of the clones that had survived treatment with the 
antibiotics blasticidin S and hygromycin B. In A expression of mtTDP1
S81E
/FLAG can 
be seen in three different clones of HEK293/mtTDP1
S81E
/FLAG in lanes 2, 4, and 6 
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whereas the uninduced samples in lanes 1, 3, and 5 show no expression. Similarly in B 
successful expression of mtTDP1
S81A
/FLAG can be seen from four different clones of 
HEK293/mtTDP1
S81A
/FLAG in lanes 2, 4, 6, and 8 whereas in induced samples there is 
no expression seen in lanes 1, 3, 5, or 7. Equal loading of the western blot was proven 





/FLAG would be used as they 
appeared to show the strongest signal on western blotting, which at the time was 
thought to be the best criterion for selection. 










/FLAG were localised to 
mitochondria upon expression in respective clones A a Proteinase K (life technologies) 
protection assay was performed. This assay, described in 2.2.3 (v), had already been 
used to show localisation of TOP1mt/FLAG and TOP1mt
Y559A
/FLAG to mitochondria 
in chapter 4 (figure 4.6) and so this procedure had been optimised from earlier 
experiments; i.e. 2µg Proteinase K (life technologies) was required to show protection 













   A 
 
   B 
 





localisation. Western blot analysis as described 2.2.3 (viii) using 10µg mitochondrial 










 HEK293 cells as described in 2.2.2 (vii). Expression of each protein was 
induced in each cell line with addition of 1µg/ml (final concentration) tetracycline 
followed by incubation for 18 hours in conditions outlined in 2.2.2 (i). Localisation of 
both proteins was assessed by addition of 2µg Proteinase K (life technologies) with or 
without Triton X-100 as described in 2.2.3 (v) and optimised from chapter 4 (figure 4.6) 
(A) Analysis of mtTDP1
S81E






The results presented here show that with 2µg Proteinase K (life technologies) in the 
presence on Triton X-100 was sufficient to degrade each expressed protein (lane 3 in 





/FLAG were protected by the outer mitochondrial membrane despite 
addition of 2µg Proteinase K (life technologies), similar to the untreated control in lane 




/FLAG are in fact 
imported to mitochondria in their respective cell lines. 
 
6.3.3 Co-IP using FLAG-tagged expressers 
 





complete as described in 6.2.2, analysis of the binding affinities of each protein could 
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then be assessed. This was carried out to determine whether phosphorylation of amino 
acid residue 81 in TDP1 is responsible for its association with LIG3α in mitochondria, 
providing this association exists. Two methods for assessing this association were 
performed and the results from these are outlined as follows.  
 
i) Silver staining 
 





/FLAG were expressed and present following the 
Co-IP, but in the main to provide preliminary data as to whether LIG3α was associated 
with any of these proteins. Results from silver staining as outlined in 6.2.3 are shown in 
figure 6.3. 
 





/FLAG. Silver staining as described in 6.2.3 following Co-IP as 





/FLAG with associated proteins from beads (B) and elution (E) from the 
Co-IP. Of each sample 10µl was separated by SDS-PAGE as described in 2.2.3 (vii) 
before silver staining was carried out. Lane 1 (also L) represents the molecular weight 
marker used for the gel. 
 
 





/FLAG were present following the Co-IP by strong 
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bands being present at a the correct molecular weight for each protein (≈70kDa, lanes 2-
7), but that there was no obvious presence of LIG3α (expected size ≈113kDa).  
 
ii) Mass spectrometry data 
 
Following the data provided in figure 6.3 that shows no obvious sign that a protein of 
the molecular weight of LIG3α (≈113kDa) was present, samples were prepared as 
described in 6.2.4 and sent for mass-spectrometry analysis. Table 6.1 lists the proteins 
that were associated with mtTDP1
S81E
/FLAG from the Co-IP that were different to the 
proteins associated with the control mtLUC/FLAG. Table 6.2 lists the proteins 
associated with mtTDP1
S81A
/FLAG that were different to the control also. 
Table 6.1. Mass spectrometry data of proteins identified following Co-IP (described in 




Protein GI Protein Gene emPAI 
83715985 
3-hydroxyacyl-CoA 


















protein, mitochondrial precursor SSBP1 
 
0.165914401 
*The proteins identified are those that were found to be different to those from the control expression and 




















Table 6.2. Mass spectrometry data of proteins identified following Co-IP (described in 





























4504897 importin subunit alpha-2 KPNA2 0.245197085 























acyl-coenzyme A thioesterase 9, 







tRNA modification GTPase 













*The proteins characterised in this table are those that were found to be different to those from expression 
of mtLUC/FLAG as a control. For full table including those for mtLUC/FLAG see appendix. 
 
 
The data in table 6.2 demonstrates that there is no association between 
mtTDP1
S81A
/FLAG and LIG3α; however this is also the case for mtTDP1S81E/FLAG 
which can be seen in table 6.1. Full data including all associated proteins from the Co-




/FLAG can be seen in the 
appendix, but this also confirms that LIG3α is not associated with mtLUC/FLAG and 
subsequently does not explain the absence of LIG3α from either table 6.1 or 6.2. This 
data suggests that phosphorylation of amino acid 81 of TDP1does not affect its 
association with LIG3α in the mitochondrion, and also raises the possibility that these 






6.4 Discussion and conclusions 
 
The data presented in this chapter was performed in order to try and determine whether 
the association of TDP1 and LIG3α was present in mitochondria, and if so whether: 
 
Phosphorylation of amino acid 81 in TDP1 promotes the association with LIG3α 
 
Although the data provided here does not demonstrate that there is an association 
between TDP1 and LIG3α, it is still relevant to discuss the details underlying this kind 
of association in mitochondria, some of the potential reasons for our own observations, 
and consideration of some future perspectives regarding our results. 
 
Phosphorylation in mitochondria 
 
Phosphorylation of proteins is one form of post-translational modification that can 
affect the activity of enzymes in a regulatory manner, with other examples including 
modifications that incorporate nitric oxide (nitrosylation) and/or introduce acetyl groups 
(acetylation) into proteins to alter their function (O'Rourke et al., 2011). These examples 
are just a small group of a huge collection of post-translation modifications that have 
been reported to modify the function of an enzyme in regulated cellular processes, and 
conversely, as for oxidative damage, affect the ability of enzymes to fulfil their 
requirements (O'Rourke et al., 2011). Although post-translation modifications have a 
wide variety of purposes in cells it is important to discuss how these modifications 




Phosphorylation of proteins by kinases is a relatively undefined in mitochondria when 
compared with the knowledge accrued for nuclear kinases and their role in DNA repair. 
Therefore, findings of nuclear mechanisms for DNA damage responses provided a basis 
for the experiments outlined in this chapter of my thesis (Chiang et al., 2010, Shiloh, 
2006). As discussed earlier, our collaborators previously reported that phosphorylation 
of TDP1 at serine 81 mediated its association with LIG3α in the nucleus; thus 
demonstrating that factors other than the actual enzyme activity of TDP1 affected the 
DNA damage response (Chiang et al., 2010). This discovery resulted from previous 
reports that the checkpoint kinases Ataxia Telangiectasia-mutated (ATM) and ATM-
Rad3-related (ATR) that phosphorylate proteins at serine-threonine-glutamine (S/TQ) 
sites, phosphorylate TDP1, and that TDP1 contains five S/TQ sites also (Zhou et al., 
2005, Mu et al., 2007). There has recently been 77 phosphoproteins identified in 
mitochondria from human skeletal muscle by mass spectrometry, and ATM was also 
shown to have a role in phosphorylation of some of these (Zhao et al., 2011, O'Rourke 
et al., 2011). Although TDP1 was not included in these findings the method for 
interpreting mitochondrial and non-mitochondrial proteins was based on the known 
mitochondrial proteins at the time of the publication (Zhao et al., 2011). At that time 
TDP1 had not been reported to be present in mitochondria and would not have been 
considered in the investigations of this group (Zhao et al., 2011). Therefore, our own 
aim to study the interaction between TDP1 and LIG3α was valid as work is on-going to 







Phosphorylation of amino acid 81 in TDP1 did not promote the association with 
LIG3α 
 
The data presented in table 6.1 demonstrates that despite the phosphomimetic amino 
acid at position 81 in TDP1, there is no observable association with LIG3α using this 
system. With this in mind the potential reasons for this result will be explored to try and 
determine whether there is no association between TDP1 and LIG3α in the 
mitochondrion, or whether the system and methods used to detect this association were 
not adequate for this purpose. 
 
The majority of support for conducting the experiments outlined in this chapter came 
from published work performed by our collaborators. However, in this publication the 
phosphomimetic TDP1
S81E
 form of TDP1 was not used to demonstrate that LIG3α still 
associated with this enzyme containing this amino acid substitution (Chiang et al., 
2010). This amino acid substitution to glutamic acid mimics the structure of 
phosphorylated serine and should form normal associations with other proteins similar 
to the wild type. But with our collaborators not using this form of TDP1 in their work 
the question was raised as to whether the association with LIG3α was ever likely to 
occur in mitochondria with the change in amino acid 81. Although the phosphomimetic 
form of TDP1 was not used in our collaborators study, previous work using this tool to 
assess phosphorylation has been carried out with success which would suggest that it 
was an acceptable method for our own purposes (Farah et al., 2012, Pepio and Sossin, 
2001).  
 
Another possibility in failing to detect the association between TDP1 and LIG3α in this 







 system. Expressing a mitochondrially targeted form of TDP1 in HEK239 
cells using this system is not exactly equivalent to the levels of expression normally 
observed in vivo, which may have caused disruption of the protein complexes in 
mitochondria in these experiments. However, this strategy of expression in HEK293 
cells has been employed in our lab with great success when expression of protein using 
this system matched that of the endogenous levels of the protein that was being studied 
(Richter et al., 2010, Rorbach et al., 2008, Temperley et al., 2010). When the 
experiments outlined in this thesis were carried out this was not taken into consideration 
when expressing TDP1 in these cells which may have saturated binding with LIG3α, 
thus accounting for the absence of any detectable association. Another point for 




HEK293 cells contained the Su9 presequence from N. crassa, which would likely alter 
the mode of transport into mitochondria than that of the TDP1 proteins without this 





/FLAG were both successfully localised to 
mitochondria and were detected at the correct molecular weight (i.e. without the 
mitochondrial presequence that would add ≈7kDa) it is unlikely that this would have 
affected any potential affinity of these proteins with LIG3α once in the mitochondrion. 
Also, the exact mechanism of TDP1 entry into mitochondria is currently unknown and 
so transforming HEK293 cells with FLAG-tagged forms of TDP1 without the 
presequence may have prevented successful entry into the mitochondrion. Other 
possibilities for not detecting an association between TDP1
S81E/FLAG and LIG3α could 
be that any association between the two proteins is transient and that crosslinking may 
have been required before the Co-IP was performed. This could have been carried out 
using paraformaldehyde, however, it is likely that many other proteins that do not 
normally associate with TDP1 would have been found from the Co-IP and this step was 
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not required for previous experiments in our lab (Richter et al., 2010, Rorbach et al., 
2008, Temperley et al., 2010). 
 
Based on the data presented in this chapter and considering the limitations of some of 
the methods used, it has not been possible to come to a firm conclusion on whether 
phosphorylation of amino acid 81 of TDP1 promotes the association with LIG3α in the 
mitochondrion. 
 






Although the association between TDP1 and LIG3α was not detected in these 
experiments it is worthwhile discussing some of the proteins that were found to be 
associated with TDP1 using these methods. The first protein for discussion was 
associated with both forms of TDP1 and was identified as 3-hydroxyacyl-CoA 
dehydrogenase type-2 isoform 2, which is known to be an RNase P enzyme (Holzmann 
et al., 2008). These enzymes are involved in the maturation of tRNAs by cleavage of 
nucleotides from the 5’ end to form the correct sequence once processing of the 3’ end 
has also taken place by tRNase Z (Robertson et al., 1972, Ceballos and Vioque, 2007). 
A mitochondrial form of human RNase P (mtRNase P) has previously been identified 
suggesting a role of this enzyme in the maturation of tRNAs in mitochondria 
(Rossmanith et al., 1995, Holzmann et al., 2008). In most cases RNase P enzymes 
consist of an RNA component with one or more proteins that act together to perform 
their desired role (Evans et al., 2006). However, it was identified that mtRNase P 
consisted only of protein subunits and did not require an RNA component for activity, 
which was the first occasion that this had been demonstrated for any RNase P 
(Holzmann et al., 2008). This was accomplished with tRNA maturation activity assays 
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that involved using reconstituted mtRNase P made with three affinity-purified proteins 
that established function of this enzyme without the need for an RNA subunit 
(Holzmann et al., 2008). The association of this protein with both forms of TDP1 may 
suggest that TDP1 is somehow involved in maturation of tRNA in mitochondria, but 
this is highly speculative as to date TDP1 has only been identified in repair of DNA.  
 
Other proteins that were identified from the Co-IP with TDP1
S81A
 that are also involved 
in RNA processing include polynucleotide nucleotidyltransferase 1 (PNPase) and tRNA 
modification GTPase (GTPBP3). PNPase was found to be involved in degradation of 
mRNA transcripts in the mitochondrion in cooperation with human SUV3 (hSUV3); 
another protein involved in mRNA degradation (Szczesny et al., 2013). Degradation by 
these proteins occurs in specific areas of the mitochondrial network (degradosome-foci, 
or D-foci) and from this it has been suggested that mRNA degradation in mitochondria 
by PNPase and hSUV3 is spatially organised, but further information on this has yet to 
be elucidated (Szczesny et al., 2013). As for GTPBP3, this protein has been found to be 
involved in maturation of mitochondrial tRNAs (Villarroya et al., 2008). More 
specifically, the protein has two isoforms in humans that have different length domains 
(G-domains) that are responsible for hydrolysing GTP from mRNA transcripts 
(Villarroya et al., 2008). Although in vitro assays performed by Villarroya et al using 
synthesised tRNAs and purified protein for each isoform of GTPBP3 the exact reasons 
for the existence of two isoforms of this protein were not found and have yet to be 
described (Villarroya et al., 2008). Another protein that was found from the Co-IP and 
is involved in maturation of tRNA is the mitochondrial seryl-tRNA synthetase 
(SARS2). Aminoacyl-tRNA synthetases are responsible for charging tRNAs with the 
correct amino acid, and in the case of SARS2 this enzyme is responsible for charging 
tRNA
Ser
 with L-serine (Konovalova and Tyynismaa, 2013). Mutations in SARS2 have 
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been linked with a disease presenting with primary pulmonary hypertension, 
progressive renal failure, and OXPHOS deficiency with patients dying before 14 
months of life (Konovalova and Tyynismaa, 2013). This highlights the importance of 
correct mitochondrial RNA processing as the damaging effects caused by the loss of 
just one amino acid can be potentially fatal. The presence PNPase, GTPBP3, and 
SARS2 in mass-spec data from the Co-IP with TDP1
S81A
 similar to 3-hydroxyacyl-CoA 
dehydrogenase type-2 isoform 2 may further implicate TDP1 in RNA maturation 
processes. However, to date there have been no data described on this and PNPase, 
GTPBP3, and SARS2 were only found in the Co-IP with TDP1
S81A
, which may suggest 
that these findings are as a result of this form of the protein being non-phosphorylatable 
or potentially as a result of structural changes caused by this amino acid substitution. 
 
An interesting protein association identified from the Co-IP of both forms of TDP1 is 
that involving thioredoxin-dependent peroxide reductase, mitochondrial isoform b 
(commonly known as peroxiredoxin 3, Prx3), which is involved in the antioxidant 
system within mitochondria (Watabe et al., 1997). Peroxiredoxins are a group of 
enzymes responsible for catalysing the reduction of hydrogen peroxide (H2O2) to water 
(H2O) with a conserved cysteine being the residue at which reduction takes place (Kil et 
al., 2012, Yang et al., 2002). The majority of peroxiredoxins are functional in the 
cytosol, however Prx3 is known to localise to mitochondria and act with its electron 
donors thioredoxin 2 (Trx2) and thioredoxin reductase 2 (TrxR2) to reduce H2O2 (Chae 
et al., 1999, Lee et al., 1999, Spyrou et al., 1997). On occasion incomplete reduction of 
oxygen (O2) to H2O can lead to the formation of reactive superoxide (O2
-
) anions that is 
converted to the less harmful H2O2 by superoxide dismutase (SOD) (Rhee et al., 2001). 
Although H2O2 on its own is not particularly reactive under certain circumstances it can 
be reduced to form the highly damaging hydroxyl radical (
.
OH) (Rhee et al., 2001). It is 
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therefore the function of peroxiredoxins to prevent this by reducing H2O2 to water, 
which will lessen the potential for damage to mtDNA in the case of Prx3 (Rhee et al., 
2001). A study using siRNA was conducted and demonstrated that the loss of Prx3 led 
to an increase in the levels of H2O2 which caused a reduction in the levels of 
mitochondrial mRNA transcripts most probably because of an increased level of 
mtDNA damage (Chang et al., 2004). It was also found that apoptosis was increased in 
HeLa cells with Prx3 knockdown due to release of cytochrome c into the cytosol and an 
increased rate of cleavage of procaspases-3 and -9 (Chang et al., 2004). These results 
suggest that Prx3 is very important as an antioxidant in mitochondria, which potentially 
makes its association with TDP1 very meaningful. However, no obvious link between 
TDP1 and Prx3 exists in terms of how these enzymes might act together in DNA repair, 
and it was decided that this association would not be pursued scientifically with general 
theme of the thesis in mind. 
 
Another protein associated with both forms of TDP1 was importin subunit alpha-2, but 
much of the information available on this protein suggest that it is nuclear with no link 
to mitochondria to date (Ito et al., 2000, Wang et al., 2011). Although this protein may 
function in mitochondria in some capacity it was decided not to carry on in any attempt 
to find a function for this protein in mitochondria. However, a protein that is known to 
be mitochondrial was associated with TDP1
S81E
, namely the mitochondrial single 
stranded DNA binding protein (mtSSB). Interestingly, this protein was not found to 
associate with TDP1
S81A
 that may suggest phosphorylation of TDP1 at amino acid 81 
facilitates the interaction between these two proteins. It may also be the case that the 
structure of TDP1
S81A
 could be altered by this amino acid change that would then 
prevent its interaction with mtSSB and account for some of the differences observed in 
tables 6.1 and 6.2. On researching mtSSB further it has been possible to find some 
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interesting facts about the protein and the reasons why it may interact with TDP1 in 
vivo. This protein was identified in Xenopus laevis oocyte mitochondria as having a 
high affinity for single stranded DNA in the D-loop of the mitochondrial genome 
(Mignotte et al., 1985). Building on this, studies using HeLa cells found that mtSSB 
was present in a much greater proportion than mtDNA and was proposed to act 
cooperatively with TFAM in maintenance of mtDNA by enveloping this genome; thus 
providing stability (Takamatsu et al., 2002). More recently it has been proposed that 
mtSSB binding of mtDNA during replication acts as a protective measure against some 
of the organelles own DNA repair enzymes (Wollen Steen et al., 2012). This was 
suggested based on activity assays that demonstrated mtDNA repair enzymes uracil-
DNA glycosylase (UNG1) NEIL1, AlkB homolog 1 (ABH1), and AP endonuclease 1 
(APE1) as being unable to cleave single stranded DNA substrates with engineered 
damage specific for each enzyme when mtSSB was present (Wollen Steen et al., 2012, 
Westbye et al., 2008). However, when mtSSB was not included in these assays or the 
assays were performed using duplex DNA substrates with specific damage for each 
enzyme to repair, each enzyme was able to remove the damage that had been 
engineered in these substrates (Wollen Steen et al., 2012). From this the authors 
suggested that when mtDNA was being replicated mtSSB was bound to single stranded 
mtDNA, which would prevent repair enzymes from compromising the integrity of 
mtDNA in trying to remove any damage that was present (Wollen Steen et al., 2012). 
This would suggest that the damaging effects created by introducing nicks in single 
stranded mtDNA during replication outweighs the damaging effects that are likely to 
occur in the presence of these forms of lesion i.e. point mutations. With regard to TDP1 
these findings imply a logical association between this enzyme and mtSSB. It would 
appear likely that TDP1 is sequestered by mtSSB or associates with the same substrate 
during mtDNA replication given that TDP1 is a single strand break repair enzyme that 
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is involved in resolving lesions formed by TOP1mt; also very likely to be involved in 
initiation of mtDNA replication. 
 
Other mitochondrial proteins that were identified in the Co-IP with TDP1
S81A
 include 
estradiol 17-beta-dehydrogenase 8 (HSD17B8), acyl-coenzyme A thioesterase 9 
(ACOT9), and glutaryl-CoA dehydrogenase (GCDH). From these it is GCDH that has 
the most data published with regard to mitochondria. This protein is involved as part of 
the process of degradation of lysine and tryptophan in mitochondria, and more 
specifically it acts as a homotetramer to catalyse the oxidative decarboxylation of 
glutaryl-CoA (Keyser et al., 2008). Mutations in GCDH can cause the autosomal 
recessive neurometabolic disorder glutaric aciduria type 1 (GA1) with more than 150 
mutations in GCDH known to cause this disease (Keyser et al., 2008). As for HSD17B8 
this protein was identified in having a role in the synthesis of androgens and oestrogens, 
and controlling their activity in mammals, but was not initially thought to be 
mitochondrial (Pletnev and Duax, 2005). However, it was suggested that this protein 
may be involved in fatty acid metabolism in mitochondria based on bioinformatics that 
analysed the structure and substrate specificity of the enzyme (Pletnev and Duax, 2005). 
Despite this publication there have been no further reports of this enzyme in 
mitochondria and also the link between TDP1 and fatty acid metabolism is not 
particularly obvious. Any link between TDP1 and GCDH is also hard to establish as 
there is also no obvious reason why these two proteins would associate with each other 
based on their known function. It may simply be the case that these proteins were found 
to associate with TDP1
S81A
 due to the relatively high levels of expression of this protein 
in mitochondria during this experiment and/or the altered structure of TDP1
S81A
 due to 
its amino acid change. This may also be true for ACOT9 for which there is no data to 
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date other than it is predicted to be mitochondrial by RefSeq based on its amino acid 
sequence.  
 
The data presented in this chapter has shown that from our experiments there was no 
evidence to show that phosphorylation of amino acid 81 in TDP1 mediates its 
association with LIG3α. . However, the limitations of experimental procedures 
discussed in this chapter cannot give us any clear conclusions on this and so the 
association between TDP1 and LIG3α in mitochondria cannot be ruled out. Although 
this association was not found the other proteins identified from the Co-IP has opened 
the possibility that TDP1 may be involved in processes other than the direct repair of 
mtDNA. This data also implies that repair of mtDNA, or even inhibition of repair, 
involves an intricate interplay between several proteins suggesting the mechanisms 
















Chapter 7. Conclusions and future perspectives 
 
The data provided in this thesis helped to delineate the role of tyrosyl-DNA-
phosphodiesterase (TDP1) in mtDNA repair. This was achieved using a variety of 
methods from DNA repair assays to assess the activity of TDP1 in mitochondria to 
protein complex immunoprecipitations to ascertain the protein associations between our 
enzyme of interest and others in mitochondria. The main findings from the studies 
carried out throughout this PhD that are outlined in this thesis include: 
 Identification of TDP1 presence and activity in mitochondria of human cells and 
in mouse brain, which provided evidence for the activity of a novel mtDNA 
repair enzyme at the time of this finding. 
 Evidence to suggest that mtBER is not dependent on TDP1 as was concluded by 
Das et al., 2010. 
 Repair of mtDNA by TDP1 is most probably limited to repair of mtDNA-
TOP1mt lesions. 
 Based on our experiments it was not possible to determine whether 
phosphorylation of amino acid 81 in TDP1 mediates the interaction between this 
enzyme and LIG3α in mitochondria. 
The identification of a novel enzyme involved in mtDNA repair that is likely not to be 
essential to the integrity of this genome suggests that the DNA repair mechanisms in 
mitochondria are more intricate than thought at the time of writing this thesis. The 
machinery involved in mtDNA repair is far less characterised than in the nucleus, and 
although it is most certainly the case that the mechanisms for nDNA repair are far more 
complex than in mitochondria, there is still the possibility for identification of many 
more repair enzymes for mtDNA. 
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In the coming years it may be possible to determine more factors involved in mtDNA 
repair and to assess the impact of mtDNA damage on downstream processes such as 
transcription and translation of mtDNA encoded proteins as this is a subject on which 
little has been reported. Also, it may be possible to expand on the current knowledge of 
the role of epigenetic factors on mtDNA that affect processes within mitochondria.  
Although the findings in this thesis may be informative in identifying relatively new 
DNA repair pathways in mitochondria, there are many questions that still exist in 
relation to this subject. Questions such as: 
 What is the exact role of mtDNA damage in ageing and disease? 
 Does mtDNA contribute to the ageing process or is it merely a sign of ageing? 
 To what extent does mtDNA need to be damaged, with reference to mtDNA 
lesions, before an impact is seen in cells? 
These are just a few examples of questions that remain on the subject of mtDNA repair 
with many more still to be answered despite the findings in this thesis and reports in the 
literature from the beginning of this PhD. 
To sum up, the results provided in this thesis provide knowledge on just a small section 
of the mtDNA repair field in which there is still much to learn. By persisting in attaining 
information on this subject on the molecular level it will be possible to determine how 
mtDNA damage impacts in ageing and disease, and from this potential advances in the 
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41399285 60 kDa heat shock 
protein, mitochondrial  
HSPD1P6 50.46813857 2.025305457 1.648969288 
20127586 tyrosyl-DNA 
phosphodiesterase 1  
TDP1 0 1.94915073 1.15443469 
24234688 stress-70 protein, 
mitochondrial precursor  
HSPA9 10.15883993 1.15443469 1.077113926 
83715985 3-hydroxyacyl-CoA 
dehydrogenase type-2 
isoform 2  
HSD17B10 0 0.318256739 0.737800829 
50345984 ATP synthase subunit 
alpha, mitochondrial 
precursor  
Atp5a1 0.865663579 0.211527659 0.467799268 
91199540 dihydrolipoyl 
dehydrogenase, 
mitochondrial precursor  
dld 0 0 0.333521432 
156071459 ADP/ATP translocase 2  SLC25A5 0.508590709 0.279802214 0.279802214 
32189394 ATP synthase subunit 
beta, mitochondrial 
precursor  
ATP5B 1.187761624 0.513561248 0.258925412 
32483377 thioredoxin-dependent 
peroxide reductase, 
mitochondrial isoform b  
prdx3 0 0.258925412 0.258925412 
295842266 3,2-trans-enoyl-CoA 
isomerase, 
mitochondrial isoform 2 
precursor  
ECI1 0 0 0.258925412 
4504897 importin subunit alpha-
2  
KPNA2 0 0.637893707 0.245197085 
15277342 estradiol 17-beta-
dehydrogenase 8  
HSD17B8 0 0 0.232846739 




isoform 3  
SHMT2 0.154781985 0.211527659 0.211527659 
8923421 seryl-tRNA synthetase, 
mitochondrial isoform b 
precursor  
SARS2 0 0 0.193776642 
10337581 keratin, type I cuticular 
Ha3-II  










TGM3 0 0 0.14280206 










1.069138081 0.223824937 0.128837892 
81295407 acyl-coenzyme A 
thioesterase 9, 
mitochondrial isoform a 
precursor  
acot9 0 0 0.113042193 
56549662 alpha-amylase 1 
precursor  





MTHFD1L 0.091376715 0 0.091376715 
67191208 polyubiquitin-C  UBC 0.058501208 0 0.089022962 
156071462 ADP/ATP translocase 3  SLC25A6 0.44974067 0.160155302 0.077105056 
70995211 delta(3,5)-Delta(2,4)-
dienoyl-CoA isomerase, 
mitochondrial precursor  
ech1 0.160155302 0 0.077105056 
301897479 beta-enolase isoform 2  ENO3 0 0 0.072267222 




GTPBP3 0 0 0.068000433 
4503943 glutaryl-CoA 
dehydrogenase, 
mitochondrial isoform a 
precursor  
gcdH 0 0 0.064209244 
4826702 desmocollin-1 isoform 
Dsc1b preproprotein  
DSC1 0 0 0.062467831 
25777721 succinate-semialdehyde 
dehydrogenase, 
mitochondrial isoform 1 
precursor  
ALDH5A1 0.05776756 0.118872212 0.05776756 
34147630 elongation factor Tu, 
mitochondrial precursor  
Tufm 0.24782547 0 0.045275495 
148539842 deleted in malignant 
brain tumors 1 protein 
isoform b precursor  
DMBT1 0 0 0.031605178 
31621305 leucine-rich PPR motif-
containing protein, 
mitochondrial precursor  
lrpprc 0.015787165 0 0.015787165 
4504523 10 kDa heat shock 
protein, mitochondrial  
HSPE1 0.232846739 0 0 
24308295 grpE protein homolog 
1, mitochondrial 
precursor  
GRPEL1 0.389495494 0 0 
11596859 39S ribosomal protein 
L17, mitochondrial 
precursor  
MRPL17 0.136463666 0 0 
6005854 prohibitin-2 isoform 2  PHB2 0.629750835 0 0 
291084742 pyruvate dehydrogenase 
E1 component subunit 
alpha, somatic form, 
mitochondrial isoform 2 





factor 1, mitochondrial 
isoform 1 precursor  
AIFM1 0.197929811 0 0 
4557237 acetyl-CoA 
acetyltransferase, 
mitochondrial precursor  
ACAT1 0.125335583 0 0 
156564403 pyruvate dehydrogenase 
E1 component subunit 
beta, mitochondrial 
isoform 1 precursor  
pdhB 0.417474163 0 0 
4507231 single-stranded DNA-
binding protein, 
mitochondrial precursor  
SSBP1 0 0.165914401 0 
13699824 kinesin-like protein 
KIF11  
KIF11 0.065425129 0 0 
4502303 ATP synthase subunit 
O, mitochondrial 
precursor  
atp5o 0.232846739 0 0 
4557809 ornithine 
aminotransferase, 
mitochondrial isoform 1 
precursor  
OAT 0.218187912 0 0 
102469034 tyrosine-protein kinase 
JAK1  
JAK1 0.110336318 0 0 
193211616 protein NipSnap 
homolog 1  








dlaT 0.478465929 0 0 
50345988 ATP synthase subunit 
gamma, mitochondrial 
isoform L (liver) 
precursor  
Atp5c1 0.115883993 0 0 
126635329 luciferase [Photinus 
pyralis] + mitochondrial 
targeting sequence and 
FLAG tag 
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